



Cancer diagnosis, treatment selection and treatment

Szallasi, Zoltan I; Richardson, Andrea L; Birkbak, Nicolai J; Wang, Zhigang

Publication date:
2014

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Szallasi, Z. I., Richardson, A. L., Birkbak, N. J., & Wang, Z. (2014). Cancer diagnosis, treatment selection and treatment. (Patent No. *WO2014160080*).

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



- (51) International Patent Classification:
C12Q 1/68 (2006.01) *G01N 33/15* (2006.01)
- (21) International Application Number:
PCT/US2014/025774
- (22) International Filing Date:
13 March 2014 (13.03.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/784,234 14 March 2013 (14.03.2013) US
- (71) Applicants: **CHILDREN'S MEDICAL CENTER CORPORATION** [US/US]; 55 Shattuck Street, Boston, Massachusetts 02115 (US). **THE BRIGHAM AND WOMEN'S HOSPITAL, INC.** [US/US]; 75 Francis Street, Boston, Massachusetts 02115 (US). **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 450 Brookline Avenue, Boston, Massachusetts 02215 (US). **THE TECHNICAL UNIVERSITY OF DENMARK** [DK/DK]; Anker Englundvej 1, DK-2800 KGS Lyngby (DK).
- (72) Inventors: **SZALLASI, Zoltan I.**; 423 Brookline Avenue #144, Boston, Massachusetts 02210 (US). **RICHARDSON, Andrea L.**; 242 Russett Road, Chestnut Hill, Massachusetts 02467 (US). **BIRKBAK, Nicolai J.**; Øster-

brogade 113, 5, 507, DK-2100 København Ø (DK). **WANG, Zhigang**; 51 Cloverdale Road, Newton, Massachusetts 02461 (US).

- (74) Agents: **RESNICK, David S.** et al.; Nixon Peabody LLP, 100 Summer Street, Boston, Massachusetts 02110-2131 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: CANCER DIAGNOSIS, TREATMENT SELECTION AND TREATMENT




FIG. 2

(57) Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.

WO 2014/160080 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). **Published:**

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

CANCER DIAGNOSIS, TREATMENT SELECTION AND TREATMENT**CROSS-REFERENCE TO RELATED APPLICATIONS**

5 [0001] This application claims benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 61/784,234, filed March 14, 2013, the content of which is incorporated herein in its entirety.

STATEMENT REGARDING FEDERALLY-SPONSORED RESEARCH

10 [0002] This invention was made with government support under Grant No. 2P50 CA89393-06 awarded by the National Cancer Institute. The Government has certain rights in the invention.

BACKGROUND

15 [0003] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.

20 [0004] Breast cancer is recognized as a collection of malignancies that all arise in the breast but are remarkably heterogeneous. Gene expression array experiments have defined at least 4 major subtypes: 1) Luminal A; 2) Luminal B; 3) HER2+; and 4) Basal. There is a strong correlation between clinically defined triple negative breast cancer "TNBC", as defined by the absence of ER, PgR, and HER2 by standard immunohistochemical staining, and the molecularly defined basal subtype.

25 [0005] TN breast cancer accounts for only 10-15% of all incident breast cancer cases in the U.S., but results in a disproportionate number of breast cancer deaths. Women who are destined to develop metastatic TN disease typically experience a short disease free interval and have a higher degree of lung and brain involvement than patients with luminal breast cancers. Furthermore, TN breast cancer is overrepresented among patients who carry a deleterious BRCA1 germline alteration, and among women of African ancestry.

30 [0006] From a clinical perspective, despite substantial efforts to develop novel targeted agents, chemotherapy remains the mainstay of therapy for TN breast cancer, as trials evaluating a number of agents either in lieu of chemotherapy or in addition to chemotherapy have failed to produce any new agent that is capable of convincingly changing the natural history of the disease. In the adjuvant setting, polychemotherapy regimens have been

demonstrated to improve both disease-free survival and overall survival. In the neoadjuvant setting, a favorable response to chemotherapy is associated with a low chance of relapse at 5 years. In contrast, women who have a significant amount of residual disease after a course of neoadjuvant chemotherapy have a particularly poor prognosis, with at least half experiencing a recurrence and death from TN breast cancer within 5 years. In the metastatic setting, although patients may respond to chemotherapy, the responses tend to be brief, and resistance tends to appear quickly.

[0007] Given the curative potential of chemotherapy in patients presenting with stage I-III TN breast cancer, and the initial responses (albeit often brief) seen with chemotherapy in the metastatic setting, the general direction of targeted therapy development for TN breast cancer has been to combine targeted agents with chemotherapy. Thus, even with a growing number of targeted therapies under investigation for TN breast cancer, chemotherapy is likely to be a significant component of the treatment of TN breast cancer for many years to come.

[0008] Across breast cancers as a whole, hormone receptor dependence and tumor proliferation appear to be associated with generic “chemosensitivity”. Using the 70 gene signature as an example, the current classifiers typically assign a “high-risk” status to the vast majority of TN tumors, and are also unable to define whether there may be differential benefit with one class of chemotherapeutic agents over another. Thus, in both clinical practice and in conventionally designed clinical trials, the tendency is to layer new therapies directly atop existing standards, increasing the risk of both overtreatment (because some, but not all of the administered therapies are efficacious) or undertreatment (because the tumor is not sensitive to any of the specific chemotherapeutic agents contained in the treatment regimen).

[0009] Accordingly, there exists a need in the art to identify the best chemotherapy for each patient and to eliminate agents that are inert and result in toxicity without benefit.

SUMMARY OF THE INVENTION

[0010] We provide novel methods, assays, systems and kits for determining if a cancer patient is responsive to platinum-comprising therapy or anthracyclin therapy. These methods, assays, systems and kits provide a significant improvement to the “trial-and-error” – therapies used in cancer therapy. The methods allow one to personalize the treatment of a cancer patient based on the cancer cells’ specific protein/gene expression profile. In other words, the methods apply the novel findings of a cancer cells responses to cancer treatment methods and allow selection of the most likely effective therapy without delay and thus

significantly improve the patient's quality of life. Avoiding use of ineffective drugs will also provide a significant saving for the cost of treatment for the cancer patient, as well avoiding exposure to side effects of ineffective drugs.

[0011] The invention is based, at least in part, on the discovery that patients having increased expression of BLM and/or FANCI genes compared to a housekeeping gene or wild-type BRCA1 gene in their cancer cells are likely to respond to platinum-comprising or anthracyclin-comprising cancer therapy.

[0012] The following embodiments and aspects thereof are described and illustrated in conjunction with compositions and methods which are meant to be exemplary and illustrative, not limiting in scope.

[0013] We provide an assay for selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression; comparing the BLM and FANCI expression to a reference value; and selecting a platinum-comprising cancer therapy for the subject when the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI, or selecting a non-platinum-comprising cancer therapy for the subject when the BLM and FANCI expression is not increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is not effective in subjects whose cancer does not have increased BLM and FANCI expression compared to the reference value.

[0014] The assay may further comprise assaying the BRCA1 and/or BRCA2 status of the subject; and selecting the platinum-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI and who are negative for BRCA1 and/or BRCA2 mutations.

[0015] In some aspects of all the embodiments of the invention, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.

[0016] In some aspects of all the embodiments of the invention, the assay further comprises assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and selecting the platinum-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when the BLM and FANCI expression is increased compared to the

reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor.

5 [0017] In some aspects of all the embodiments of the invention, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.

[0018] In some aspects of all the embodiments of the invention, the assay further comprises administering the selected therapy to the subject.

10 [0019] In some aspects of all the embodiments of the invention, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[0020] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

15 [0021] In some aspects of all the embodiments of the invention, the reference value is based on at least BRCA1 gene expression in the cancer cell.

[0022] In some aspects of all the embodiments of the invention, the reference value is based on at least one housekeeping gene expression in the cancer cell.

20 [0023] We also provide a method for selecting platinum-comprising therapy for a subject having cancer, and optionally administering the platinum-comprising therapy, the method comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression; detecting the BLM and FANCI expression in the sample compared to a reference value; and electing a platinum-comprising cancer therapy for the subject when the BLM and FANCI expression compared to a reference value is increased based on the recognition that platinum-comprising cancer therapy is effective in patients
25 whose cancer has increased BLM and FANCI expression compared to the reference value.

[0024] In some aspects of all the embodiments of the invention, the method further comprises administering to the subject the platinum-comprising cancer therapy when the platinum-comprising cancer therapy is selected. One can further select a therapy other than platinum-comprising therapy when it is determined using the assay that the cancer is not
30 likely responsive to platinum-comprising therapy.

[0025] In some aspects of all the embodiments of the invention, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.

[0026] In some aspects of all the embodiments of the invention, the subject's cancer or cancer cell is known to not or determined to not express a detectable quantity of ER, PgR, and HER2 receptor.

5 [0027] In some aspects of all the embodiments of the invention, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[0028] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

10 [0029] In some aspects of all the embodiments of the invention, the reference value is based on at least BRCA1 gene expression in the cancer cell.

[0030] In some aspects of all the embodiments of the invention, the reference value is based on at least one housekeeping gene expression in the cancer cell.

[0031] In some aspects of all the embodiments of the invention, the housekeeping gene is selected from beta-actin, GAPDH, RPLP0, GUS, TFRC and any combination thereof.

15 [0032] In some aspects of all the embodiments of the invention, the housekeeping gene is RPLP0, and the BLM and/or FANCI expression is increased by at least six-fold.

[0033] We further provide a method for selecting a non-platinum-comprising therapy, and optionally administering the non-platinum-comprising therapy, for a subject having cancer comprising: subjecting a sample comprising a cancer cell taken from the subject to an
20 analysis for BLM and FANCI expression; detecting the BLM and FANCI expression in the sample compared to a reference value; and selecting the non-platinum-comprising cancer therapy for the subject when the BLM and FANCI expression compared to the reference value is not increased based on the recognition that non-platinum-comprising cancer therapy is effective in patients whose cancer does not have increased gene expression of BLM and
25 FANCI compared to the reference value.

[0034] In some aspects of all the embodiments of the invention, the method further comprises administering to the subject the non-platinum-comprising cancer therapy when non-platinum-comprising cancer therapy is selected.

30 [0035] In some aspects of all the embodiments of the invention, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[0036] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0037] In some aspects of all the embodiments of the invention, the reference value is based on at least BRCA1 gene expression in the cancer cell.

[0038] In some aspects of all the embodiments of the invention, the reference value is based on at least one housekeeping gene expression in the cancer cell.

5 [0039] We provide an assay for selecting a therapy for a subject having cancer, comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression; comparing the BLM and FANCI expression to a reference value; and selecting an anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression is increased compared to a reference value based on
10 the recognition that anthracycline-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI, or selecting a non-anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression is not increased compared to a reference value based on the recognition that anthracycline-comprising cancer therapy is not effective in subjects whose cancer does not have increased
15 BLM expression compared to a reference value.

[0040] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0041] We provide a method for selecting an anthracycline-comprising cancer
20 therapy for a subject having cancer and determined to be negative for BRCA1 and/or BRCA2 mutations, comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression; comparing the BLM and FANCI expression to a reference value; and selecting the anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression compared to the reference value is increased based on
25 the recognition that anthracycline-comprising cancer therapy is effective in patients whose cancer has increased expression of BLM and FANCI compared to the reference value.

[0042] In some aspects of all the embodiments of the invention, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

30 [0043] We further provide a method of treating cancer in a human subject, comprising: detecting BLM and FANCI expression in a sample comprising a cancer cell taken from the human subject; and comparing the BLM and FANCI expression to a reference value; and administering a platinum-comprising cancer therapy to the human subject wherein an increase of BLM and FANCI expression compared to the reference value is detected.

[0044] In some aspects of all the embodiments of the invention, the human subject's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.

5 [0045] In some aspects of all the embodiments of the invention, the cancer is selected from breast, ovarian, and lung cancers.

[0046] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

10 [0047] In some aspects of all the embodiments of the invention, the reference value is based on BRCA1 gene expression in the cancer cell.

[0048] In some aspects of all the embodiments of the invention, the reference value is based on a housekeeping gene expression in the cancer cell.

15 [0049] We provide method of treating cancer in a human subject, comprising: detecting BLM and FANCI expression in a sample comprising a cancer cell taken from the human subject; and comparing the BLM and FANCI expression to a reference value; and administering an anthracycline-comprising cancer therapy to the human subject wherein an increase of BLM and FANCI expression compared to the reference value is detected.

20 [0050] In some aspects of all the embodiments of the invention, the human subject's cancer or cancer cell is known to not or is determined to not to express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.

[0051] In some aspects of all the embodiments of the invention, the cancer is selected from breast, ovarian, and lung cancers.

25 [0052] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0053] In some aspects of all the embodiments of the invention, the reference value is based on BRCA1 gene expression in the cancer cell.

[0054] In some aspects of all the embodiments of the invention, the reference value is based on a housekeeping gene expression in the cancer cell.

30 [0055] We provide a method for assessing responsiveness of a cancer cell to cancer therapy, comprising: assaying, in a cancer cell or mRNA derived therefrom, BLM and FANCI expression; and comparing said BLM and FANCI expression to a reference value, wherein the cancer cell is assessed as responsive to a platinum-comprising therapy if the BLM and FANCI expression is increased compared to the reference value, or wherein the

cancer cell is assessed as poorly or not responsive to platinum-comprising cancer therapy cancer if the BLM and FANCI expression is not increased.

[0056] In some aspects of all the embodiments of the invention, the step of assaying comprises: contacting the cancer cell or mRNA derived therefrom with at least one detectably labeled probe capable of specifically binding to BLM mRNA, at least one detectably probe
5 capable of specifically binding to FANCI, at least one detectably labeled probe capable of specifically binding to BRCA1 and/or at least one housekeeping gene; and measuring the expression of BLM and FANCI compared to the BRCA1 and/or the at least one housekeeping gene.

10 **[0057]** In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0058] We provide a method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising: determining, in a
15 cancer cell from the cancer patient, BLM and FANCI expression; and correlating the expression to a reference value, wherein when the expression is increased the patient is predicted to respond well to a cancer treatment regimen comprising platinum or anthracycline.

[0059] In some aspects of all the embodiments of the invention, the reference value is
20 BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0060] We also provide a method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising: determining, in a
25 cancer cell or mRNA derived therefrom from said cancer patient, BLM and FANCI expression; and correlating the expression to a reference value, wherein when the expression is not increased the patient is predicted to respond poorly to a cancer treatment regimen comprising platinum or anthracycline.

[0061] In some aspects of all the embodiments of the invention, the reference value is
30 BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0062] We provide a method of treating cancer, comprising: assaying, in a cancer cell from a cancer patient or mRNA obtained therefrom, the BLM and FANCI expression compared to a reference value; and administering to the cancer patient a cancer treatment

regimen comprising platinum or anthracycline if the BLM and FANCI expression is increased compared to the reference value.

[0063] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0064] We also provide a use of platinum comprising cancer therapy for treating a cancer patient that has been determined to have a tumor comprising cancer cells wherein BLM and FANCI expression is increased compared to a reference value.

[0065] In some aspects of all the embodiments of the invention, the cancer patient has been determined to be negative for BRCA1 and/or BRCA2 mutations.

[0066] In some aspects of all the embodiments of the invention, the cancer patient's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.

[0067] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0068] We provide a system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising: a sample analyzer configured to produce a signal for the mRNA from each one of BLM and FANCI from a cancer cell sample of a cancer patient; and a computer sub-system programmed to calculate, based on the mRNA whether the signal is greater or not than a reference value.

[0069] In some aspects of all the embodiments of the invention, said computer sub-system is programmed to compare the mRNA to determine a likelihood of responsiveness of said cancer cell to platinum-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a platinum-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the platinum-comprising therapy if the BLM and FANCI expression is not increased; or a likelihood of responsiveness of said cancer cell to anthracycline-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a anthracycline-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the anthracycline-comprising therapy if the BLM and FANCI expression is not increased.

[0070] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0071] We provide a computer program product embodied in a computer readable medium that, when executing on a computer, performs steps comprising: detecting the BLM and FANCI gene expression in sample comprising a cancer cell from a cancer patient; and comparing the BLM and FANCI expression to a reference value.

5 [0072] In some aspects of all the embodiments of the invention, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[0073] We provide a diagnostic kit for detecting a likelihood of a cancer patient to respond to platinum- or anthracycline-comprising comprising cancer therapy, comprising: no
10 more than 10 probes comprising a combination of detectably labeled probes or primers for BLM and FANCI, and optionally for BRCA1 and/or at least one housekeeping gene; and the computer program product of Claim 59.

[0074] We provide use of a plurality of oligonucleotides comprising no more than 10 oligonucleotides capable of hybridizing to BLM and FANCI, and optionally to BRCA1
15 and/or at least one housekeeping gene, in a diagnostic kit for determining an increased likelihood that a cancer patient will respond to cancer treatment regimen comprising a platinum and/or anthracycline.

[0075] In some aspects of all the embodiments of the invention, said anthracycline is epirubicin or doxorubicin.

20 [0076] In some aspects of all the embodiments of the invention, said platinum comprising cancer therapy comprises cisplatinum or cis-diamminedichloroplatinum, phenanthriplatin, carboplatin, oxaliplatin, or a platinum complex that is activated by ultraviolet A light.

[0077] We provide an assay for selecting a therapy for a subject having cancer, and
25 optionally administering the therapy, the assay comprising: assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number; comparing the chromosome 15q26 copy number to a reference value; and selecting a platinum-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or selecting a non-platinum-comprising cancer therapy for the subject if
30 there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.

[0078] In some aspects of all the embodiments of the invention, the assay further comprises: assaying the BRCA1 and/or BRCA2 status of the subject; and selecting the platinum-comprising cancer therapy for the subject when the subject is negative for BRCA1

and/or BRCA2 mutations, and there is a chromosome 15q26 copy number gain based on the recognition that platinum-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain who are negative for BRCA1 and/or BRCA2 mutations.

5 [0079] In some aspects of all the embodiments of the invention, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.

[0080] In some aspects of all the embodiments of the invention, the assay further comprises: assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and selecting the platinum-comprising cancer therapy
10 for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when there is a chromosome 15q26 copy number gain based on the recognition that platinum-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor.

15 [0081] In some aspects of all the embodiments of the invention, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.

[0082] In some aspects of all the embodiments of the invention, the assay further comprises administering the selected therapy to the subject.

20 [0083] In some aspects of all the embodiments of the invention, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[0084] In some aspects of all the embodiments of the invention, the reference value is chromosome 15 centromere copy number in the sample.

[0085] We provide an assay for selecting a therapy for a subject having cancer, and
25 optionally administering the therapy, the assay comprising: assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number; comparing the chromosome 15q26 copy number to a reference value; and selecting an anthracycline-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or selecting a non-anthracycline-comprising cancer therapy
30 for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.

[0086] In some aspects of all the embodiments of the invention, the assay further comprises: assaying the BRCA1 and/or BRCA2 status of the subject; and selecting the anthracycline-comprising cancer therapy for the subject when the subject is negative for

BRCA1 and/or BRCA2 mutations, and there is a chromosome 15q26 copy number gain based on the recognition that anthracycline-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain who are negative for BRCA1 and/or BRCA2 mutations.

5 [0087] In some aspects of all the embodiments of the invention, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.

[0088] In some aspects of all the embodiments of the invention, the assay further comprises assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and selecting the anthracycline-comprising cancer
10 therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when there is a chromosome 15q26 copy number gain based on the recognition that anthracycline-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor.

15 [0089] In some aspects of all the embodiments of the invention, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.

[0090] In some aspects of all the embodiments of the invention, the assay further comprises administering the selected therapy to the subject.

20 [0091] In some aspects of all the embodiments of the invention, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[0092] In some aspects of all the embodiments of the invention, the reference value is chromosome 15 centromere copy number in the sample.

[0093] We provide a method of treating cancer in a human subject, comprising:
25 detecting a chromosome 15q26 copy number in a sample comprising a cancer cell taken from the subject; comparing the chromosome 15q26 copy number to a reference value; and administering an platinum-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or administering a non-platinum-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number
30 gain, or if there is a chromosome 15q26 copy number loss.

[0094] In some aspects of all the embodiments of the invention, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[0095] In some aspects of all the embodiments of the invention, the reference value is chromosome 15 centromere copy number in the sample.

[0096] In some aspects of all the embodiments of the invention, the subject's cancer is known to not express a detectable quantity of ER, PgR, and HER2 receptor.

[0097] We provide a method of treating cancer in a human subject, comprising: detecting a chromosome 15q26 copy number in a sample comprising a cancer cell taken from
5 the subject; comparing the chromosome 15q26 copy number to a reference value; and administering an anthracycline-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or administering a non-anthracycline-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.

10 [0098] In some aspects of all the embodiments of the invention, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[0099] In some aspects of all the embodiments of the invention, the reference value is chromosome 15 centromere copy number in the sample.

[00100] In some aspects of all the embodiments of the invention, the subject's cancer
15 or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.

[00101] We provide a method for assessing responsiveness of a cancer cell to a cancer therapy, and optionally administering the cancer therapy, comprising: assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number; and
20 comparing the chromosome 15q26 copy number to a reference value, wherein the cancer cell is assessed as responsive to a platinum-comprising therapy if there is a chromosome 15q26 copy number gain compared to the reference value, or wherein the cancer cell is assessed as poorly or not responsive to platinum-comprising cancer therapy cancer if there is not a chromosome 15q26 copy number gain or if there is a chromosome 15q26 copy number loss.

25 [00102] In some aspects of all the embodiments of the invention, the reference value is copy number of chromosome 15.

[00103] In some aspects of all the embodiments of the invention, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[00104] In some aspects of all the embodiments of the invention, the method further
30 comprises administering the platinum-comprising therapy if there is a chromosome 15q26 copy number gain.

[00105] We provide a method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising: determining, in a cancer cell from the cancer patient, chromosome 15q26 copy number; and correlating the

chromosome 15q26 copy number to a reference value, wherein when there is a chromosome 15q26 copy number gain, the patient is predicted to respond well to a cancer treatment comprising platinum or anthracycline, or wherein when there is not a chromosome 15q26 copy number gain or a chromosome 15q26 copy number loss, the patient is predicted respond
5 poorly to a cancer treatment comprising platinum or anthracycline.

[00106] In some aspects of all the embodiments of the invention, the reference value is chromosome 15 centromere copy number in the sample.

[00107] We provide use of platinum comprising cancer therapy for treating a cancer patient that has been determined to have a tumor comprising cancer cells wherein a
10 chromosome 15q26 copy gain is detected compared to a reference value.

[00108] In some aspects of all the embodiments of the invention, the cancer patient is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.

[00109] In some aspects of all the embodiments of the invention, the cancer patient's cancer or cancer cell is known to not or is determined to not express detectable quantities of
15 estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.

[00110] In some aspects of all the embodiments of the invention, the reference value is chromosome 15 centromere copy number in the sample.

[00111] We provide a system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising: a sample
20 analyzer configured to produce a signal for chromosome 15q26 copy number from a cancer cell sample of a cancer patient; and a computer sub-system programmed to calculate, based on the mRNA whether the signal is greater or not than a reference value.

[00112] In some aspects of all the embodiments of the invention, said computer sub-system is programmed to compare the mRNA to determine a likelihood of responsiveness of
25 said cancer cell to platinum-comprising cancer therapy and/or or a anthracycline-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a platinum-comprising therapy if there is a chromosome 15q26 copy number gain and as unlikely to respond to the platinum-comprising therapy if there is not a chromosome 15q26 copy number gain or if there is a chromosome 15q26 copy number loss.

[00113] In some aspects of all the embodiments of the invention, the reference value is chromosome 15 centromere copy number in the sample.

[00114] We provide a computer program product embodied in a computer readable medium that, when executing on a computer, performs steps comprising: detecting

chromosome 15q26 copy number in sample comprising a cancer cell from a cancer patient; and comparing the chromosome 15q26 copy number to a reference value.

[00115] In some aspects of all the embodiments of the invention, the reference value is chromosome 15 centromere copy number in the sample.

5 [00116] We provide a diagnostic kit for detecting a likelihood of a cancer patient to respond to platinum- or anthracycline-comprising cancer therapy, comprising: no more than 10 probes comprising a combination of detectably labeled probes or primers for chromosome 15q26, and optionally for chromosome 15 centromere; and a computer program as described herein.

10 [00117] We provide us of a plurality of oligonucleotides comprising no more than 10 oligonucleotides capable of hybridizing to chromosome 15q26, and optionally for chromosome 15 centromere, in a diagnostic kit for determining an increased likelihood that a cancer patient will respond to cancer treatment regimen comprising a platinum and/or anthracycline.

15 [00118] In some aspects of all the embodiments of the invention, said anthracycline is epirubicin or doxorubicin.

[00119] In some aspects of all the embodiments of the invention, said platinum comprising cancer therapy comprises cisplatin or cis-diamminedichloroplatinum, phenanthriplatin, carboplatin, oxaliplatin, or a platinum complex that is activated by
20 ultraviolet A light.

[00120] Other features and advantages of the invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, various features of embodiments of the invention.

25 BRIEF DESCRIPTION OF THE FIGURES

[00121] This patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

[00122] Exemplary embodiments are illustrated in referenced figures. It is intended
30 that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.

[00123] **Figures 1A and 1B** show that GISTIC identifies 169 chromosomal regions as either gained or lost. Several contained genes with significantly different copy number between sensitive and resistant cases.

- [00124] **Figure 2** shows a 10 MB region with 59 genes on chr. 15q26.1-2 showed significant gain in sensitive samples.
- [00125] **Figure 3** shows correlation between copy number and mRNA expression, Genes on 15q26.1-2. 23 genes show significant correlation.
- 5 [00126] **Figure 4** depicts leave-one-out analysis of gene expression data.
- [00127] **Figure 5** shows that expression of BLM and FANCI is only associated with response to carboplatin, but not paclitaxel in OV01. (A) BLM expression; (B) FANCI Expression. Ahmed et al., Cancer Cell 2007.
- [00128] **Figure 6** depicts expression of BLM or FANCI is not associated with response to multi-agent chemotherapy regimens in triple negative breast cancer (TNBC). (A) BLM expression; (B) FANCI Expression. ¹Hess et al., JCO 2006; Popovici et al., ²Breast Cancer Res 2010; ³André et al., Clin Cancer Res 2009.
- 10 [00129] **Figure 7** shows that BLM is also associated with response to single agent epirubicin. TOP trial, single agent epirubicin in ER-negative breast cancer. ¹Desmedt et al., JCO 2011.
- 15 [00130] **Figure 8** depicts repair of cisplatin induced damage.
- [00131] **Figure 9** depicts the metaphase spread, BRCA1 knock-out in MEFs. BRCA1 is an essential part of the homologous repair system. BRCA1 knock out cause high levels of quadrachromosomes, which is a prime substrate for the Bloom helicase. Gain of BLM is a possible compensation mechanism for deficient HR. Silver DP et al, Cell 2007.
- 20 [00132] **Figures 10A-10B** show gene signatures. Figure **10A** shows receiver operating characteristic curves showing the ability of the BRCA1-BLM-FANCI RNA 3-gene signature to predict for response to cisplatin in the two cisplatin trials. Figure **10B** shows ROC curves showing the ability of number of telomeric allelic imbalance (NtAI) + 3-gene mRNA signature to predict for sensitivity to cisplatin in the combined trials.
- 25 [00133] **Figure 11** depicts ROC analysis of 3 gene signature to determine cisplatin sensitivity in cisplatin 2 trial. Blue: all cases; red; BRCA normal cases only.
- [00134] **Figure 12** depicts functional modules of various embodiments of the invention.
- 30 [00135] **Figure 13** depicts survival time with Kaplan-Meier plot, showing over-all survival of patients from the TCGA squamous cell lung cancer cohort, split by the median of the three gene signature calculated as the ratio of BRCA1 expression over the mean of FANCI and BLM expression.

[00136] **Figure 14** shows the BLM+FANCI/BRCA1 signature. The Cisplatin-2 trial, separating resistant (MP 1-2-3) from sensitive (MP 4-5) cases is optimized for qPCR data. Blue line is based on all samples, while red is based on wtBRCA1. The optimum ratio is calculated by ROC curve, and shows an optimum ratio of 5.5 for all cases, on a log₂ scale. In un-logged values, this is equivalent of 45 fold.

[00137] **Figure 15** shows BLM/BRCA1 signature. The Cisplatin-2 trial, separating resistant (MP 1-2-3) from sensitive (MP 4-5) cases is optimized for qPCR data. The optimum ratio is 7.5 for all cases, on a log₂ scale, which is equivalent of 180 fold or 7.5 cycles on a PCR machine. This is a very large difference.

[00138] **Figure 16** shows FANCI/BRCA1 signature. The Cisplatin-2 trial, separating resistant (MP 1-2-3) from sensitive (MP 4-5) cases is optimized for qPCR data. The optimum ratio is 5.1 for all cases, on a log₂ scale, which is equivalent of 34 fold.

[00139] **Figure 17** shows the BRCA1/RPLP0 signature. BRCA1 is compared to a housekeeping gene, RPLP0. The optimum ratio here is -14 for all cases, on a log₂ scale, which is approximately equivalent to 1/1600, or 14 cycles on a PCR machine. This is a very large difference, but HK genes are expressed in very high numbers.

[00140] **Figure 18** shows BLM/RPLP0 signature. BLM is compared to a housekeeping gene, RPLP0. The optimum ratio is higher, and separation of sensitive/resistant cases is good.

[00141] **Figure 19** shows FANCI/RPLP0 signature. FANCI is compared to a housekeeping gene, RPLP0. The optimum ratio is higher than BRCA1 alone.

[00142] **Figures 20A and 20B** show how the expression of each of the three genes looks like in a large cohort of breast cancer patients from the TCGA, and how their ratios is to RPLP0 and BRCA1. These patients were not treated with platinum. This was focused on DNBC cases (ER/HER2 negative), and the normal breast samples. The ratio is much lower than using PCR data, yet there still appear to be a clear increase in some cases. The normal samples have lower BLM and BRCA1 expression, but that the ratio between these is inversed, with higher BRCA1 than BLM, probably reflecting the normal balance between these genes.

DETAILED DESCRIPTION

[00143] All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which

this invention belongs. Singleton *et al.*, *Dictionary of Microbiology and Molecular Biology 3rd ed.*, J. Wiley & Sons (New York, NY 2001); March, *Advanced Organic Chemistry Reactions, Mechanisms and Structure 5th ed.*, J. Wiley & Sons (New York, NY 2001); and Sambrook and Russel, *Molecular Cloning: A Laboratory Manual 3rd ed.*, Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY 2001), provide one skilled in the art with a general guide to many of the terms used in the present application. For references on how to prepare antibodies, see D. Lane, *Antibodies: A Laboratory Manual* (Cold Spring Harbor Press, Cold Spring Harbor NY, 1988); Kohler and Milstein, (1976) *Eur. J. Immunol.* 6: 511; Queen *et al.* U. S. Patent No. 5,585,089; and Riechmann *et al.*, *Nature* 332: 323 (1988).

10 **[00144]** One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described.

[00145] To investigate whether specific genomic aberrations may affect cancer sensitivity to cisplatin, the inventors generated tumor DNA copy number profiles of 21 and 24 TNBC patients who received pre-operative cisplatin-based chemotherapy in two separate clinical trials. Using the GISTIC algorithm (1), the inventors found that only a single region on chromosome 15q26 showed consistent significant differential copy number in responders versus non-responders, being preferentially lost in non-responders, but preferentially gained in responders in both trials.

[00146] To see if genes on 15q26 were associated with platinum sensitivity, the inventors acquired gene expression data from the cisplatin TNBC trial (2), and from the carboplatin-only arm of an ovarian cancer trial (3). The inventors then performed a leave-one-out analysis, and found 9 genes significantly associated with platinum response in at least 75% of all rounds in both cohorts. These included BLM and FANCI located in the 15q26 region, both showing higher expression in sensitive tumors, and known to be involved in related DNA repair processes. To investigate if BLM and FANCI were specifically associated with genotoxic chemotherapy sensitivity, the inventors analyzed their expression in TNBCs from three neoadjuvant trials of epirubicin alone (4) or taxane-containing combination therapy (5, 6) and in ovarian cancers from the taxane-only treatment arm(3). In the epirubicin trial, BLM and FANCI expression was again significantly associated with increased sensitivity to therapy. In contrast, there was no association between either BLM or FANCI expression and TNBC response to the taxane-containing regimen or ovarian cancer response to single agent taxane treatment. These data suggest that high expression of BLM

and FANCI are associated with improved response to DNA damaging agents, but not with response to other types of chemotherapeutics. Furthermore, it suggests that the patient subpopulations that respond to drugs such as anthracyclines and taxanes are not overlapping, and that it will therefore be difficult to robustly identify predictors of single agent response based on multi-drug trials.

5 [00147] While not wishing to be bound by any particular theory, the inventors believe that FANCI and BLM functions in multiple DNA repair processes; increased FANCI and BLM is associated with response to platinum-comprising therapy and anthracycline-comprising therapy; low copy gain might be a compensatory mechanism of HR deficient cells, trying to rescue some DNA repair capacity; and if so, FANCI/BLM expression is a marker for DNA repair deficiency, and increased sensitivity to genotoxic chemotherapy drugs, such as platinum-comprising therapy and anthracycline-comprising therapy.

10 [00148] Therefore, while the cancers specifically investigated for their responses in the particular studies, such as breast cancer, such as triple negative breast cancer, ovarian cancer and lung cancer, Applicants believe that the finding of the association between increased FANCI and BLM expression and responsiveness to platinum-comprising therapy and anthracycline-comprising therapy is applicable to most cancers.

15 [00149] The present invention is based, at least in part, on these findings, and those further described herein and in the figures and examples.

20 *Selecting therapy*

[00150] Various embodiments provide for assays, methods and systems for selecting an appropriate therapy for a subject based on an analysis of the subject's BLM and FANCI expression, or based on the subject's 15q26 copy number.

25 [00151] In various embodiments, the invention provide for an assay for selecting a therapy, and optionally administering the therapy, for a subject having cancer, the assay comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression; comparing the BLM and FANCI expression to a reference value; and selecting a platinum-comprising cancer therapy for the subject when the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI, or selecting a non-platinum-comprising cancer therapy for the subject when the BLM and FANCI expression is not increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is not

30

effective in subjects whose cancer does not have increased BLM and FANCI expression compared to the reference value.

[00152] In various embodiments, the assay further comprises: assaying the BRCA1 and/or BRCA2 status of the subject; and selecting the platinum-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI and who are negative for BRCA1 and/or BRCA2 mutations.

In various embodiments, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations. The determination can be made before, concurrently with, or after the analysis for BLM and FANCI expression.

[00153] In some aspects of all the embodiments of the invention, a mutation that inactivates BRCA2 is highly predictive of response.

[00154] In various embodiments, the assay further comprises: assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and selecting the platinum-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor. In various embodiments, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor. The determination can be made before, concurrently with, or after analysis for BLM and FANCI expression.

[00155] In various embodiments, the assay further comprises administering the selected therapy to the subject.

[00156] In various embodiments, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[00157] In various embodiments, the reference value is based on BRCA1 gene expression in the cancer cell. In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

[00158] In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold,

1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 4-fold, 5-fold, or 6-fold, 10-20 fold, 20-50 fold or higher, depending on the expression level of the gene used as a standard, such as one or more housekeeping genes or BRCA1.

5 [00159] Typically, an increase in expression of at least 1.5 or at least 2 fold is considered as a cut-off point for increased expression if BRCA1 gene expression is used as a standard. Thus, in certain embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

10 [00160] For example, in our examples, we calculated the ratios, and in cells expressing wild type BRCA1 (wtBRCA1) the ratio was around 6.6 for BLM+FANCI / BRCA1. Thus, in some aspects, the expression level can be over 5, or over 6 or over 7 times that of BRCA1.

[00161] For analysis with qPCR, each of the analyzed genes is first normalized to a housekeeping gene, such as RPLP0. For example, with 6 cycles of PCT, we calculated the
15 optimum for BRCA1/BLM/FANCI normalized to RPLP0, expression of which is typically very low. All values are \log_2 , which means that a ratio of 6 reflects an amount of 64 times higher than the reference gene, namely RPLP0.

[00162] In various embodiments, the reference value is based on a housekeeping gene expression in the cancer cell. Examples of useful housekeeping genes are described herein,
20 e.g., in Table 1.

[00163] Various embodiments of the present invention provide for a method for selecting platinum-comprising therapy, and optionally administering the platinum-comprising therapy, for a subject having cancer, comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression; detecting the
25 BLM and FANCI expression in the sample compared to a reference value; and selecting a platinum-comprising cancer therapy for the subject when the BLM and FANCI expression compared to a reference value is increased based on the recognition that platinum-comprising cancer therapy is effective in patients whose cancer has increased BLM and FANCI expression compared to the reference value.

30 [00164] In various embodiments, the method further comprises administering to the subject the platinum-comprising cancer therapy when the platinum-comprising cancer therapy is selected.

[00165] In various embodiments, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations. The determination can be made before,

concurrently with, or after the analysis for BLM and FANCI expression. In various embodiments, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor. The determination can be made before, concurrently with, or after analysis for BLM and FANCI expression.

5 [00166] In various embodiments, the reference value is based on BRCA1 gene expression in the cancer cell. In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

[00167] In various embodiments, the reference value is BRCA1 expression, and the
10 BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold 2.8-fold 2.9-fold or 3-fold compared to BRCA1 expression. In certain embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about two-fold compared to BRCA1
15 expression. In certain embodiments, the BLM and/or FANCI expression is increased by at least or about 6-fold compared to BRCA1 expression.

[00168] In various embodiments, the reference value is based on a housekeeping gene expression in the cancer cell. Housekeeping genes are described herein.

[00169] In certain embodiments, the cancer is selected from breast cancer, ovarian
20 cancer and lung cancer.

[00170] Various embodiments of the present invention provide for a method for selecting a non-platinum-comprising therapy, and optionally administering the non-platinum-comprising therapy, for a subject having cancer comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression; detecting
25 the BLM and FANCI expression in the sample compared to a reference value; and selecting the non-platinum-comprising cancer therapy for the subject when the BLM and FANCI expression compared to the reference value is not increased based on the recognition that non-platinum-comprising cancer therapy is effective in patients whose cancer does not have increased gene expression of BLM and FANCI compared to the reference value.

30 [00171] In some aspects of all the embodiments of the invention a dual assay allowing analysis of both BLM and FANCI expression to be compared in the same assay is used. The dual assay may be based on detecting RNA or protein. The assay may be specific for the dual analysis of BLM and FANCI or may comprise reagents for assaying one, two, three or

more other biomolecules as well. In some aspects of all the embodiments of the invention the one other biomolecule is BRCA1.

5 [00172] In various embodiments, the method further comprises administering to the subject the non-platinum-comprising cancer therapy when non-platinum-comprising cancer therapy is selected.

[00173] In various embodiments, the reference value is based on BRCA1 gene expression in the cancer cell. In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

10 [00174] In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold 2.8-fold 2.9-fold or 3-fold compared to BRCA1 expression. In certain embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

15 [00175] In various embodiments, the reference value is based on a housekeeping gene expression in the cancer cell. Examples of housekeeping genes are described herein although these genes are well known to one of ordinary skill in the art.

20 [00176] In various embodiments, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[00177] Various embodiments of the present invention provide for an assay for selecting a therapy for a subject having cancer, comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression; comparing the BLM and FANCI expression, optionally in a dual assay, to a reference value; and
25 selecting an anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression is increased compared to a reference value based on the recognition that anthracycline-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI, or selecting a non-anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression is not increased compared to a
30 reference value based on the recognition that anthracycline-comprising cancer therapy is not effective in subjects whose cancer does not have increased BLM expression compared to a reference value.

[00178] Various embodiments of the present invention provide for a method for selecting an anthracycline-comprising cancer therapy for a subject having cancer and

determined to be negative for BRCA1 and BRCA2 mutations, comprising: subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression comparing the BLM and FANCI expression to a reference value; and selecting the anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression compared to the reference value is increased based on the recognition that anthracycline-comprising cancer therapy is effective in patients whose cancer has increased expression of BLM and FANCI compared to the reference value.

[00179] Various embodiments provide for an assay for selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising: assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number; comparing the chromosome 15q26 copy number to a reference value; and selecting a platinum-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or selecting a non-platinum-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.

[00180] In various embodiments, the assay further comprises assaying the BRCA1 and/or BRCA2 status of the subject; and selecting the platinum-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and there is a chromosome 15q26 copy number gain based on the recognition that platinum-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain who are negative for BRCA1 and/or BRCA2 mutations. In various embodiments, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations. The determination can be made before, concurrently with, or after the analysis for BLM and FANCI expression.

[00181] In various embodiments, the assay further comprises assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and selecting the platinum-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when there is a chromosome 15q26 copy number gain based on the recognition that platinum-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor. In various embodiments, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor. The

determination can be made before, concurrently with, or after analysis for chromosome 15q26 copy number.

[00182] In various embodiments, the assay further comprises administering the selected therapy to the subject.

5 [00183] In various embodiments, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[00184] In various embodiments, the reference value is chromosome 15 centromere copy number.

[00185] Various embodiments of the present invention provide for an assay for
10 selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising: assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number; comparing the chromosome 15q26 copy number to a reference value; and selecting an anthracycline-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or selecting
15 a non-anthracycline-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.

[00186] In various embodiments, the assay further comprises assaying the BRCA1 and/or BRCA2 status of the subject; and selecting the anthracycline-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations,
20 and there is a chromosome 15q26 copy number gain based on the recognition that anthracycline-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain and who are negative for BRCA1 and/or BRCA2 mutations. In various embodiments, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations. In some aspects of all the embodiments of the invention, a
25 mutation that inactivates BRCA2 is highly predictive of response to platinum-comprising cancer therapy. The determination can be made before, concurrently with, or after analysis for chromosome 15q26 copy number.

[00187] In various embodiments, the assay further comprises assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's
30 cancer; and selecting the anthracycline-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when there is a chromosome 15q26 copy number gain based on the recognition that anthracycline-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain and whose cancer does not express a detectable quantity of ER,

PgR, and HER2 receptor. In various embodiments, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor. The determination can be made before, concurrently with, or after analysis for chromosome 15q26 copy number.

5 [00188] In various embodiments, the assay further comprises administering the selected therapy to the subject.

[00189] In various embodiments, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[00190] In various embodiments, the reference value is chromosome 15 centromere
10 copy number.

Cancer Treatment

[00191] Various embodiments of the present invention provide for a method of treating cancer in a human subject, comprising: detecting BLM and FANCI expression in a sample
15 comprising a cancer cell taken from the human subject; and comparing the BLM and FANCI expression to a reference value; and administering a platinum-comprising cancer therapy to the human subject wherein an increase of BLM and FANCI expression compared to the reference value is detected.

[00192] In various embodiments, the cancer is selected from breast, ovarian, and lung
20 cancers.

[00193] In various embodiments, the reference value is based on BRCA1 gene expression in the cancer cell. In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

[00194] In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-
25 fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold 2.8-fold 2.9-fold or 3-fold compared to BRCA1 expression. In certain embodiments, the reference value is BRCA1 expression, and the BLM
30 and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[00195] In various embodiments, the reference value is based on a housekeeping gene expression in the cancer cell. Housekeeping genes are described herein.

[00196] In certain embodiments, the human subject's cancer or cancer cell is known to not or determined not to express detectable quantities of estrogen receptor (ER), progesterone

receptor (PgR) and HER2 receptor. The determination can be made before, concurrently with, or after analysis for chromosome 15q26 copy number.

[00197] Various embodiments of the present invention provide for a method of treating cancer in a human subject, comprising: detecting BLM and FANCI expression in a sample
5 comprising a cancer cell taken from the human subject; and comparing the BLM and FANCI expression to a reference value; and administering an anthracycline-comprising cancer therapy to the human subject wherein an increase of BLM and FANCI expression compared to the reference value is detected.

[00198] In various embodiments, the human subject's cancer is known to not or
10 determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor. The determination can be made before, concurrently with, or after analysis for chromosome 15q26 copy number.

[00199] In various embodiments, the cancer is selected from breast, ovarian, and lung cancers.

15 [00200] In various embodiments, the reference value is based on BRCA1 gene expression in the cancer cell. In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

[00201] In various embodiments, the reference value is BRCA1 expression, and the
20 BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold 2.8-fold 2.9-fold or 3-fold compared to BRCA1 expression. In certain embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

25 [00202] In various embodiments, the reference value is based on a housekeeping gene expression in the cancer cell. Housekeeping genes are described herein, e.g., in Table 1.

[00203] Various embodiments of the present invention provide for a method of treating cancer, comprising: assaying, in a cancer cell from a cancer patient or mRNA obtained
therefrom, the BLM and FANCI expression compared to a reference value; and administering
30 to the cancer patient a cancer treatment regimen comprising platinum or anthracycline if the BLM and FANCI expression is increased compared to the reference value.

[00204] Various embodiments provide for a use of platinum comprising cancer therapy for treating a cancer patient that has been determined to have a tumor comprising cancer cells wherein BLM and FANCI expression is increased compared to a reference value.

[00205] In various embodiments, the cancer patient is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations. The determination can be made before, concurrently with, or after the analysis for BLM and FANCI expression. In certain embodiments, the cancer patient's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor. The determination can be made before, concurrently with, or after analysis of BLM and FANCI expression.

[00206] Various embodiments of the present invention provide for a method of treating cancer in a human subject whose cancer has increased BLM and FANCI expression, comprising: identifying the human subject whose cancer has increased BLM and FANCI expression; and administering a platinum-comprising cancer therapy or an anthracycline-comprising therapy to the human subject. In certain embodiments, the human subject's cancer is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor. In various embodiments, the human subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations. These determinations can be made before, concurrently with, or after analysis of BLM and FANCI expression.

[00207] Various embodiments of the present invention provide for a method of treating cancer in a human subject, comprising: detecting a chromosome 15q26 copy number in a sample comprising a cancer cell taken from the subject; comparing the chromosome 15q26 copy number to a reference value; and administering an platinum-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or administering a non-platinum-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.

[00208] In various embodiments, the cancer is selected from breast cancer, ovarian cancer and lung cancer. In various embodiments, the reference value is chromosome 15 centromere copy number. In various embodiments, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor. The determination can be made before, concurrently with, or after analysis of chromosome 15q26 copy number.

[00209] Various embodiments of the present invention provide for a method of treating cancer in a human subject, comprising: detecting a chromosome 15q26 copy number in a sample comprising a cancer cell taken from the subject; comparing the chromosome 15q26

copy number to a reference value; and administering an anthracycline-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or administering a non-anthracycline-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome
5 15q26 copy number loss.

[00210] In various embodiments, the cancer is selected from breast cancer, ovarian cancer and lung cancer. In various embodiments, the reference value is chromosome 15 centromere copy number. In various embodiments, the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2
10 receptor. The determination can be made before, concurrently with, or after analysis of chromosome 15q26 copy number.

Assessing and predicting responsiveness to cancer therapy

[00211] Various embodiments of the present invention provide for a method for
15 assessing responsiveness of a cancer cell to cancer therapy, comprising: assaying, in a cancer cell or mRNA derived therefrom, BLM and FANCI expression; and comparing said BLM and FANCI expression to a reference value, wherein the cancer cell is assessed as responsive to a platinum-comprising therapy if the BLM and FANCI expression is increased compared to the reference value, or wherein the cancer cell is assessed as poorly or not responsive to
20 platinum-comprising cancer therapy cancer if the BLM and FANCI expression is not increased.

[00212] In various embodiments, the step of assaying comprises: contacting the cancer cell or mRNA derived therefrom with at least one detectably labeled probe capable of specifically binding to BLM mRNA, at least one detectably probe capable of specifically
25 binding to FANCI, at least one detectably labeled probe capable of specifically binding to BRCA1 and/or at least one housekeeping gene; and measuring the expression of BLM and FANCI compared to the BRCA1 and/or the at least one housekeeping gene.

[00213] In various embodiments, the reference value is based on BRCA1 gene expression in the cancer cell. In various embodiments, the reference value is BRCA1
30 expression, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

[00214] In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-

fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold 2.8-fold 2.9-fold or 3-fold compared to BRCA1 expression. In certain embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[00215] In various embodiments, the reference value is based on a housekeeping gene expression in the cancer cell. Housekeeping genes are described herein, e.g., in Table 1.

[00216] Various embodiments of the present invention provide for a method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising: determining, in a cancer cell from the cancer patient, BLM and FANCI expression; and correlating the expression to a reference value, wherein when the expression is increased the patient is predicted to respond well to a cancer treatment regimen comprising platinum or anthracycline.

[00217] In various embodiments, the reference value is based on BRCA1 gene expression in the cancer cell. In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

[00218] In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold 2.8-fold 2.9-fold or 3-fold compared to BRCA1 expression. In certain embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[00219] In various embodiments, the reference value is based on a housekeeping gene expression in the cancer cell. Housekeeping genes are described herein, e.g., in Table 1.

[00220] Various embodiments of the present invention provide for a method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising: determining, in a cancer cell or mRNA derived therefrom from said cancer patient, BLM and FANCI expression; and correlating the expression to a reference value, wherein when the expression is not increased the patient is predicted to respond poorly to a cancer treatment regimen comprising platinum or anthracycline.

[00221] In various embodiments, the reference value is based on BRCA1 gene expression in the cancer cell. In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

[00222] In various embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold 2.8-fold 2.9-fold or 3-fold compared to BRCA1 expression. In certain embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

[00223] In various embodiments, the reference value is based on a housekeeping gene expression in the cancer cell. Housekeeping genes are described herein.

[00224] Various embodiments provide for a method for assessing responsiveness of a cancer cell to a cancer therapy, and optionally administering the cancer therapy, comprising: assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number; and comparing the chromosome 15q26 copy number to a reference value, wherein the cancer cell is assessed as responsive to a platinum-comprising therapy if there is a chromosome 15q26 copy number gain compared to the reference value, or wherein the cancer cell is assessed as poorly or not responsive to platinum-comprising cancer therapy cancer if there is not a chromosome 15q26 copy number gain or if there is a chromosome 15q26 copy number loss.

[00225] In various embodiments, the reference value is chromosome 15 centromere copy number. In various embodiments, the cancer is selected from breast cancer, ovarian cancer and lung cancer.

[00226] In various embodiments, the method further comprises administering the platinum-comprising therapy if there is a chromosome 15q26 copy number gain.

[00227] Various embodiments provide for a method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising: determining, in a cancer cell from the cancer patient, chromosome 15q26 copy number; and correlating the chromosome 15q26 copy number to a reference value, wherein when there is a chromosome 15q26 copy number gain, the patient is predicted to respond well to a cancer treatment comprising platinum or anthracycline, or wherein when there is not a chromosome 15q26 copy number gain or a chromosome 15q26 copy number loss, the patient is predicted respond poorly to a cancer treatment comprising platinum or anthracycline.

[00228] In various embodiments, the reference value is chromosome 15 centromere copy number.

[00229] Various embodiments provide for the use of platinum comprising cancer therapy for treating a cancer patient that has been determined to have a tumor comprising

cancer cells wherein a chromosome 15q26 copy gain is detected compared to a reference value. In various embodiments, cancer patient is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations. The determination can be made before, concurrently with, or after the analysis for BLM and FANCI expression. In various embodiments, the cancer patient is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor. In various embodiments, the reference value is chromosome 15 centromere copy number.

Systems, computers, kits and uses

10 **[00230]** Various embodiments of the present invention provide for a system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising: a sample analyzer configured to produce a signal for the mRNA from each one of BLM and FANCI from a cancer cell sample of a cancer patient; and a computer sub-system programmed to calculate, based on the mRNA whether the signal is
15 greater or not than a reference value.

[00231] In various embodiments, said computer sub-system is programmed to compare the mRNA to determine a likelihood of responsiveness of said cancer cell to platinum-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a platinum-comprising therapy if the BLM and FANCI expression is increased
20 and as unlikely to respond to the platinum-comprising therapy if the BLM and FANCI expression is not increased; or a likelihood of responsiveness of said cancer cell to anthracycline-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a anthracycline-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the anthracycline-comprising therapy if the BLM and
25 FANCI expression is not increased.

[00232] Various embodiments of the present invention provide for a system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising: a sample analyzer configured to produce a signal for the protein from each one of BLM and FANCI from a cancer cell sample of a cancer patient; and
30 a computer sub-system programmed to calculate, based on the protein whether the signal is greater or not than a reference value.

[00233] In various embodiments, said computer sub-system is programmed to compare the protein to determine a likelihood of responsiveness of said cancer cell to platinum-comprising cancer therapy based on an algorithm that classifies the patient as likely to

respond to a platinum-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the platinum-comprising therapy if the BLM and FANCI expression is not increased; or a likelihood of responsiveness of said cancer cell to anthracycline-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a anthracycline-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the anthracycline-comprising therapy if the BLM and FANCI expression is not increased.

[00234] Various embodiments of the present invention provide for a computer program product embodied in a computer readable medium that, when executing on a computer, performs steps comprising: detecting the BLM and FANCI expression in sample comprising a cancer cell from a cancer patient; and comparing the BLM and FANCI expression to a reference value.

[00235] Various embodiments of the present invention provide for a diagnostic kit for detecting a likelihood of a cancer patient to respond to platinum- or anthracycline-comprising cancer therapy, comprising: no more than 10 probes comprising a combination of detectably labeled probes or primers for BLM and FANCI, and optionally for BRCA1 and/or at least one housekeeping gene; and the computer program product.

[00236] Various embodiments of the present invention provide for the use of a plurality of oligonucleotides comprising no more than 10 oligonucleotides capable of hybridizing to BLM and FANCI, and optionally to BRCA1 and/or at least one housekeeping gene, in a diagnostic kit for determining an increased likelihood that a cancer patient will respond to cancer treatment regimen comprising a platinum and/or anthracycline.

[00237] Various embodiments provide for a system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising: a sample analyzer configured to produce a signal for chromosome 15q26 copy number from a cancer cell sample of a cancer patient; and a computer sub-system programmed to calculate, based on the mRNA whether the signal is greater or not than a reference value.

[00238] In various embodiments, the computer sub-system is programmed to compare the mRNA to determine a likelihood of responsiveness of said cancer cell to platinum-comprising cancer therapy and/or or a anthracycline-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a platinum-comprising therapy if there is a chromosome 15q26 copy number gain and as unlikely to respond to the platinum-comprising therapy if there is not a chromosome 15q26 copy number gain or if there is a

chromosome 15q26 copy number loss. In various embodiments, the reference value is chromosome 15 centromere copy number.

[00239] Various embodiments of the present invention provide for a computer program product embodied in a computer readable medium that, when executing on a computer,
5 performs steps comprising: detecting chromosome 15q26 copy number in sample comprising a cancer cell from a cancer patient; and comparing the chromosome 15q26 copy number to a reference value. In various embodiments, the reference value is chromosome 15 centromere copy number.

[00240] Various embodiments of the present invention provide for a diagnostic kit for
10 detecting a likelihood of a cancer patient to respond to platinum- or anthracycline-comprising cancer therapy, comprising: no more than 10 probes comprising a combination of detectably labeled probes or primers for chromosome 15q26, and optionally for chromosome 15 centromere; and the computer program product of described herein.

[00241] Various embodiments of the present invention provide for the use of a
15 plurality of oligonucleotides comprising no more than 10 oligonucleotides capable of hybridizing to chromosome 15q26, and optionally for chromosome 15 centromere, in a diagnostic kit for determining an increased likelihood that a cancer patient will respond to cancer treatment regimen comprising a platinum and/or anthracycline.

20 *Reference values*

[00242] In various embodiments of the present invention, the reference value is based on BRCA1 gene expression in the cancer cell.

[00243] In various embodiments, the reference value for BLM expression or FANCI expression is BRCA1 expression.

[00244] In various embodiments, the reference value is BRCA1 expression, and the
25 BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to BRCA1 expression.

[00245] In various embodiments, the reference value is BRCA1 expression, and the
30 BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, or 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or 10-fold compared to BRCA1 expression. In certain embodiments, the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least or about two-fold to about 7-fold compared to BRCA1 expression.

[00246] In various embodiments of the present invention, the reference value can be one or more housekeeping gene as described herein. In certain embodiments, one or more housekeeping gene as described herein, and the BLM and/or FANCI expression is increased by at least or about 10, 20, 30, 40, 50, 60, 70, 80, or 90% compared to the one or more housekeeping gene expression.

[00247] In certain embodiments, one or more housekeeping gene as described herein, and the BLM and/or FANCI expression is increased by at least or about 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold 2.2-fold 2.3-fold 2.4-fold 2.5-fold, 2.6-fold, 2.7-fold 2.8-fold 2.9-fold or 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold or higher compared to the one or more housekeeping gene expression depending on the level of the expression of the housekeeping gene in the cell.

[00248] In various embodiments, the housekeeping gene can be selected from the group consisting of beta-actin, GAPDH, RPLP0, GUS, TFRC and combinations thereof.

(See e.g., Cronin et al., *Clinical Chemistry* 53:6, 1084–1091 (2007), and ONCOTYPE DX ASSAY®, herein incorporated by reference in its entirety.) Thus, in some embodiments, the house keeping gene is one of these genes, and in other embodiments, the housekeeping gene is a combination of 2, 3, 4, or all 5 of these genes. In particular embodiments, the housekeeping gene is RPLP0, also called 36b4.

[00249] In various embodiments, the house keeping gene can be selected from the genes listed in Table 1. Accordingly, in some embodiments, the housekeeping gene is one of the genes from Table 1, and in other embodiments, the housekeeping gene is a combination of any number or all of the genes from Table 1. (See e.g., Eisenberg and Levanon, *Human housekeeping genes are compact. Trends in Genetics*, Volume 19, Issue 7, 362-365, 1 July 2003). Each gene name/description is followed by its geometric average expression level according to the data published by Su et al. Thus, based on our experimental data on the RPLP0 housekeeping gene as a reference gene, one of ordinary skill in the art can easily determine what the cut-off points for increased expression for any one of these genes is. For example, genes designated by asterisk are in popular use as reference in real-time PCR or quantitative PCR (qPCR), which is most often used in gene expression analysis.

[00250] In some aspects of all the embodiments on the invention, the assays, methods, kits, and systems incorporate qPCR as the gene expression analysis method to determine the amount compared to a reference value.

Table 1. Housekeeping Genes.

Accession No.	Description
*NM_001101	Homo sapiens actin, beta (ACTB), mRNA 6988
*NM_000034	Homo sapiens aldolase A, fructose-bisphosphate (ALDOA), mRNA 3425
*NM_002046	Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPD), mRNA 828
*NM_000291	Homo sapiens phosphoglycerate kinase 1 (PGK1), mRNA 2727
*NM_005566	Homo sapiens lactate dehydrogenase A (LDHA), mRNA 2105
*NM_002954	Homo sapiens ribosomal protein S27a (RPS27A), mRNA 4156
*NM_000981	Homo sapiens ribosomal protein L19 (RPL19), mRNA 6997
*NM_000975	Homo sapiens ribosomal protein L11 (RPL11), mRNA 6060
*NM_007363	Homo sapiens non-POU domain containing, octamer-binding (NONO), mRNA 1708
*NM_004309	Homo sapiens Rho GDP dissociation inhibitor (GDI) alpha (ARHGDI), mRNA 1358
*NM_000994	Homo sapiens ribosomal protein L32 (RPL32), mRNA 9523
*NM_022551	Homo sapiens ribosomal protein S18 (RPS18), mRNA 11261
*NM_007355	Homo sapiens heat shock 90kDa protein 1, beta (HSPCB), mRNA 4119
NM_004515	Homo sapiens interleukin enhancer binding factor 2, 45kDa (ILF2), mRNA 1000
NM_004651	Homo sapiens ubiquitin specific protease 11 (USP11), mRNA 1950
NM_004888	Homo sapiens ATPase, H ⁺ transporting, lysosomal 13kDa, V1 subunit G isoform 1 (ATP6V1G1), mRNA 928
NM_003334	Homo sapiens ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing) (UBE1), transcript variant 1, mRNA 1351
NM_001320	Homo sapiens casein kinase 2, beta polypeptide (CSNK2B), mRNA 1233
NM_003915	Homo sapiens copine I (CPNE1), transcript variant 3, mRNA 698
NM_001250	Homo sapiens tumor necrosis factor receptor superfamily, member 5 (TNFRSF5), transcript variant 1, mRNA 524
NM_001904	Homo sapiens catenin (cadherin-associated protein), beta 1, 88kDa (CTNNB1), mRNA 1165
NM_003753	Homo sapiens eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa (EIF3S7), mRNA 1363
NM_004541	Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa (NDUFA1), nuclear gene encoding mitochondrial protein, mRNA 2307
NM_001654	Homo sapiens v-raf murine sarcoma 3611 viral oncogene homolog 1 (ARAF1), mRNA 846
NM_002967	Homo sapiens scaffold attachment factor B (SAFB), mRNA 545
NM_001183	Homo sapiens ATPase, H ⁺ transporting, lysosomal interacting protein 1 (ATP6IP1), mRNA 1089
NM_003526	Homo sapiens H2B histone family, member L (H2BFL), mRNA 2232
NM_004718	Homo sapiens cytochrome c oxidase subunit VIIa polypeptide 2 like (COX7A2L), nuclear gene encoding mitochondrial protein, mRNA 1013

NM_004436	Homo sapiens endosulfine alpha (ENSA), mRNA	659
NM_001207	Homo sapiens basic transcription factor 3 (BTF3), mRNA	3348
NM_004907	Homo sapiens immediate early protein (ETR101), mRNA	1249
NM_004889	Homo sapiens ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit f, isoform 2 (ATP5J2), mRNA	1513
NM_003769	Homo sapiens splicing factor, arginine/serine-rich 9 (SFRS9), mRNA	1207
NM_003910	Homo sapiens maternal G10 transcript (G10), mRNA	696
NM_000100	Homo sapiens cystatin B (stefin B) (CSTB), mRNA	1422
NM_004785	Homo sapiens solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulatory factor 2 (SLC9A3R2), mRNA	455
NM_001120	Homo sapiens tetracycline transporter-like protein (TETRAN), mRNA	935
NM_000182	Homo sapiens hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit (HADHA), mRNA	609
NM_003377	Homo sapiens vascular endothelial growth factor B (VEGFB), mRNA	649
NM_003576	Homo sapiens serine/threonine kinase 24 (STE20 homolog, yeast) (STK24), mRNA	769
NM_000918	Homo sapiens procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid hormone binding protein p55) (P4HB), mRNA	2719
NM_004584	Homo sapiens RAD9 homolog (<i>S. pombe</i>) (RAD9), mRNA	860
NM_004952	Homo sapiens ephrin-A3 (EFNA3), mRNA	505
NM_004308	Homo sapiens Rho GTPase activating protein 1 (ARHGAP1), mRNA	893
NM_003190	Homo sapiens TAP binding protein (tapasin) (TAPBP), mRNA	1213
NM_004640	Homo sapiens HLA-B associated transcript 1 (BAT1), transcript variant 1, mRNA	1022
NM_001064	Homo sapiens transketolase (Wernicke-Korsakoff syndrome) (TKT), mRNA	1139
NM_002117	Homo sapiens major histocompatibility complex, class I, C (HLA-C), mRNA	4696
NM_004161	Homo sapiens RAB1A, member RAS oncogene family (RAB1A), mRNA	2163
NM_003339	Homo sapiens ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) (UBE2D2), mRNA	514
NM_003969	Homo sapiens ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) (UBE2M), mRNA	1197
NM_000516	Homo sapiens GNAS complex locus (GNAS), transcript variant 1, mRNA	4358
NM_002819	Homo sapiens polypyrimidine tract binding protein 1 (PTBP1), transcript variant 1, mRNA	1138
NM_001001	Homo sapiens ribosomal protein L36a-like (RPL36AL), mRNA	1740
NM_004649	Homo sapiens chromosome 21 open reading frame 33 (C21orf33), mRNA	585
NM_000175	Homo sapiens glucose phosphate isomerase (GPI), mRNA	1633

NM_001867	Homo sapiens cytochrome c oxidase subunit VIIc (COX7C), nuclear gene encoding mitochondrial protein, mRNA 3004
NM_001967	Homo sapiens eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2), mRNA 2935
NM_001863	Homo sapiens cytochrome c oxidase subunit VIb (COX6B), nuclear gene encoding mitochondrial protein, mRNA 1719
NM_001997	Homo sapiens Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal protein S30 (FAU), mRNA 3898
NM_002088	Homo sapiens glutamate receptor, ionotropic, kainate 5 (GRIK5), mRNA 535
NM_001862	Homo sapiens cytochrome c oxidase subunit Vb (COX5B), nuclear gene encoding mitochondrial protein, mRNA 1087
NM_004255	Homo sapiens cytochrome c oxidase subunit Va (COX5A), nuclear gene encoding mitochondrial protein, mRNA 853
NM_001788	Homo sapiens CDC10 cell division cycle 10 homolog (S. cerevisiae) (CDC10), mRNA 1340
NM_004781	Homo sapiens vesicle-associated membrane protein 3 (cellubrevin) (VAMP3), mRNA 684
NM_003801	Homo sapiens GPAA1P anchor attachment protein 1 homolog (yeast) (GPAA1), mRNA 776
NM_004643	Homo sapiens poly(A) binding protein, nuclear 1 (PABPN1), mRNA 502
NM_001537	Homo sapiens heat shock factor binding protein 1 (HSBP1), mRNA 874
NM_003680	Homo sapiens tyrosyl-tRNA synthetase (YARS), mRNA 535
NM_003345	Homo sapiens ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) (UBE2I), mRNA 1283
NM_002568	Homo sapiens poly(A) binding protein, cytoplasmic 1 (PABPC1), mRNA 3199
NM_001487	Homo sapiens GCN5 general control of amino-acid synthesis 5-like 1 (yeast) (GCN5L1), mRNA 313
NM_001861	Homo sapiens cytochrome c oxidase subunit IV isoform 1 (COX4I1), nuclear gene encoding mitochondrial protein, mRNA 2738
NM_004890	Homo sapiens sperm associated antigen 7 (SPAG7), mRNA 618
NM_002812	Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 (PSMD8), mRNA 942
NM_004926	Homo sapiens zinc finger protein 36, C3H type-like 1 (ZFP36L1), mRNA 1168
NM_002539	Homo sapiens ornithine decarboxylase 1 (ODC1), mRNA 1361
NM_000979	Homo sapiens ribosomal protein L18 (RPL18), mRNA 4417
NM_000977	Homo sapiens ribosomal protein L13 (RPL13), transcript variant 1, mRNA 6407
NM_001015	Homo sapiens ribosomal protein S11 (RPS11), mRNA 7614
NM_001760	Homo sapiens cyclin D3 (CCND3), mRNA 676
NM_003973	Homo sapiens ribosomal protein L14 (RPL14), mRNA 3135
NM_002815	Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 (PSMD11), mRNA 536

NM_000367	Homo sapiens thiopurine S-methyltransferase (TPMT), mRNA 1574
NM_000973	Homo sapiens ribosomal protein L8 (RPL8), transcript variant 1, mRNA 8138
NM_004689	Homo sapiens metastasis associated 1 (MTA1), mRNA 506
NM_001848	Homo sapiens collagen, type VI, alpha 1 (COL6A1), mRNA 757
NM_004068	Homo sapiens adaptor-related protein complex 2, mu 1 subunit (AP2M1), mRNA 2188
NM_001687	Homo sapiens ATP synthase, H ⁺ transporting, mitochondrial F1 complex, delta subunit (ATP5D), mRNA 1167
NM_004197	Homo sapiens serine/threonine kinase 19 (STK19), transcript variant 1, mRNA 574
NM_001028	Homo sapiens ribosomal protein S25 (RPS25), mRNA 4683
NM_001022	Homo sapiens ribosomal protein S19 (RPS19), mRNA 6683
NM_004759	Homo sapiens mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), transcript variant 1, mRNA 641
NM_001623	Homo sapiens allograft inflammatory factor 1 (AIF1), transcript variant 3, mRNA 497
NM_004894	Homo sapiens chromosome 14 open reading frame 2 (C14orf2), mRNA 704
NM_002375	Homo sapiens microtubule-associated protein 4 (MAP4), transcript variant 1, mRNA 717
NM_001013	Homo sapiens ribosomal protein S9 (RPS9), mRNA 6868
NM_003779	Homo sapiens UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3 (B4GALT3), mRNA 565
NM_001296	Homo sapiens chemokine binding protein 2 (CCBP2), mRNA 394
NM_001009	Homo sapiens ribosomal protein S5 (RPS5), mRNA 6739
NM_003021	Homo sapiens small glutamine-rich tetratricopeptide repeat (TPR)- containing (SGT), mRNA 488
NM_004285	Homo sapiens hexose-6-phosphate dehydrogenase (glucose 1- dehydrogenase) (H6PD), mRNA 646
NM_004142	Homo sapiens matrix metalloproteinase-like 1 (MMPL1), mRNA 695
NM_001950	Homo sapiens E2F transcription factor 4, p107/p130-binding (E2F4), mRNA 956
NM_003815	Homo sapiens a disintegrin and metalloproteinase domain 15 (metargidin) (ADAM15), mRNA 771
NM_001119	Homo sapiens adducin 1 (alpha) (ADD1), transcript variant 1, mRNA 1356
NM_001111	Homo sapiens adenosine deaminase, RNA-specific (ADAR), transcript variant ADAR-a, mRNA 1036
NM_003466	Homo sapiens paired box gene 8 (PAX8), transcript variant PAX8A, mRNA 901
NM_001155	Homo sapiens annexin A6 (ANXA6), transcript variant 1, mRNA 718
NM_003465	Homo sapiens chitinase 1 (chitotriosidase) (CHIT1), mRNA 561
NM_003186	Homo sapiens transgelin (TAGLN), mRNA 1209
NM_000802	Homo sapiens folate receptor 1 (adult) (FOLR1), transcript variant 2, mRNA 514

NM_004924	Homo sapiens actinin, alpha 4 (ACTN4), mRNA	1187
NM_002931	Homo sapiens ring finger protein 1 (RING1), mRNA	576
NM_000020	Homo sapiens activin A receptor type II-like 1 (ACVRL1), mRNA	849
NM_001785	Homo sapiens cytidine deaminase (CDA), mRNA	391
NM_004339	Homo sapiens pituitary tumor-transforming 1 interacting protein (PTTG1IP), mRNA	1200
NM_003860	Homo sapiens Breakpoint cluster region protein, uterine leiomyoma, 1; barrier to autointegration factor (BCRP1), mRNA	1303
NM_000214	Homo sapiens jagged 1 (Alagille syndrome) (JAG1), mRNA	536
NM_002167	Homo sapiens inhibitor of DNA binding 3, dominant negative helix-loop-helix protein (ID3), mRNA	1192
NM_001664	Homo sapiens ras homolog gene family, member A (ARHA), mRNA	4050
NM_003166	Homo sapiens sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (SULT1A3), mRNA	461
NM_001746	Homo sapiens calnexin (CANX), mRNA	1923
NM_001662	Homo sapiens ADP-ribosylation factor 5 (ARF5), mRNA	724
NM_001660	Homo sapiens ADP-ribosylation factor 4 (ARF4), mRNA	1014
NM_001658	Homo sapiens ADP-ribosylation factor 1 (ARF1), mRNA	2195
NM_003313	Homo sapiens tissue specific transplantation antigen P35B (TSTA3), mRNA	440
NM_001494	Homo sapiens GDP dissociation inhibitor 2 (GDI2), mRNA	1352
NM_003145	Homo sapiens signal sequence receptor, beta (translocon-associated protein beta) (SSR2), mRNA	1265
NM_001619	Homo sapiens adrenergic, beta, receptor kinase 1 (ADRBK1), mRNA	695
NM_001420	Homo sapiens ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu antigen C) (ELAVL3), mRNA	1070
NM_004930	Homo sapiens capping protein (actin filament) muscle Z-line, beta (CAPZB), mRNA	1183
NM_004596	Homo sapiens small nuclear ribonucleoprotein polypeptide A (SNRPA), mRNA	734
NM_004168	Homo sapiens succinate dehydrogenase complex, subunit A, flavoprotein (Fp) (SDHA), nuclear gene encoding mitochondrial protein, mRNA	1106
NM_004156	Homo sapiens protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (PPP2CB), mRNA	1195
NM_004910	Homo sapiens phosphatidylinositol transfer protein, membrane-associated (PITPNM), mRNA	869
NM_004517	Homo sapiens integrin-linked kinase (ILK), mRNA	654
NM_004494	Homo sapiens hepatoma-derived growth factor (high-mobility group protein 1-like) (HDGF), mRNA	1385
NM_004121	Homo sapiens gamma-glutamyltransferase-like activity 1 (GGTLA1), mRNA	412
NM_004404	Homo sapiens neural precursor cell expressed, developmentally down-regulated 5 (NEDD5), mRNA	1571
NM_004394	Homo sapiens death-associated protein (DAP), mRNA	623
NM_004383	Homo sapiens c-src tyrosine kinase (CSK), mRNA	899

NM_004074	Homo sapiens cytochrome c oxidase subunit VIII (COX8), nuclear gene encoding mitochondrial protein, mRNA 3188
NM_004039	Homo sapiens annexin A2 (ANXA2), mRNA 2417
NM_001053	Homo sapiens somatostatin receptor 5 (SSTR5), mRNA 423
NM_001328	Homo sapiens C-terminal binding protein 1 (CTBP1), mRNA 798
NM_001273	Homo sapiens chromodomain helicase DNA binding protein 4 (CHD4), mRNA 775
NM_003430	Homo sapiens zinc finger protein 91 (HPF7, HTF10) (ZNF91), mRNA 716
NM_003314	Homo sapiens tetratricopeptide repeat domain 1 (TTC1), mRNA 651
NM_003217	Homo sapiens testis enhanced gene transcript (TEGT), mRNA 1766
NM_003132	Homo sapiens spermidine synthase (SRM), mRNA 1093
NM_000199	Homo sapiens N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH), mRNA 565
NM_002818	Homo sapiens proteasome (prosome, macropain) activator subunit 2 (PA28 beta) (PSME2), mRNA 697
NM_002733	Homo sapiens protein kinase, AMP-activated, gamma 1 non-catalytic subunit (PRKAG1), mRNA 497
NM_002631	Homo sapiens phosphogluconate dehydrogenase (PGD), mRNA 1009
NM_002574	Homo sapiens peroxiredoxin 1 (PRDX1), mRNA 2241
NM_002512	Homo sapiens non-metastatic cells 2, protein (NM23B) expressed in (NME2), nuclear gene encoding mitochondrial protein, mRNA 2553
NM_002455	Homo sapiens metaxin 1 (MTX1), mRNA 845
NM_002444	Homo sapiens moesin (MSN), mRNA 1798
NM_000529	Homo sapiens melanocortin 2 receptor (adrenocorticotrophic hormone) (MC2R), mRNA 420
NM_003573	Homo sapiens latent transforming growth factor beta binding protein 4 (LTBP4), mRNA 740
NM_002315	Homo sapiens LIM domain only 1 (rhombotin 1) (LMO1), mRNA 469
NM_000884	Homo sapiens IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2), mRNA 1288
NM_003641	Homo sapiens interferon induced transmembrane protein 1 (9-27) (IFITM1), mRNA 4898
NM_000841	Homo sapiens glutamate receptor, metabotropic 4 (GRM4), mRNA 1369
NM_002070	Homo sapiens guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2), mRNA 1877
NM_001493	Homo sapiens GDP dissociation inhibitor 1 (GDI1), mRNA 1387
NM_002048	Homo sapiens growth arrest-specific 1 (GAS1), mRNA 940
NM_002032	Homo sapiens ferritin, heavy polypeptide 1 (FTH1), mRNA 2616
NM_001418	Homo sapiens eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2), mRNA 3646
NM_001350	Homo sapiens death-associated protein 6 (DAXX), mRNA 510

NM_001843	Homo sapiens contactin 1 (CNTN1), mRNA	535
NM_001728	Homo sapiens basigin (BSG), mRNA	1508
NM_001667	Homo sapiens ADP-ribosylation factor-like 2 (ARL2), mRNA	965
NM_001659	Homo sapiens ADP-ribosylation factor 3 (ARF3), mRNA	1327
NM_003746	Homo sapiens dynein, cytoplasmic, light polypeptide 1 (DNCL1), mRNA	2758
NM_002127	Homo sapiens HLA-G histocompatibility antigen, class I, G (HLA-G), mRNA	1090
NM_004712	Homo sapiens hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), mRNA	505
NM_003475	Homo sapiens chromosome 11 open reading frame 13 (C11orf13), mRNA	413
NM_004046	Homo sapiens ATP synthase, H ⁺ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1), mRNA	1348
NM_001894	Homo sapiens casein kinase 1, epsilon (CSNK1E), transcript variant 2, mRNA	613
NM_003795	Homo sapiens sorting nexin 3 (SNX3), transcript variant 1, mRNA	1426
NM_001909	Homo sapiens cathepsin D (lysosomal aspartyl protease) (CTSD), mRNA	1512
NM_002792	Homo sapiens proteasome (prosome, macropain) subunit, alpha type, 7 (PSMA7), transcript variant 1, mRNA	728
NM_002799	Homo sapiens proteasome (prosome, macropain) subunit, beta type, 7 (PSMB7), mRNA	545
NM_002300	Homo sapiens lactate dehydrogenase B (LDHB), mRNA	4144
NM_004176	Homo sapiens sterol regulatory element binding transcription factor 1 (SREBF1), mRNA	632
NM_002796	Homo sapiens proteasome (prosome, macropain) subunit, beta type, 4 (PSMB4), mRNA	1229
NM_002794	Homo sapiens proteasome (prosome, macropain) subunit, beta type, 2 (PSMB2), mRNA	1304
NM_002793	Homo sapiens proteasome (prosome, macropain) subunit, beta type, 1 (PSMB1), mRNA	2084
NM_002473	Homo sapiens myosin, heavy polypeptide 9, non-muscle (MYH9), mRNA	1381
NM_001810	Homo sapiens centromere protein B, 80kDa (CENPB), mRNA	532
NM_002624	Homo sapiens prefoldin 5 (PFDN5), transcript variant 1, mRNA	1718
NM_004710	Homo sapiens synaptogyrin 2 (SYNGR2), mRNA	1414
NM_001127	Homo sapiens adaptor-related protein complex 1, beta 1 subunit (AP1B1), transcript variant 1, mRNA	873
NM_002107	Homo sapiens H3 histone, family 3A (H3F3A), mRNA	9328
NM_003899	Homo sapiens Rho guanine nucleotide exchange factor (GEF) 7 (ARHGEF7), transcript variant 1, mRNA	558
NM_003406	Homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ), transcript variant	

	1, mRNA 2008
NM_002419	Homo sapiens mitogen-activated protein kinase kinase kinase 11 (MAP3K11), mRNA 535
NM_001130	Homo sapiens amino-terminal enhancer of split (AES), mRNA 2395
NM_003379	Homo sapiens villin 2 (ezrin) (VIL2), mRNA 1356
NM_002636	Homo sapiens PHD finger protein 1 (PHF1), transcript variant 1, mRNA 640
NM_002622	Homo sapiens prefoldin 1 (PFDN1), mRNA 658
NM_001823	Homo sapiens creatine kinase, brain (CKB), mRNA 1407
NM_003405	Homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide (YWHAH), mRNA 2195
NM_002939	Homo sapiens ribonuclease/angiogenin inhibitor (RNH), mRNA 726
NM_003562	Homo sapiens solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11 (SLC25A11), mRNA 517
NM_001916	Homo sapiens cytochrome c-1 (CYC1), mRNA 895
NM_002823	Homo sapiens prothymosin, alpha (gene sequence 28) (PTMA), mRNA 3723
NM_003096	Homo sapiens small nuclear ribonucleoprotein polypeptide G (SNRPG), mRNA 687
NM_003321	Homo sapiens Tu translation elongation factor, mitochondrial (TUFM), mRNA 1543
NM_003404	Homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide (YWHAB), transcript variant 1, mRNA 1144
NM_002946	Homo sapiens replication protein A2, 32kDa (RPA2), mRNA 537
NM_004356	Homo sapiens CD81 antigen (target of antiproliferative antibody 1) (CD81), mRNA 3638
NM_001743	Homo sapiens calmodulin 2 (phosphorylase kinase, delta) (CALM2), mRNA 4675
NM_004231	Homo sapiens ATPase, H ⁺ transporting, lysosomal 14kDa, V1 subunit F (ATP6V1F), mRNA 997
NM_004893	Homo sapiens H2A histone family, member Y (H2AFY), transcript variant 2, mRNA 788
NM_004146	Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa (NDUFB7), mRNA 967
NM_002128	Homo sapiens high-mobility group box 1 (HMGB1), mRNA 1295
NM_002002	Homo sapiens Fc fragment of IgE, low affinity II, receptor for (CD23A) (FCER2), mRNA 969
NM_000858	Homo sapiens guanylate kinase 1 (GUK1), mRNA 1166
NM_001469	Homo sapiens thyroid autoantigen 70kDa (Ku antigen) (G22P1), mRNA 1684
NM_003766	Homo sapiens beclin 1 (coiled-coil, myosin-like BCL2 interacting protein) (BECN1), mRNA 948
NM_003906	Homo sapiens MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) associated protein (MCM3AP), mRNA 430

NM_000757	Homo sapiens colony stimulating factor 1 (macrophage) (CSF1), mRNA 797
NM_002149	Homo sapiens hippocalcin-like 1 (HPCAL1), transcript variant 1, mRNA 1026
NM_001694	Homo sapiens ATPase, H ⁺ transporting, lysosomal 16kDa, V0 subunit c (ATP6V0C), mRNA 2105
NM_004047	Homo sapiens ATPase, H ⁺ transporting, lysosomal 21kDa, V0 subunit c" (ATP6V0B), mRNA 1212
NM_001696	Homo sapiens ATPase, H ⁺ transporting, lysosomal 31kDa, V1 subunit E isoform 1 (ATP6V1E1), mRNA 784
NM_001865	Homo sapiens cytochrome c oxidase subunit VIIa polypeptide 2 (liver) (COX7A2), nuclear gene encoding mitochondrial protein, mRNA 1818
NM_004373	Homo sapiens cytochrome c oxidase subunit VIa polypeptide 1 (COX6A1), nuclear gene encoding mitochondrial protein, mRNA 5529
NM_000801	Homo sapiens FK506 binding protein 1A, 12kDa (FKBP1A), transcript variant 12B, mRNA 4273
NM_000992	Homo sapiens ribosomal protein L29 (RPL29), mRNA 6060
NM_000988	Homo sapiens ribosomal protein L27 (RPL27), mRNA 6101
NM_001004	Homo sapiens ribosomal protein, large P2 (RPLP2), mRNA 5924
NM_001003	Homo sapiens ribosomal protein, large, P1 (RPLP1), mRNA 10300
NM_000405	Homo sapiens GM2 ganglioside activator protein (GM2A), mRNA 1250
NM_000967	Homo sapiens ribosomal protein L3 (RPL3), mRNA 7416
NM_001428	Homo sapiens enolase 1, (alpha) (ENO1), mRNA 3668
NM_000999	Homo sapiens ribosomal protein L38 (RPL38), mRNA 8302
NM_000997	Homo sapiens ribosomal protein L37 (RPL37), mRNA 6689
NM_000995	Homo sapiens ribosomal protein L34 (RPL34), transcript variant 1, mRNA 5424
NM_002948	Homo sapiens ribosomal protein L15 (RPL15), mRNA 5450
NM_002952	Homo sapiens ribosomal protein S2 (RPS2), mRNA 8825
NM_001026	Homo sapiens ribosomal protein S24 (RPS24), transcript variant 2, mRNA 5701
NM_001020	Homo sapiens ribosomal protein S16 (RPS16), mRNA 7477
NM_001018	Homo sapiens ribosomal protein S15 (RPS15), mRNA 6261
NM_001017	Homo sapiens ribosomal protein S13 (RPS13), mRNA 5430
NM_000969	Homo sapiens ribosomal protein L5 (RPL5), mRNA 4653
NM_000985	Homo sapiens ribosomal protein L17 (RPL17), mRNA 4369
NM_000937	Homo sapiens polymerase (RNA) II (DNA directed) polypeptide A, 220kDa (POLR2A), mRNA 753
NM_001016	Homo sapiens ribosomal protein S12 (RPS12), mRNA 8265
NM_002140	Homo sapiens heterogeneous nuclear ribonucleoprotein K (HNRPK), transcript variant 1, mRNA 2429
NM_002138	Homo sapiens heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa) (HNRPD), transcript variant 3, mRNA 1157
NM_004499	Homo sapiens heterogeneous nuclear ribonucleoprotein A/B (HNRPAB),

	transcript variant 2, mRNA	654
NM_001014	Homo sapiens ribosomal protein S10 (RPS10), mRNA	8074
NM_002383	Homo sapiens MYC-associated zinc finger protein (purine-binding transcription factor) (MAZ), mRNA	2580
NM_002467	Homo sapiens v-myc myelocytomatosis viral oncogene homolog (avian) (MYC), mRNA	537
NM_001436	Homo sapiens fibrillarlin (FBL), mRNA	1408
NM_004069	Homo sapiens adaptor-related protein complex 2, sigma 1 subunit (AP2S1), transcript variant AP17, mRNA	979
NM_001614	Homo sapiens actin, gamma 1 (ACTG1), mRNA	6560
NM_002355	Homo sapiens mannose-6-phosphate receptor (cation dependent) (M6PR), mRNA	388
NM_004597	Homo sapiens small nuclear ribonucleoprotein D2 polypeptide 16.5kDa (SNRPD2), mRNA	1136
NM_002308	Homo sapiens lectin, galactoside-binding, soluble, 9 (galectin 9) (LGALS9), transcript variant short, mRNA	888
NM_000398	Homo sapiens diaphorase (NADH) (cytochrome b-5 reductase) (DIA1), nuclear gene encoding mitochondrial protein, transcript variant M, mRNA	2190
NM_000754	Homo sapiens catechol-O-methyltransferase (COMT), transcript variant MB-COMT, mRNA	845
NM_002406	Homo sapiens mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT1), mRNA	893
NM_003752	Homo sapiens eukaryotic translation initiation factor 3, subunit 8, 110kDa (EIF3S8), mRNA	1871
NM_001355	Homo sapiens D-dopachrome tautomerase (DDT), mRNA	631
NM_004960	Homo sapiens fusion, derived from t(12;16) malignant liposarcoma (FUS), mRNA	1019
NM_004729	Homo sapiens Ac-like transposable element (ALTE), mRNA	963
NM_004587	Homo sapiens ribosome binding protein 1 homolog 180kDa (dog) (RRBP1), mRNA	658
NM_004552	Homo sapiens NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa (NADH-coenzyme Q reductase) (NDUFS5), mRNA	936
NM_004450	Homo sapiens enhancer of rudimentary homolog (Drosophila) (ERH), mRNA	1028
NM_004048	Homo sapiens beta-2-microglobulin (B2M), mRNA	4992
NM_000239	Homo sapiens lysozyme (renal amyloidosis) (LYZ), mRNA	796
NM_000269	Homo sapiens non-metastatic cells 1, protein (NM23A) expressed in (NME1), mRNA	887
NM_000431	Homo sapiens mevalonate kinase (mevalonic aciduria) (MVK), mRNA	753
NM_001247	Homo sapiens ectonucleoside triphosphate diphosphohydrolase 6 (putative function) (ENTPD6), mRNA	495
NM_003365	Homo sapiens ubiquinol-cytochrome c reductase core protein I (UQCRC1), mRNA	1026
NM_003329	Homo sapiens thioredoxin (TXN), mRNA	1002
NM_001069	Homo sapiens tubulin, beta polypeptide (TUBB), mRNA	1013
NM_000356	Homo sapiens Treacher Collins-Franceschetti syndrome 1 (TCOF1), mRNA	673

NM_003134	Homo sapiens signal recognition particle 14kDa (homologous Alu RNA binding protein) (SRP14), mRNA 2911
NM_003131	Homo sapiens serum response factor (c-fos serum response element-binding transcription factor) (SRF), mRNA 664
NM_000454	Homo sapiens superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) (SOD1), mRNA 1739
NM_003091	Homo sapiens small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB), mRNA 1609
NM_003089	Homo sapiens small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen) (SNRP70), mRNA 1672
NM_003016	Homo sapiens splicing factor, arginine/serine-rich 2 (SFRS2), mRNA 1476
NM_003952	Homo sapiens ribosomal protein S6 kinase, 70kDa, polypeptide 2 (RPS6KB2), mRNA 476
NM_002950	Homo sapiens ribophorin I (RPN1), mRNA 495
NM_002743	Homo sapiens protein kinase C substrate 80K-H (PRKCSH), mRNA 691
NM_002686	Homo sapiens phenylethanolamine N-methyltransferase (PNMT), mRNA 501
NM_002654	Homo sapiens pyruvate kinase, muscle (PKM2), mRNA 2474
NM_002648	Homo sapiens pim-1 oncogene (PIM1), mRNA 1052
NM_002635	Homo sapiens solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 (SLC25A3), nuclear gene encoding mitochondrial protein, transcript variant 1b, mRNA 2310
NM_002494	Homo sapiens NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa (NDUFC1), mRNA 2247
NM_002488	Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa (NDUFA2), mRNA 689
NM_002434	Homo sapiens N-methylpurine-DNA glycosylase (MPG), mRNA 1808
NM_002415	Homo sapiens macrophage migration inhibitory factor (glycosylation-inhibiting factor) (MIF), mRNA 3774
NM_002227	Homo sapiens Janus kinase 1 (a protein tyrosine kinase) (JAK1), mRNA 990
NM_001536	Homo sapiens HMT1 hnRNP methyltransferase-like 2 (S. cerevisiae) (HRMT1L2), mRNA 832
NM_000183	Homo sapiens hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit (HADHB), mRNA 1087
NM_002085	Homo sapiens glutathione peroxidase 4 (phospholipid hydroperoxidase) (GPX4), mRNA 1279
NM_001502	Homo sapiens glycoprotein 2 (zymogen granule membrane) (GP2), mRNA 572
NM_002080	Homo sapiens glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2) (GOT2), nuclear gene encoding mitochondrial protein, mRNA 1000
NM_001440	Homo sapiens exostoses (multiple)-like 3 (EXTL3), mRNA 592
NM_003754	Homo sapiens eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa (EIF3S5), mRNA 1585

NM_003755	Homo sapiens eukaryotic translation initiation factor 3, subunit 4 delta, 44kDa (EIF3S4), mRNA 1085
NM_003757	Homo sapiens eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa (EIF3S2), mRNA 622
NM_001360	Homo sapiens 7-dehydrocholesterol reductase (DHCR7), mRNA 653
NM_001344	Homo sapiens defender against cell death 1 (DAD1), mRNA 812
NM_001914	Homo sapiens cytochrome b-5 (CYB5), nuclear gene encoding mitochondrial protein, mRNA 667
NM_001834	Homo sapiens clathrin, light polypeptide (Lcb) (CLTB), transcript variant nonbrain, mRNA 447
NM_001833	Homo sapiens clathrin, light polypeptide (Lca) (CLTA), transcript variant nonbrain, mRNA 1315
NM_001281	Homo sapiens cytoskeleton-associated protein 1 (CKAP1), mRNA 1066
NM_001749	Homo sapiens calpain, small subunit 1 (CAPNS1), mRNA 1308
NM_001697	Homo sapiens ATP synthase, H ⁺ transporting, mitochondrial F1 complex, O subunit (oligomycin sensitivity conferring protein) (ATP5O), mRNA 1155
NM_001689	Homo sapiens ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit c (subunit 9) isoform 3 (ATP5G3), mRNA 1152
NM_001675	Homo sapiens activating transcription factor 4 (tax-responsive enhancer element B67) (ATF4), mRNA 1392
NM_001642	Homo sapiens amyloid beta (A4) precursor-like protein 2 (APLP2), mRNA 1341
NM_014724	Homo sapiens zinc finger protein 305 (ZNF305), mRNA 719
NM_005494	Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 6 (DNAJB6), transcript variant 2, mRNA 923
NM_006597	Homo sapiens heat shock 70kDa protein 8 (HSPA8), transcript variant 1, mRNA 1650
NM_006623	Homo sapiens phosphoglycerate dehydrogenase (PHGDH), mRNA 888
NM_015646	Homo sapiens RAP1B, member of RAS oncogene family (RAP1B), mRNA 736
NM_016532	Homo sapiens skeletal muscle and kidney enriched inositol phosphatase (SKIP), transcript variant 1, mRNA 1529
NM_015292	Homo sapiens likely ortholog of mouse membrane bound C2 domain containing protein (MBC2), mRNA 475
NM_005870	Homo sapiens sin3-associated polypeptide, 18kDa (SAP18), mRNA 1651
NM_006833	Homo sapiens COP9 subunit 6 (MOV34 homolog, 34 kD) (COPS6), mRNA 1338
NM_005718	Homo sapiens actin related protein 2/3 complex, subunit 4, 20kDa (ARPC4), mRNA 433
NM_005719	Homo sapiens actin related protein 2/3 complex, subunit 3, 21kDa (ARPC3), mRNA 949
NM_006372	Homo sapiens NS1-associated protein 1 (NSAP1), mRNA 704
NM_005180	Homo sapiens B lymphoma Mo-MLV insertion region (mouse) (BM11), mRNA 732

NM_018975	Homo sapiens telomeric repeat binding factor 2, interacting protein (TERF2IP), mRNA 684
NM_005731	Homo sapiens actin related protein 2/3 complex, subunit 2, 34kDa (ARPC2), transcript variant 2, mRNA 2262
NM_020151	Homo sapiens START domain containing 7 (STARD7), transcript variant 1, mRNA 1562
NM_005103	Homo sapiens fasciculation and elongation protein zeta 1 (zygin I) (FEZ1), transcript variant 1, mRNA 672
NM_012179	Homo sapiens F-box only protein 7 (FBXO7), mRNA 865
NM_020360	Homo sapiens phospholipid scramblase 3 (PLSCR3), mRNA 3645
NM_014891	Homo sapiens PDGFA associated protein 1 (PDAP1), mRNA 1045
NM_005745	Homo sapiens accessory protein BAP31 (DXS1357E), mRNA 1525
NM_005418	Homo sapiens suppression of tumorigenicity 5 (ST5), transcript variant 1, mRNA 2305
NM_006262	Homo sapiens peripherin (PRPH), mRNA 484
NM_133476	Homo sapiens zinc finger protein 384 (ZNF384), mRNA 448
NM_006570	Homo sapiens Ras-related GTP-binding protein (RAGA), mRNA 903
NM_006333	Homo sapiens nuclear DNA-binding protein (CID), mRNA 740
NM_007285	Homo sapiens GABA(A) receptor-associated protein-like 2 (GABARAPL2), mRNA 1265
NM_006354	Homo sapiens transcriptional adaptor 3-like (TADA3L) transcript variant 1, mRNA 1060
NM_014302	Homo sapiens Sec61 gamma (SEC61G), mRNA 644
NM_006118	Homo sapiens HS1 binding protein (HAX1), mRNA 1493
NM_012100	Homo sapiens aspartyl aminopeptidase (DNPEP), mRNA 419
NM_015680	Homo sapiens hypothetical protein CGI-57 (CGI-57), mRNA 976
NM_030796	Homo sapiens hypothetical protein DKFZp564K0822 (DKFZP564K0822), mRNA 572
NM_024069	Homo sapiens hypothetical protein MGC2749 (MGC2749), mRNA 573
NM_013234	Homo sapiens muscle specific gene (M9), mRNA 1056
NM_013310	Homo sapiens hypothetical protein AF038169 (AF038169), mRNA 1319
NM_018507	Homo sapiens hypothetical protein PRO1843 (PRO1843), mRNA 1081
NM_017670	Homo sapiens hypothetical protein FLJ20113 (FLJ20113), mRNA 999
NM_016292	Homo sapiens heat shock protein 75 (TRAP1), mRNA 615
NM_014916	Homo sapiens KIAA1079 protein (KIAA1079), mRNA 772
NM_014696	Homo sapiens KIAA0514 gene product (KIAA0514), mRNA 746
NM_014630	Homo sapiens KIAA0211 gene product (KIAA0211), mRNA 750
NM_014761	Homo sapiens KIAA0174 gene product (KIAA0174), mRNA 679
NM_007286	Homo sapiens synaptopodin (KIAA1029), mRNA 1349
NM_007263	Homo sapiens coatomer protein complex, subunit epsilon (COPE), mRNA 1272
NM_006349	Homo sapiens putative cyclin G1 interacting protein (CG1I), mRNA 591
NM_006004	Homo sapiens ubiquinol-cytochrome c reductase hinge protein (UQCRH), mRNA 1285
NM_005787	Homo sapiens Not56 (D. melanogaster)-like protein (NOT56L), mRNA 458

NM_012412	Homo sapiens histone H2A.F/Z variant (H2AV), transcript variant 1, mRNA 1070
NM_012401	Homo sapiens plexin B2 (PLXNB2), mRNA 929
NM_007262	Homo sapiens RNA-binding protein regulatory subunit (DJ-1), mRNA 1514
NM_007273	Homo sapiens repressor of estrogen receptor activity (REA), mRNA 1804
NM_021009	Homo sapiens ubiquitin C (UBC), mRNA 8892
NM_023009	Homo sapiens macrophage myristoylated alanine-rich C kinase substrate (MACMARCKS), mRNA 2025
NM_015456	Homo sapiens cofactor of BRCA1 (COBRA1), mRNA 848
NM_005053	Homo sapiens RAD23 homolog A (S. cerevisiae) (RAD23A), mRNA 1015
NM_006830	Homo sapiens ubiquinol-cytochrome c reductase (6.4kD) subunit (UQCR), mRNA 1489
NM_005682	Homo sapiens G protein-coupled receptor 56 (GPR56), mRNA 742
NM_012102	Homo sapiens arginine-glutamic acid dipeptide (RE) repeats (RERE), mRNA 940
NM_005550	Homo sapiens kinesin family member C3 (KIFC3), mRNA 603
NM_021960	Homo sapiens myeloid cell leukemia sequence 1 (BCL2-related) (MCL1), mRNA 961
NM_021959	Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 11 (PPP1R11), mRNA 462
NM_014730	Homo sapiens KIAA0152 gene product (KIAA0152), mRNA 713
NM_014402	Homo sapiens low molecular mass ubiquinone-binding protein (9.5kD) (QP-C), mRNA 2805
NM_007067	Homo sapiens histone acetyltransferase (HBOA), mRNA 510
NM_006086	Homo sapiens tubulin, beta, 4 (TUBB4), mRNA 2239
NM_014972	Homo sapiens KIAA1049 protein (KIAA1049), mRNA 1011
NM_024092	Homo sapiens hypothetical protein MGC5508 (MGC5508), mRNA 749
NM_021983	Homo sapiens major histocompatibility complex, class II, DR beta 4 (HLA-DRB4), mRNA 1095
NM_006510	Homo sapiens ret finger protein (RFP), transcript variant alpha, mRNA 420
NM_006711	Homo sapiens RNA binding protein S1, serine-rich domain (RNPS1), transcript variant 1, mRNA 1376
NM_006145	Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1), mRNA 667
NM_033142	Homo sapiens chorionic gonadotropin, beta polypeptide 7 (CGB7), mRNA 773
NM_006351	Homo sapiens translocase of inner mitochondrial membrane 44 homolog (yeast) (TIMM44), mRNA 717
NM_014281	Homo sapiens fuse-binding protein-interacting repressor (SIAHBP1), transcript variant 2, mRNA 632
NM_012106	Homo sapiens binder of Arl Two (BART1), mRNA 760
NM_021975	Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, p65 (avian) (RELA), mRNA 767

NM_014874	Homo sapiens mitofusin 2 (MFN2), mRNA	453
NM_006796	Homo sapiens AFG3 ATPase family gene 3-like 2 (yeast) (AFG3L2), nuclear gene encoding mitochondrial protein, mRNA	724
NM_006666	Homo sapiens RuvB-like 2 (E. coli) (RUVBL2), mRNA	690
NM_005219	Homo sapiens diaphanous homolog 1 (Drosophila) (DIAPH1), mRNA	592
NM_033546	Homo sapiens myosin regulatory light chain (MLC-B), mRNA	1231
NM_032348	Homo sapiens hypothetical protein MGC3047 (MGC3047), mRNA	553
NM_024798	Homo sapiens hypothetical protein FLJ13952 (FLJ13952), mRNA	2142
NM_021103	Homo sapiens thymosin, beta 10 (TMSB10), mRNA	1890
NM_020195	Homo sapiens HCDI protein (HCDI), mRNA	612
NM_017432	Homo sapiens prostate tumor over expressed gene 1 (PTOV1), mRNA	1509
NM_014901	Homo sapiens KIAA1100 protein (KIAA1100), mRNA	1999
NM_014694	Homo sapiens KIAA0605 gene product (KIAA0605), mRNA	532
NM_007369	Homo sapiens G-protein coupled receptor (RE2), mRNA	963
NM_006156	Homo sapiens neural precursor cell expressed, developmentally down-regulated 8 (NEDD8), mRNA	867
NM_006429	Homo sapiens chaperonin containing TCP1, subunit 7 (eta) (CCT7), mRNA	1434
NM_006513	Homo sapiens seryl-tRNA synthetase (SARS), mRNA	1130
NM_005022	Homo sapiens profilin 1 (PFN1), mRNA	2793
NM_014654	Homo sapiens syndecan 3 (N-syndecan) (SDC3), mRNA	1082
NM_007209	Homo sapiens ribosomal protein L35 (RPL35), mRNA	3463
NM_006082	Homo sapiens tubulin, alpha, ubiquitous (K-ALPHA-1), mRNA	4261
NM_006362	Homo sapiens nuclear RNA export factor 1 (NXF1), mRNA	729
NM_014228	Homo sapiens solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 (SLC6A7), mRNA	1037
NM_006411	Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha) (AGPAT1), mRNA	742
NM_021134	Homo sapiens mitochondrial ribosomal protein L23 (MRPL23), mRNA	771
NM_021974	Homo sapiens polymerase (RNA) II (DNA directed) polypeptide F (POLR2F), mRNA	1169
NM_006808	Homo sapiens protein translocation complex beta (SEC61B), mRNA	679
NM_005617	Homo sapiens ribosomal protein S14 (RPS14), mRNA	7764
NM_005520	Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (H) (HNRPH1), mRNA	2234
NM_006755	Homo sapiens transaldolase 1 (TALDO1), mRNA	874
NM_006010	Homo sapiens arginine-rich, mutated in early stage tumors (ARMET), mRNA	617
NM_005088	Homo sapiens DNA segment on chromosome X and Y (unique) 155 expressed sequence (DXYS155E), mRNA	524
NM_014754	Homo sapiens phosphatidylserine synthase 1 (PTDSS1), mRNA	930
NM_021953	Homo sapiens forkhead box M1 (FOXM1), mRNA	567

NM_006908	Homo sapiens ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) (RAC1), transcript variant Rac1, mRNA 1978
NM_014231	Homo sapiens vesicle-associated membrane protein 1 (synaptobrevin 1) (VAMP1), transcript variant VAMP-1A, mRNA 745
NM_014833	Homo sapiens KIAA0618 gene product (KIAA0618), mRNA 607
NM_005157	Homo sapiens v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), transcript variant a, mRNA 777
NM_006325	Homo sapiens RAN, member RAS oncogene family (RAN), mRNA 3100
NM_007245	Homo sapiens ataxin 2 related protein (A2LP), transcript variant 1, mRNA 564
NM_007008	Homo sapiens reticulon 4 (RTN4), mRNA 1267
NM_006782	Homo sapiens zinc finger protein-like 1 (ZFPL1), mRNA 712
NM_006694	Homo sapiens jumping translocation breakpoint (JTB), mRNA 2394
NM_006703	Homo sapiens nudix (nucleoside diphosphate linked moiety X)-type motif 3 (NUDT3), mRNA 566
NM_006032	Homo sapiens copine VI (neuronal) (CPNE6), mRNA 1540
NM_012227	Homo sapiens Pseudoautosomal GTP-binding protein-like (PGPL), mRNA 494
NM_014604	Homo sapiens Tax interaction protein 1 (TIP-1), mRNA 748
NM_021642	Homo sapiens Fc fragment of IgG, low affinity IIa, receptor for (CD32) (FCGR2A), mRNA 772
NM_005354	Homo sapiens jun D proto-oncogene (JUND), mRNA 4967
NM_020529	Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA), mRNA 922
NM_005561	Homo sapiens lysosomal-associated membrane protein 1 (LAMP1), mRNA 2865
NM_014774	Homo sapiens KIAA0494 gene product (KIAA0494), mRNA 604
NM_014390	Homo sapiens EBNA-2 co-activator (100kD) (p100), mRNA 867
NM_014623	Homo sapiens male-enhanced antigen (MEA), mRNA 548
NM_014453	Homo sapiens putative breast adenocarcinoma marker (32kD) (BC-2), mRNA 597
NM_012127	Homo sapiens Cip1-interacting zinc finger protein (CIZ1), mRNA 1051
NM_012099	Homo sapiens CD3-epsilon-associated protein; antisense to ERCC-1 (ASE-1), mRNA 472
NM_006888	Homo sapiens calmodulin 1 (phosphorylase kinase, delta) (CALM1), mRNA 2161
NM_006867	Homo sapiens RNA-binding protein gene with multiple splicing (RBPMS), mRNA 1255
NM_006743	Homo sapiens RNA binding motif protein 3 (RBM3), mRNA 2949
NM_006688	Homo sapiens C1q-related factor (CRF), mRNA 3604
NM_006295	Homo sapiens valyl-tRNA synthetase 2 (VAR2), mRNA 721
NM_006283	Homo sapiens transforming, acidic coiled-coil containing protein 1 (TACC1), mRNA 867
NM_006221	Homo sapiens protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1 (PIN1), mRNA 561

NM_006148	Homo sapiens LIM and SH3 protein 1 (LASP1), mRNA	1067
NM_005954	Homo sapiens metallothionein 3 (growth inhibitory factor (neurotrophic)) (MT3), mRNA	2311
NM_006003	Homo sapiens ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 (UQCRFS1), nuclear gene encoding mitochondrial protein, mRNA	951
NM_005998	Homo sapiens chaperonin containing TCP1, subunit 3 (gamma) (CCT3), mRNA	1098
NM_005997	Homo sapiens transcription factor-like 1 (TCFL1), mRNA	505
NM_005629	Homo sapiens solute carrier family 6 (neurotransmitter transporter, creatine), member 8 (SLC6A8), mRNA	628
NM_005548	Homo sapiens lysyl-tRNA synthetase (KARS), mRNA	1193
NM_005545	Homo sapiens immunoglobulin superfamily containing leucine-rich repeat (ISLR), mRNA	796
NM_005507	Homo sapiens cofilin 1 (non-muscle) (CFL1), mRNA	5155
NM_005381	Homo sapiens nucleolin (NCL), mRNA	2043
NM_005439	Homo sapiens myeloid leukemia factor 2 (MLF2), mRNA	697
NM_006445	Homo sapiens PRP8 pre-mRNA processing factor 8 homolog (yeast) (PRPF8), mRNA	1384
NM_019059	Homo sapiens homolog of Tom7 (S. cerevisiae) (TOM7), mRNA	2364
NM_006039	Homo sapiens mannose receptor, C type 2 (MRC2), mRNA	564
NM_006066	Homo sapiens aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1), transcript variant 1, mRNA	879
NM_013318	Homo sapiens hypothetical protein LQFBS-1 (LQFBS-1), mRNA	485
NM_006098	Homo sapiens guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 (GNB2L1), mRNA	7556
NM_007359	Homo sapiens MLN51 protein (MLN51), mRNA	975
NM_017510	Homo sapiens gp25L2 protein (HSGP25L2G), mRNA	1032
NM_015399	Homo sapiens breast cancer metastasis-suppressor 1 (BRMS1), mRNA	476
NM_014508	Homo sapiens apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C (APOBEC3C), mRNA	816
NM_018955	Homo sapiens ubiquitin B (UBB), mRNA	6074
NM_006368	Homo sapiens cAMP responsive element binding protein 3 (luman) (CREB3), mRNA	533
NM_015024	Homo sapiens RAN binding protein 16 (RANBP16), mRNA	559
NM_031420	Homo sapiens mitochondrial ribosomal protein L9 (MRPL9), nuclear gene encoding mitochondrial protein, mRNA	476
NM_013232	Homo sapiens programmed cell death 6 (PDCD6), mRNA	816
NM_005917	Homo sapiens malate dehydrogenase 1, NAD (soluble) (MDH1), mRNA	1724
NM_032801	Homo sapiens junctional adhesion molecule 3 (JAM3), mRNA	624
NM_030662	Homo sapiens mitogen-activated protein kinase kinase 2 (MAP2K2), mRNA	663
NM_006268	Homo sapiens requiem, apoptosis response zinc finger gene (REQ), mRNA	784
NM_006826	Homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase	

	activation protein, theta polypeptide (YWHAQ), mRNA 1917
NM_144582	Homo sapiens hypothetical protein MGC32043 (MGC32043), mRNA 712
NM_144565	Homo sapiens hypothetical protein FLJ32334 (FLJ32334), mRNA 5319
NM_005984	Homo sapiens solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 (SLC25A1), mRNA 620
NM_017828	Homo sapiens hypothetical protein FLJ20452 (FLJ20452), mRNA 546
NM_020150	Homo sapiens SAR1 protein (SAR1), mRNA 581
NM_014610	Homo sapiens alpha glucosidase II alpha subunit (G2AN), mRNA 1293
NM_014225	Homo sapiens protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (PPP2R1A), mRNA 1687
NM_006937	Homo sapiens SMT3 suppressor of mif two 3 homolog 2 (yeast) (SMT3H2), mRNA 2940
NM_005726	Homo sapiens Ts translation elongation factor, mitochondrial (TSFM), mRNA 408
NM_005347	Homo sapiens heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) (HSPA5), mRNA 1111
NM_014255	Homo sapiens transmembrane protein 4 (TMEM4), mRNA 505
NM_006815	Homo sapiens coated vesicle membrane protein (RNP24), mRNA 1642
NM_005456	Homo sapiens mitogen-activated protein kinase 8 interacting protein 1 (MAPK8IP1), mRNA 885
NM_005273	Homo sapiens guanine nucleotide binding protein (G protein), beta polypeptide 2 (GNB2), mRNA 1478
NM_007260	Homo sapiens lysophospholipase II (LYPLA2), mRNA 2000
NM_007103	Homo sapiens NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa (NDUFV1), mRNA 803
NM_017797	Homo sapiens BTB (POZ) domain containing 2 (BTBD2), mRNA 1030
NM_016237	Homo sapiens anaphase promoting complex subunit 5 (ANAPC5), mRNA 935
NM_005801	Homo sapiens putative translation initiation factor (SUI1), mRNA 1058
NM_005216	Homo sapiens dolichyl-diphosphooligosaccharide-protein glycosyltransferase (DDOST), mRNA 1421
NM_016457	Homo sapiens protein kinase D2 (PKD2), mRNA 662
NM_006442	Homo sapiens DR1-associated protein 1 (negative cofactor 2 alpha) (DRAP1), mRNA 561
NM_021019	Homo sapiens myosin, light polypeptide 6, alkali, smooth muscle and non-muscle (MYL6), transcript variant 1, mRNA 5933
NM_005112	Homo sapiens WD repeat domain 1 (WDR1), transcript variant 2, mRNA 809
NM_005370	Homo sapiens mel transforming oncogene (derived from cell line NK14)-RAB8 homolog (MEL), mRNA 682
NM_006289	Homo sapiens talin 1 (TLN1), mRNA 1811
NM_005698	Homo sapiens secretory carrier membrane protein 3 (SCAMP3), transcript variant 1, mRNA 602
NM_024011	Homo sapiens cell division cycle 2-like 2 (CDC2L2), transcript variant 1, mRNA 430

NM_005105	Homo sapiens RNA binding motif protein 8A (RBM8A), mRNA 785
NM_006013	Homo sapiens ribosomal protein L10 (RPL10), mRNA 10721
NM_005786	Homo sapiens serologically defined colon cancer antigen 33 (SDCCAG33), mRNA 1435
NM_007104	Homo sapiens ribosomal protein L10a (RPL10A), mRNA 3006
NM_005762	Homo sapiens tripartite motif-containing 28 (TRIM28), mRNA 1473
NM_012138	Homo sapiens apoptosis antagonizing transcription factor (AATF), mRNA 504
NM_015318	Homo sapiens Rho-specific guanine nucleotide exchange factor p114 (P114-RHO-GEF), mRNA 405
NM_012423	Homo sapiens ribosomal protein L13a (RPL13A), mRNA 9545
NM_021128	Homo sapiens polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa (POLR2L), mRNA 1524
NM_032635	Homo sapiens seven transmembrane domain protein (NIFIE14), mRNA 1121
NM_005080	Homo sapiens X-box binding protein 1 (XBP1), mRNA 1772
NM_006389	Homo sapiens hypoxia up-regulated 1 (HYOU1), mRNA 1076
NM_024112	Homo sapiens chromosome 9 open reading frame 16 (C9orf16), mRNA 598
NM_006817	Homo sapiens chromosome 12 open reading frame 8 (C12orf8), mRNA 910
NM_022830	Homo sapiens hypothetical protein FLJ22347 (FLJ22347), mRNA 6021
NM_019884	Homo sapiens glycogen synthase kinase 3 alpha (GSK3A), mRNA 963
NM_021107	Homo sapiens mitochondrial ribosomal protein S12 (MRPS12), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA 828
NM_021074	Homo sapiens NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa (NDUFV2), mRNA 539
NM_014944	Homo sapiens calsyntenin 1 (CLSTN1), mRNA 1620
NM_014764	Homo sapiens DAZ associated protein 2 (DAZAP2), mRNA 1802
NM_015343	Homo sapiens likely ortholog of Xenopus dullard (HSA011916), mRNA 933
NM_014420	Homo sapiens dickkopf homolog 4 (Xenopus laevis) (DKK4), mRNA 426
NM_005884	Homo sapiens p21(CDKN1A)-activated kinase 4 (PAK4), mRNA 375
NM_012407	Homo sapiens protein kinase C, alpha binding protein (PRKCABP), mRNA 553
NM_012111	Homo sapiens chromosome 14 open reading frame 3 (C14orf3), mRNA 717
NM_007144	Homo sapiens zinc finger protein 144 (Mel-18) (ZNF144), mRNA 798
NM_007108	Homo sapiens transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B) (TCEB2), mRNA 1192
NM_007278	Homo sapiens GABA(A) receptor-associated protein (GABARAP), mRNA 2335
NM_007100	Homo sapiens ATP synthase, H ⁺ transporting, mitochondrial F0 complex, subunit e (ATP5I), mRNA 2623

NM_006936	Homo sapiens SMT3 suppressor of mif two 3 homolog 1 (yeast) (SMT3H1), mRNA 1187
NM_006899	Homo sapiens isocitrate dehydrogenase 3 (NAD+) beta (IDH3B), mRNA 565
NM_006801	Homo sapiens KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 (KDEL1), mRNA 1270
NM_006612	Homo sapiens kinesin family member 1C (KIF1C), mRNA 600
NM_006659	Homo sapiens tubulin, gamma complex associated protein 2 (TUBGCP2), mRNA 701
NM_006595	Homo sapiens apoptosis inhibitor 5 (API5), mRNA 1173
NM_006401	Homo sapiens acidic (leucine-rich) nuclear phosphoprotein 32 family, member B (ANP32B), mRNA 2354
NM_006423	Homo sapiens Rab acceptor 1 (prenylated) (RABAC1), mRNA 1706
NM_006460	Homo sapiens HMBA-inducible (HIS1), mRNA 369
NM_006356	Homo sapiens ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d (ATP5H), mRNA 1047
NM_005891	Homo sapiens acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase) (ACAT2), mRNA 911
NM_005839	Homo sapiens serine/arginine repetitive matrix 1 (SRRM1), mRNA 745
NM_005594	Homo sapiens nascent-polypeptide-associated complex alpha polypeptide (NACA), mRNA 3678
NM_005340	Homo sapiens histidine triad nucleotide binding protein 1 (HINT1), mRNA 2270
NM_005175	Homo sapiens ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 (ATP5G1), mRNA 1266
NM_005165	Homo sapiens aldolase C, fructose-bisphosphate (ALDOC), mRNA 1052
NM_005001	Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDa (NDUFA7), mRNA 806
NM_001402	
NM_001958	
NM_001961	
NM_002714	
NM_002808	
NM_002809	
NM_004898	
NM_007182	
NM_032378	

[00251] In various embodiments of the present invention, the reference value is chromosome 15 centromere copy number. In various embodiments, the reference value for chromosome 15q26 copy number is chromosome 15 centromere copy number.

- 5 **[00252]** The chromosome 15q26 copy number and chromosome 15 centromere copy number can be ascertained by various methods. For example, they can be ascertained through chip based measurements with or without a normal reference, or by using

centromeric FISH probes, which is an assay for testing for copy number changes using microscopy.

[00253] In various embodiments, the number of chromosome 15 centromere probes is compared to the number of 15q26.1 probes, in each cell using a microscope. If the numbers match, there is no relative gain of 15q26. Increase in this context can be a numerical increase, e.g., 2 \rightarrow 3 copies. In various embodiments, copy gain can be defined by the absolute copy number determined in an interphase FISH assay averaged by counting a minimum of 20 tumor cells. In various embodiments, copy gain can be defined as the ratio of 15q26/centromere 15 determined in an interphase FISH assay counting both spots (15q26 and cent15) in the same cells and averaging over a minimum of 20 cells. In various embodiments, copy gain can be determined using a normalized genome wide assay such as SNP array, genome sequencing and the like, wherein the normalization is done using the ASCAT algorithm or other appropriate algorithms. In various embodiments, the cutpoints can be anything above normal, which is 2 absolute copies of 15q26, or ratio > 1 for 15q26/cent15. Due to the typical noise in these assays, in certain embodiments, the cutoff is defined by adding a standard error. Accordingly, copy > 2.6 or ratio > 1.3 signify copy number gain.

[00254] Thus, in various embodiments, a copy number gain of over 2.6 or a ratio of over 1.3 indicates a copy number gain in the sample.

[00255] In other embodiments, the reference value for chromosome 15q26 is determined from a non-cancer cell sample from the subject or a member of the same species to which the subject belongs. In certain embodiments, the reference value is determined from a non-cancerous cell or tissue sample that is the same type of cell or tissue as the cancer cell from the subject. In certain embodiments, the reference value is determined from a non-cancerous cell or tissue sample that is not the same type of cell or tissue as the cancer cell from the subject. In various embodiments, array-based or sequencing-based technologies can be used wherein the reference can be from patients' normal cells (e.g., blood), or it can be a collection of blood samples.

[00256] Copy number abnormalities can be detected using methods, such as, for example, array CGH using BAC, cDNA and/or oligonucleotide arrays; microsatellite markers; STRs, RFLPS; etc.

[00257] Additional methods for evaluating copy number of nucleic acid in a sample include, but are not limited to, hybridization-based assays. One method for evaluating the copy number of encoding nucleic acid in a sample involves a Southern Blot. In a Southern

Blot, the genomic DNA (typically fragmented and separated on an electrophoretic gel) is hybridized to a probe specific for the target region. Comparison of the intensity of the hybridization signal from the probe for the target region with control probe signal from analysis of normal genomic DNA (*e.g.*, a non-amplified portion of the same or related cell, tissue, organ, *etc.*) provides an estimate of the relative copy number of the target nucleic acid. Alternatively, a Northern blot may be utilized for evaluating the copy number of encoding nucleic acid in a sample. In a Northern blot, mRNA is hybridized to a probe specific for the target region. Comparison of the intensity of the hybridization signal from the probe for the target region with control probe signal from analysis of normal mRNA (*e.g.*, a non-amplified portion of the same or related cell, tissue, organ, *etc.*) provides an estimate of the relative copy number of the target nucleic acid. Similar methods for determining copy number can be performed using transcriptional arrays, which are well-known in the art.

[00258] An alternative means for determining the copy number is *in situ* hybridization (*e.g.*, Angerer (1987) *Meth. Enzymol* 152: 649). Generally, *in situ* hybridization comprises the following steps: (1) fixation of tissue or biological structure to be analyzed; (2) prehybridization treatment of the biological structure to increase accessibility of target DNA, and to reduce nonspecific binding; (3) hybridization of the mixture of nucleic acids to the nucleic acid in the biological structure or tissue; (4) post-hybridization washes to remove nucleic acid fragments not bound in the hybridization and (5) detection of the hybridized nucleic acid fragments. The reagent used in each of these steps and the conditions for use vary depending on the particular application.

[00259] Preferred hybridization-based assays include, but are not limited to, traditional “direct probe” methods such as Southern blots or *in situ* hybridization (*e.g.*, FISH and FISH plus SKY), and “comparative probe” methods such as comparative genomic hybridization (CGH), *e.g.*, cDNA-based or oligonucleotide-based CGH. The methods can be used in a wide variety of formats including, but not limited to, substrate (*e.g.* membrane or glass) bound methods or array-based approaches.

[00260] In a typical *in situ* hybridization assay, cells are fixed to a solid support, typically a glass slide. If a nucleic acid is to be probed, the cells are typically denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of labeled probes specific to the nucleic acid sequence encoding the protein. The targets (*e.g.*, cells) are then typically washed at a predetermined stringency or at an increasing stringency until an appropriate signal to noise ratio is obtained.

[00261] The probes are typically labeled, *e.g.*, with radioisotopes or fluorescent reporters. Preferred probes are sufficiently long so as to specifically hybridize with the target nucleic acid(s) under stringent conditions. The preferred size range is from about 200 bases to about 1000 bases.

5 [00262] In some applications it is necessary to block the hybridization capacity of repetitive sequences. Thus, in some embodiments, tRNA, human genomic DNA, or Cot-I DNA is used to block non-specific hybridization.

[00263] In CGH methods, a first collection of nucleic acids (*e.g.*, from a sample, *e.g.*, a possible tumor) is labeled with a first label, while a second collection of nucleic acids (*e.g.*, a control, *e.g.*, from a healthy cell/tissue) is labeled with a second label. The ratio of hybridization of the nucleic acids is determined by the ratio of the two (first and second) labels binding to each fiber in the array. Where there are chromosomal deletions or multiplications, differences in the ratio of the signals from the two labels will be detected and the ratio will provide a measure of the copy number. Array-based CGH may also be performed with single-color labeling (as opposed to labeling the control and the possible tumor sample with two different dyes and mixing them prior to hybridization, which will yield a ratio due to competitive hybridization of probes on the arrays). In single color CGH, the control is labeled and hybridized to one array and absolute signals are read, and the possible tumor sample is labeled and hybridized to a second array (with identical content) and absolute signals are read. Copy number difference is calculated based on absolute signals from the two arrays. Hybridization protocols suitable for use with the methods of the invention are described, *e.g.*, in Albertson (1984) *EMBO J.* 3: 1227-1234; Pinkel (1988) *Proc. Natl. Acad. Sci. USA* 85: 9138-9142; EPO Pub. No. 430,402; *Methods in Molecular Biology*, Vol. 33: *In situ* Hybridization Protocols, Choo, ed., Humana Press, Totowa, N.J. (1994), *etc.* In one embodiment, the hybridization protocol of Pinkel, *et al.* (1998) *Nature Genetics* 20: 207-211, or of Kallioniemi (1992) *Proc. Natl Acad Sci USA* 89:5321-5325 (1992) is used.

10
15
20
25

[00264] The methods of the invention are particularly well suited to array-based hybridization formats. Array-based CGH is described in U.S. Patent No. 6,455,258, the contents of which are incorporated herein by reference. In still another embodiment, amplification-based assays can be used to measure copy number. In such amplification-based assays, the nucleic acid sequences act as a template in an amplification reaction (*e.g.*, Polymerase Chain Reaction (PCR)). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample.

30

Comparison to appropriate controls, *e.g.* healthy tissue, provides a measure of the copy number.

[00265] Methods of “quantitative” amplification are well known to those of skill in the art. For example, quantitative PCR involves simultaneously co-amplifying a known quantity of a control sequence using the same primers. This provides an internal standard that may be used to calibrate the PCR reaction. Detailed protocols for quantitative PCR are provided in Innis, *et al.* (1990) *PCR Protocols, A Guide to Methods and Applications*, Academic Press, Inc. N.Y.). Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis is described in Ginzonger, *et al.* (2000) *Cancer Research* 60:5405-5409. The known nucleic acid sequence for the genes is sufficient to enable one of skill in the art to routinely select primers to amplify any portion of the gene. Fluorogenic quantitative PCR may also be used in the methods of the invention. In fluorogenic quantitative PCR, quantitation is based on amount of fluorescence signals, *e.g.*, TaqMan and sybr green.

[00266] Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu and Wallace (1989) *Genomics* 4: 560, Landegren, *et al.* (1988) *Science* 241:1077, and Barringer *et al.* (1990) *Gene* 89: 117), transcription amplification (Kwoh, *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86: 1173), self-sustained sequence replication (Guatelli, *et al.* (1990) *Proc. Nat. Acad. Sci. USA* 87: 1874), dot PCR, and linker adapter PCR, *etc.*

[00267] In still other embodiments of the methods provided herein, sequencing of individual nucleic molecules (or their amplification products) is performed, as an alternative to hybridization-based assays, using nucleic acid sequencing techniques. In one embodiment, a high throughput parallel sequencing technique that isolates single nucleic acid molecules of a population of nucleic acid molecules prior to sequencing may be used. Such strategies may use so-called “next generation sequencing systems” including, without limitation, sequencing machines and/or strategies well known in the art, such as those developed by Illumina/Solexa (the Genome Analyzer; Bennett *et al.* (2005) *Pharmacogenomics*, 6:373-20 382), by Applied Biosystems, Inc. (the SOLiD Sequencer; solid.appliedbiosystems.com), by Roche (*e.g.*, the 454 GS FLX sequencer; Margulies *et al.* (2005) *Nature*, 437:376-380; U.S. Pat. Nos. 6,274,320; 6,258,568; 6,210,891), by Heliscope™ system from Helicos Biosciences (see, *e.g.*, U.S. Patent App. Pub. No. 2007/0070349), and by others. Other sequencing strategies such as stochastic sequencing (*e.g.*, as developed by Oxford Nanopore) may also be used, *e.g.*, as described in International Application No. PCT/GB2009/001690 (pub. no. WO/2010/004273). All of the copy number determining strategies described herein can

similarly be applied to any of other nucleic acid-based analysis described herein, such as for BLM, FANCI, or 15q26 the like described further below.

Therapies

5 [00268] These therapies can be selected, used, administered, etc., in accordance with various embodiment of the present invention.

[00269] Platinum-comprising therapy, include but are not limited platinum
chemotherapeutic agents, such as cisplatin, carboplatin, oxaliplatin, nedaplatin, and
iproplatin. Other antineoplastic platinum coordination compounds are well known in the art,
10 can be modified according to well- known methods in the art, and include the compounds
disclosed in U.S. Pat. Nos. 4,996,337, 4,946,954, 5,091,521, 5,434,256, 5,527,905, and
5,633,243, all of which are incorporated herein by reference. In various embodiments
described herein, the platinum comprising cancer therapy comprises cisplatin or cis-
diamminedichloroplatinum, phenanthriplatin, carboplatin, oxaliplatin, or a platinum complex
15 that is activated by ultraviolet A light.

[00270] In various embodiments, non-platinum comprising therapies include, non-
platinum chemotherapy. Non-platinum chemotherapy may be, but is not limited to, those
selected from among the following groups of compounds: cytotoxic antibiotics,
antimetabolites, anti-mitotic agents, alkylating agents, arsenic compounds, DNA
20 topoisomerase inhibitors, taxanes, nucleoside analogues, plant alkaloids, and toxins; and
synthetic derivatives thereof. Exemplary compounds include, but are not limited to,
alkylating agents: treosulfan, and trofosfamide; plant alkaloids: vinblastine, paclitaxel,
docetaxol; DNA topoisomerase inhibitors: doxorubicin, epirubicin, etoposide, camptothecin,
topotecan, irinotecan, teniposide, crisnatol, and mitomycin; anti-folates: methotrexate,
25 mycophenolic acid, and hydroxyurea; pyrimidine analogs: 5-fluorouracil, doxifluridine, and
cytosine arabinoside; purine analogs: mercaptopurine and thioguanine; DNA antimetabolites:
2'-deoxy-5-fluorouridine, aphidicolin glycinate, and pyrazoloimidazole; and antimitotic
agents: halichondrin, colchicine, and rhizoxin. Compositions comprising one or more
chemotherapeutic agents (*e.g.*, FLAG, CHOP) may also be used. FLAG comprises
30 fludarabine, cytosine arabinoside (Ara-C) and G-CSF. CHOP comprises cyclophosphamide,
vincristine, doxorubicin, and prednisone. In another embodiments, PARP (*e.g.*, PARP-1
and/or PARP-2) inhibitors are used and such inhibitors are well known in the art (*e.g.*,
Olaparib, ABT-888, BSI-201, BGP-15 (N-Gene Research Laboratories, Inc.); INO-1001
(Inotek Pharmaceuticals Inc.); PJ34 (Soriano *et al.*, 2001; Pacher *et al.*, 2002b); 3-

aminobenzamide (Trevigen); 4-amino-1,8-naphthalimide; (Trevigen); 6(5H)-phenanthridinone (Trevigen); benzamide (U.S. Pat. Re. 36,397); and NU1025 (Bowman et al.). The foregoing examples of non-platinum chemotherapeutic agents are illustrative, and are not intended to be limiting.

5 [00271] In various embodiments, non-platinum comprising therapies include, for example, radiation therapy. The radiation used in radiation therapy can be ionizing radiation. Radiation therapy can also be gamma rays, X-rays, or proton beams. Examples of radiation therapy include, but are not limited to, external-beam radiation therapy, interstitial
10 implantation of radioisotopes (I-125, palladium, iridium), radioisotopes such as strontium-89, thoracic radiation therapy, intraperitoneal P-32 radiation therapy, and/or total abdominal and pelvic radiation therapy. For a general overview of radiation therapy, see Hellman, Chapter 16: Principles of Cancer Management: Radiation Therapy, 6th edition, 2001, DeVita et al., eds., J. B. Lippencott Company, Philadelphia. The radiation therapy can be administered as external beam radiation or teletherapy wherein the radiation is directed from a remote source.
15 The radiation treatment can also be administered as internal therapy or brachytherapy wherein a radioactive source is placed inside the body close to cancer cells or a tumor mass. Also encompassed is the use of photodynamic therapy comprising the administration of photosensitizers, such as hematoporphyrin and its derivatives, Vertoporphin (BPD-MA), phthalocyanine, photosensitizer Pc4, demethoxy-hypocrellin A; and 2BA-2-DMHA.

20 [00272] In various embodiments, non-platinum comprising therapies include, for example, immunotherapy. Immunotherapy may comprise, for example, use of cancer vaccines and/or sensitized antigen presenting cells. The immunotherapy can involve passive immunity for short-term protection of a host, achieved by the administration of pre-formed antibody directed against a cancer antigen or disease antigen (*e.g.*, administration of a
25 monoclonal antibody, optionally linked to a chemotherapeutic agent or toxin, to a tumor antigen). Immunotherapy can also focus on using the cytotoxic lymphocyte-recognized epitopes of cancer cell lines.

[00273] In various embodiments, non-platinum comprising therapies include, for example, hormonal therapy, Hormonal therapeutic treatments can comprise, for example,
30 hormonal agonists, hormonal antagonists (*e.g.*, flutamide, bicalutamide, tamoxifen, raloxifene, leuprolide acetate (LUPRON), LH-RH antagonists), inhibitors of hormone biosynthesis and processing, and steroids (*e.g.*, dexamethasone, retinoids, deltoids, betamethasone, cortisol, cortisone, prednisone, dehydrotestosterone, glucocorticoids, mineralocorticoids, estrogen, testosterone, progestins), vitamin A derivatives (*e.g.*, all-trans

retinoic acid (ATRA)); vitamin D3 analogs; antigestagens (*e.g.*, mifepristone, onapristone), or antiandrogens (*e.g.*, cyproterone acetate).

[00274] In various embodiments described herein, the anthracycline is epirubicin or doxorubicin.

5 [00275] The duration and/or dose of treatment with anti-cancer therapies may vary according to the particular anti-cancer agent or combination thereof. An appropriate treatment time for a particular cancer therapeutic agent will be appreciated by the skilled artisan. The invention contemplates the continued assessment of optimal treatment schedules for each cancer therapeutic agent, where the genetic signature of the cancer of the subject as
10 determined by the methods of the invention is a factor in determining optimal treatment doses and schedules.

Cancers for which the genetic signature can be determined

[00276] The methods of the invention can be used to determine the genetic signature of
15 many different cancers. Specific examples of types of cancers for which the genetic signature can be determined by the methods encompassed by the invention include, but are not limited to, human sarcomas and carcinomas, *e.g.*, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma,
20 mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct
25 carcinoma, liver cancer, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, bone cancer, brain tumor, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma; leukemias, *e.g.*,
30 acute lymphocytic leukemia and acute myelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, and heavy chain disease.

[00277] In some embodiments, the cancer whose genetic signature is determined by the method of the invention is an epithelial cancer such as, but not limited to, bladder cancer, breast cancer, cervical cancer, colon cancer, gynecologic cancers, renal cancer, laryngeal cancer, lung cancer, oral cancer, head and neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, or skin cancer. In other embodiments, the cancer is breast cancer, prostate cancer, lung cancer, or colon cancer. In still other embodiments, the epithelial cancer is non-small-cell lung cancer, nonpapillary renal cell carcinoma, cervical carcinoma, ovarian carcinoma (e.g., serous ovarian carcinoma), or breast carcinoma. The epithelial cancers may be characterized in various other ways including, but not limited to, serous, endometrioid, mucinous, clear cell, brenner, or undifferentiated. In still other embodiments, the cancer is breast cancer, ovarian cancer or lung cancer. In particular embodiments, the cancer is triple negative breast cancer.

Subjects

[00278] In various embodiments, the subject for whom predicted efficacy of an anti-cancer therapy is determined, is a mammal (e.g., mouse, rat, primate, non-human mammal, domestic animal such as dog, cat, cow, horse), and is preferably a human. In another embodiment of the methods of the invention, the subject has not undergone chemotherapy or radiation therapy. In alternative embodiments, the subject has undergone chemotherapy or radiation therapy (e.g., such as with cisplatin, carboplatin, and/or taxane). In related embodiments, the subject has not been exposed to levels of radiation or chemotoxic agents above those encountered generally or on average by the subjects of a species. In certain embodiments, the subject has had surgery to remove cancerous or precancerous tissue. In other embodiments, the cancerous tissue has not been removed, e.g., the cancerous tissue may be located in an inoperable region of the body, such as in a tissue that is essential for life, or in a region where a surgical procedure would cause considerable risk of harm to the patient, or e.g., the subject is given the anti-cancer therapy prior to removal of the cancerous tissue.

Nucleic Acid Sample Preparation

A. Nucleic Acid Isolation

[00279] Nucleic acid samples derived from cancerous and non-cancerous cells of a subject that can be used in the methods of the invention to determine the genetic signature of a cancer can be prepared by means well known in the art. For example, surgical procedures or needle biopsy aspiration can be used to collect cancerous samples from a subject. In some

embodiments, it is important to enrich and/or purify the cancerous tissue and/or cell samples from the non-cancerous tissue and/or cell samples. In other embodiments, the cancerous tissue and/or cell samples can then be microdissected to reduce the amount of normal tissue contamination prior to extraction of genomic nucleic acid or pre-RNA for use in the methods of the invention. In still another embodiment, the cancerous tissue and/or cell samples are enriched for cancer cells by at least 50%, 55%, 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more or any range in between, in cancer cell content. Such enrichment can be accomplished according to methods well-known in the art, such as needle microdissection, laser microdissection, fluorescence activated cell sorting, and immunological cell sorting. In one embodiment, an automated machine performs the hyperproliferative cell enrichment to thereby transform the biological sample into a purified form enriched for the presence of hyperproliferative cells.

[00280] Collecting nucleic acid samples from non-cancerous cells of a subject can also be accomplished with surgery or aspiration. In surgical procedures where cancerous tissue is removed, surgeons often remove non-cancerous tissue and/or cell samples of the same tissue type of the cancer patient for comparison. Nucleic acid samples can be isolated from such non-cancerous tissue of the subject for use in the methods of the invention. In certain embodiments of the methods of the invention, nucleic acid samples from non-cancerous tissues are not derived from the same tissue type as the cancerous tissue and/or cells sampled, and/or are not derived from the cancer patient. The nucleic acid samples from non-cancerous tissues may be derived from any non-cancerous and/or disease-free tissue and/or cells. Such non-cancerous samples can be collected by surgical or non-surgical procedures. In certain embodiments, non-cancerous nucleic acid samples are derived from tumor-free tissues. For example, non-cancerous samples may be collected from lymph nodes, peripheral blood lymphocytes, and/or mononuclear blood cells, or any subpopulation thereof. In a preferred embodiment, the non-cancerous tissue is not pre-cancerous tissue, *e.g.*, it does not exhibit any indicia of a pre-neoplastic condition such as hyperplasia, metaplasia, or dysplasia.

[00281] In one embodiment, the nucleic acid samples used to compute a reference value are taken from at least 1, 2, 5, 10, 20, 30, 40, 50, 100, or 200 different organisms of that species. According to certain aspects of the invention, nucleic acid “derived from” genomic DNA, as used in the methods of the invention, *e.g.*, in hybridization experiments to determine BLM expression, FANCI expression, or 15q26 copy number, chromosome 15 centromere copy number can be fragments of genomic nucleic acid generated by restriction enzyme

digestion and/or ligation to other nucleic acid, and/or amplification products of genomic nucleic acids, or pre-messenger RNA (pre-mRNA), amplification products of pre-mRNA, or genomic DNA fragments grown up in cloning vectors generated, *e.g.*, by “shotgun” cloning methods. In certain embodiments, genomic nucleic acid samples are digested with restriction enzymes.

B. Amplification of Nucleic Acids

[00282] Though the nucleic acid sample need not comprise amplified nucleic acid, in some embodiments, the isolated nucleic acids can be processed in manners requiring and/or taking advantage of amplification. The genomic DNA samples of a subject optionally can be fragmented using restriction endonucleases and/or amplified prior to determining analysis. In one embodiment, the DNA fragments are amplified using polymerase chain reaction (PCR). Methods for practicing PCR are well known to those of skill in the art. One advantage of PCR is that small quantities of DNA can be used. For example, genomic DNA from a subject may be about 150 ng, 175 ng, 200 ng, 225 ng, 250 ng, 275 ng, or 300 ng of DNA.

[00283] In certain embodiments of the methods of the invention, the nucleic acid from a subject is amplified using a single primer pair. For example, genomic DNA samples can be digested with restriction endonucleases to generate fragments of genomic DNA that are then ligated to an adaptor DNA sequence which the primer pair recognizes. In other embodiments of the methods of the invention, the nucleic acid of a subject is amplified using sets of primer pairs specific to BLM, FANCI, 15q26, or chromosome 15 centromere copy and in instances wherein BRCA1, BRCA2, ER, PgR and/or HER2 receptor expression is also to be assessed, sets of primer pairs specific to BRCA1, BRCA2, ER, PgR and/or HER2 receptor. Such sets of primer pairs each recognize genomic DNA sequences flanking BLM, FANCI, 15q26, or chromosome 15 centromere and BRCA1, BRCA2, ER, PgR and/or HER2 receptor wherein the expression is also to be assessed. A DNA sample suitable for hybridization can be obtained, *e.g.*, by polymerase chain reaction (PCR) amplification of genomic DNA, fragments of genomic DNA, fragments of genomic DNA ligated to adaptor sequences or cloned sequences. Computer programs that are well known in the art can be used in the design of primers with the desired specificity and optimal amplification properties, such as Oligo version 5.0 (National Biosciences). PCR methods are well known in the art, and are described, for example, in Innis et al., eds., 1990, PCR Protocols: A Guide to Methods And Applications, Academic Press Inc., San Diego, Calif. It will be apparent to one skilled in the art that controlled robotic systems are useful for isolating and amplifying nucleic acids and can be used.

[00284] In other embodiments, where genomic DNA of a subject is fragmented using restriction endonucleases and amplified prior to analysis, the amplification can comprise cloning regions of genomic DNA of the subject. In such methods, amplification of the DNA regions is achieved through the cloning process. For example, expression vectors can be engineered to express large quantities of particular fragments of genomic DNA of the subject (Sambrook, J. et al., eds., 1989, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., at pp. 9.47-9.51).

[00285] In yet other embodiments, where the DNA of a subject is fragmented using restriction endonucleases and amplified prior to analysis, the amplification comprises expressing a nucleic acid encoding a gene, or a gene and flanking genomic regions of nucleic acids, from the subject. RNA (pre-messenger RNA) that comprises the entire transcript including introns is then isolated and used in the methods of the invention to analyze and provide a genetic signature of a cancer. In certain embodiments, no amplification is required. In such embodiments, the genomic DNA, or pre-RNA, of a subject may be fragmented using restriction endonucleases or other methods. The resulting fragments may be hybridized to SNP probes. Typically, greater quantities of DNA are needed to be isolated in comparison to the quantity of DNA or pre-mRNA needed where fragments are amplified. For example, where the nucleic acid of a subject is not amplified, a DNA sample of a subject for use in hybridization may be about 400 ng, 500 ng, 600 ng, 700 ng, 800 ng, 900 ng, or 1000 ng of DNA or greater. Alternatively, in other embodiments, methods are used that require very small amounts of nucleic acids for analysis, such as less than 400 ng, 300 ng, 200 ng, 100 ng, 90 ng, 85 ng, 80 ng, 75 ng, 70 ng, 65 ng, 60 ng, 55 ng, 50 ng, or less, such as is used for molecular inversion probe (MIP) assays. These techniques are particularly useful for analyzing clinical samples, such as paraffin embedded formalin-fixed material or small core needle biopsies, characterized as being readily available but generally having reduced DNA quality (e.g., small, fragmented DNA) and/or not providing large amounts of nucleic acids.

C. Hybridization

[00286] The nucleic acid samples derived from a subject used in the methods of the invention can be hybridized to arrays comprising probes (e.g., oligonucleotide probes) in order to identify BLM, FANCI, 15q26, or chromosome 15 centromere and in instances wherein BRCA1, BRCA2, ER, PgR and/or HER2 receptor expression is also to be assessed, comprising probes in order to identify BRCA1, BRCA2, ER, PgR and/or HER2 receptor. Hybridization can also be used to determine whether the BLM, FANCI, 15q26, or chromosome 15 centromere identified exhibit total copy number change, copy number gain,

and copy number loss in nucleic acid samples from cancerous tissues and/or cells of the subject. In preferred embodiments, the probes used in the methods of the invention comprise an array of probes that can be tiled on a DNA chip (*e.g.*, SNP oligonucleotide probes). In some embodiments, BLM expression, FANCI expression, 15q26 copy number, or
5 chromosome 15 centromere copy number is determined by a method that does not comprise detecting a change in size of restriction enzyme-digested nucleic acid fragments. In other embodiments, SNPs are analyzed to identify BLM expression or FANCI expression, 15q26 copy number or chromosome 15 centromere copy number. Hybridization and wash
10 conditions used in the methods of the invention are chosen so that the nucleic acid samples to be analyzed by the invention specifically bind or specifically hybridize to the complementary oligonucleotide sequences of the array, preferably to a specific array site, wherein its complementary DNA is located. In some embodiments, the complementary DNA can be completely matched or mismatched to some degree as used, for example, in Affymetrix oligonucleotide arrays such as those used to analyze SNPs in MIP assays. The single-
15 stranded synthetic oligodeoxyribonucleic acid DNA probes of an array may need to be denatured prior to contact with the nucleic acid samples from a subject, *e.g.*, to remove hairpins or dimers which form due to self-complementary sequences.

[00287] Optimal hybridization conditions will depend on the length of the probes and type of nucleic acid samples from a subject. General parameters for specific (*i.e.*, stringent)
20 hybridization conditions for nucleic acids are described in Sambrook, J. et al., eds., 1989, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., at pp. 9.47-9.51 and 11.55-11.61; Ausubel et al., eds., 1989, *Current Protocols in Molecular Biology*, Vol. 1, Green Publishing Associates, Inc., John Wiley & Sons, Inc., New York, at pp. 2.10.1-2.10.16. Exemplary useful hybridization
25 conditions are provided in, *e.g.*, Tijessen, 1993, *Hybridization with Nucleic Acid Probes*, Elsevier Science Publishers B. V. and Kricka, 1992, *Nonisotopic DNA Probe Techniques*, Academic Press, San Diego, Calif.

D. Oligonucleotide Nucleic Acid Arrays

[00288] In some embodiments of the methods of the present invention, DNA arrays
30 can be used to determine total copy number change, copy number gain, and copy number loss by measuring the level of hybridization of the nucleic acid sequence to oligonucleotide probes that comprise complementary sequences. Hybridization can be used to determine the presence or absence of heterozygosity. Various formats of DNA arrays that employ oligonucleotide “probes,” (*i.e.*, nucleic acid molecules having defined sequences) are well

known to those of skill in the art. Typically, a set of nucleic acid probes, each of which has a defined sequence, is immobilized on a solid support in such a manner that each different probe is immobilized to a predetermined region. In certain embodiments, the set of probes forms an array of positionally-addressable binding (*e.g.*, hybridization) sites on a support.

5 Each of such binding sites comprises a plurality of oligonucleotide molecules of a probe bound to the predetermined region on the support. More specifically, each probe of the array is preferably located at a known, predetermined position on the solid support such that the identity (*i.e.*, the sequence) of each probe can be determined from its position on the array (*i.e.*, on the support or surface). Microarrays can be made in a number of ways, of which
10 several are described herein. However produced, microarrays share certain characteristics, they are reproducible, allowing multiple copies of a given array to be produced and easily compared with each other.

[00289] Preferably, the microarrays are made from materials that are stable under binding (*e.g.*, nucleic acid hybridization) conditions. The microarrays are preferably small,
15 *e.g.*, between about 1 cm² and 25 cm², preferably about 1 to 3 cm². However, both larger and smaller arrays are also contemplated and may be preferable, *e.g.*, for simultaneously evaluating a very large number of different probes. Oligonucleotide probes can be synthesized directly on a support to form the array. The probes can be attached to a solid support or surface, which may be made, *e.g.*, from glass, plastic (*e.g.*, polypropylene, nylon),
20 polyacrylamide, nitrocellulose, gel, or other porous or nonporous material. The set of immobilized probes or the array of immobilized probes is contacted with a sample containing labeled nucleic acid species so that nucleic acids having sequences complementary to an immobilized probe hybridize or bind to the probe. After separation of, *e.g.*, by washing off, any unbound material, the bound, labeled sequences are detected and measured. The
25 measurement is typically conducted with computer assistance. Using DNA array assays, complex mixtures of labeled nucleic acids, *e.g.*, nucleic acid fragments derived a restriction digestion of genomic DNA from non-cancerous tissue, can be analyzed. DNA array technologies have made it possible to determine the expression level or copy number BLM, FANCI, 15q26, or chromosome 15 centromere, or BRCA1, BRCA2, ER, PgR and/or HER2
30 receptor expression in instances where BRCA1, BRCA2, ER, PgR and/or HER2 receptor expression is also assessed.

[00290] In certain embodiments, high-density oligonucleotide arrays are used in the methods of the invention. These arrays containing thousands of oligonucleotides complementary to defined sequences, at defined locations on a surface can be synthesized *in*

situ on the surface by, for example, photolithographic techniques (see, *e.g.*, Fodor et al., 1991, *Science* 251:767-773; Pease et al., 1994, *Proc. Natl. Acad. Sci. U.S.A.* 91:5022-5026; Lockhart et al., 1996, *Nature Biotechnology* 14:1675; U.S. Pat. Nos. 5,578,832; 5,556,752; 5,510,270; 5,445,934; 5,744,305; and 6,040,138). Methods for generating arrays using inkjet
5 technology for *in situ* oligonucleotide synthesis are also known in the art (see, *e.g.*,
Blanchard, International Patent Publication WO 98/41531, published Sep. 24, 1998;
Blanchard et al., 1996, *Biosensors And Bioelectronics* 11:687-690; Blanchard, 1998, in
Synthetic DNA Arrays in Genetic Engineering, Vol. 20, J. K. Setlow, Ed., Plenum Press,
New York at pages 111-123). Another method for attaching the nucleic acids to a surface is
10 by printing on glass plates, as is described generally by Schena et al. (1995, *Science* 270:467-
470). Other methods for making microarrays, *e.g.*, by masking (Maskos and Southern, 1992,
Nucl. Acids. Res. 20:1679-1684), may also be used. When these methods are used,
oligonucleotides (*e.g.*, 15 to 60-mers) of known sequence are synthesized directly on a
surface such as a derivatized glass slide. The array produced can be redundant, with several
15 oligonucleotide molecules corresponding to each informative locus of interest (*e.g.*, SNPs,
RFLPs, STRs, *etc.*).

[00291] One exemplary means for generating the oligonucleotide probes of the DNA
array is by synthesis of synthetic polynucleotides or oligonucleotides, *e.g.*, using N-
phosphonate or phosphoramidite chemistries (Froehler et al., 1986, *Nucleic Acid Res.*
20 14:5399-5407; McBride et al., 1983, *Tetrahedron Lett.* 24:246-248). Synthetic sequences are
typically between about 15 and about 600 bases in length, more typically between about 20
and about 100 bases, most preferably between about 40 and about 70 bases in length. In
some embodiments, synthetic nucleic acids include non-natural bases, such as, but by no
means limited to, inosine. As noted above, nucleic acid analogues may be used as binding
25 sites for hybridization. An example of a suitable nucleic acid analogue is peptide nucleic acid
(see, *e.g.*, Egholm et al., 1993, *Nature* 363:566-568; U.S. Pat. No. 5,539,083). In alternative
embodiments, the hybridization sites (*i.e.*, the probes) are made from plasmid or phage clones
of regions of genomic DNA corresponding to SNPs or the complement thereof. The size of
the oligonucleotide probes used in the methods of the invention can be at least 10, 20, 25, 30,
30 35, 40, 45, or 50 nucleotides in length. It is well known in the art that although hybridization
is selective for complementary sequences, other sequences which are not perfectly
complementary may also hybridize to a given probe at some level. Thus, multiple
oligonucleotide probes with slight variations can be used, to optimize hybridization of
samples. To further optimize hybridization, hybridization stringency condition, *e.g.*, the

hybridization temperature and the salt concentrations, may be altered by methods that are well known in the art.

[00292] In preferred embodiments, the high-density oligonucleotide arrays used in the methods of the invention comprise oligonucleotides corresponding to BLM, FANCI, 15q26, or chromosome 15 centromere or in instances wherein BRCA1, BRCA2, ER, PgR and/or HER2 receptor expression is also assessed, the arrays also comprise oligonucleotides corresponding to BRCA1, BRCA2, ER, PgR and/or HER2 receptor. The oligonucleotide probes may comprise DNA or DNA “mimics” (*e.g.*, derivatives and analogues) corresponding to a portion of each informative locus of interest (*e.g.*, SNPs, RFLPs, STRs, *etc.*) in a subject’s genome. The oligonucleotide probes can be modified at the base moiety, at the sugar moiety, or at the phosphate backbone. Exemplary DNA mimics include, *e.g.*, phosphorothioates. For each SNP locus, a plurality of different oligonucleotides may be used that are complementary to the sequences of sample nucleic acids. For example, for a single informative locus of interest (*e.g.*, SNPs, RFLPs, STRs, *etc.*) about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more different oligonucleotides can be used. Each of the oligonucleotides for a particular informative locus of interest may have a slight variation in perfect matches, mismatches, and flanking sequence around the SNP. In certain embodiments, the probes are generated such that the probes for a particular informative locus of interest comprise overlapping and/or successive overlapping sequences which span or are tiled across a genomic region containing the target site, where all the probes contain the target site. By way of example, overlapping probe sequences can be tiled at steps of a predetermined base interval, *e. g.* at steps of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases intervals. In certain embodiments, the assays can be performed using arrays suitable for use with molecular inversion probe protocols such as described by Wang *et al.* (2007) *Genome Biol.* 8, R246. For oligonucleotide probes targeted at nucleic acid species of closely resembled (*i.e.*, homologous) sequences, “cross-hybridization” among similar probes can significantly contaminate and confuse the results of hybridization measurements. Cross-hybridization is a particularly significant concern in the detection of SNPs since the sequence to be detected (*i.e.*, the particular SNP) must be distinguished from other sequences that differ by only a single nucleotide. Cross-hybridization can be minimized by regulating either the hybridization stringency condition and/or during post-hybridization washings. Highly stringent conditions allow detection of allelic variants of a nucleotide sequence, *e.g.*, about 1 mismatch per 10-30 nucleotides. There is no single hybridization or washing condition

which is optimal for all different nucleic acid sequences. For particular arrays of BLM, FANCI, 15q26, or chromosome 15 centromere, or of BRCA1, BRCA2, ER, PgR and/or HER2 receptor these conditions can be identical to those suggested by the manufacturer or can be adjusted by one of skill in the art. In preferred embodiments, the probes used in the methods of the invention are immobilized (*i.e.*, tiled) on a glass slide called a chip. For example, a DNA microarray can comprises a chip on which oligonucleotides (purified single-stranded DNA sequences in solution) have been robotically printed in an (approximately) rectangular array with each spot on the array corresponds to a single DNA sample which encodes an oligonucleotide. In summary the process comprises, flooding the DNA microarray chip with a labeled sample under conditions suitable for hybridization to occur between the slide sequences and the labeled sample, then the array is washed and dried, and the array is scanned with a laser microscope to detect hybridization. In certain embodiments there are at least 250, 500, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, 30,000, 31,000, 32,000, 33,000, 34,000, 35,000, 36,000, 37,000, 38,000, 39,000, 40,000, 41,000, 42,000, 43,000, 44,000, 45,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100,000 or more or any range in between, of BLM, FANCI, 15q26, or chromosome 15 centromere, or of BRCA1, BRCA2, ER, PgR and/or HER2 receptor for which probes appear on the array (with match/mismatch probes for a single locus of interest or probes tiled across a single locus of interest counting as one locus of interest). The maximum number of BLM, FANCI, 15q26, or chromosome 15 centromere, or of BRCA1, BRCA2, ER, PgR and/or HER2 receptor being probed per array is determined by the size of the genome and genetic diversity of the subjects species. DNA chips are well known in the art and can be purchased in pre-fabricated form with sequences specific to particular species. In some embodiments, the Genome-Wide Human SNP Array 6.0™ and/or the 50K XbaI arrays (Affymetrix, Santa Clara, Calif.) are used in the methods of the invention. In other embodiments, SNPs and/or DNA copy number can be detected and quantitated using sequencing methods, such as “next-generation sequencing methods” as described further above.

30 E. Signal Detection

[00293] In some embodiments, nucleic acid samples derived from a subject are hybridized to the binding sites of an array described herein. In certain embodiments, nucleic acid samples derived from each of the two sample types of a subject (*i.e.*, cancerous and non-cancerous) are hybridized to separate, though identical, arrays. In certain embodiments,

nucleic acid samples derived from one of the two sample types of a subject (*i.e.*, cancerous and non-cancerous) is hybridized to such an array, then following signal detection the chip is washed to remove the first labeled sample and reused to hybridize the remaining sample. In other embodiments, the array is not reused more than once. In certain embodiments, the

5 nucleic acid samples derived from each of the two sample types of a subject (*i.e.*, cancerous and non-cancerous) are differently labeled so that they can be distinguished. When the two samples are mixed and hybridized to the same array, the relative intensity of signal from each sample is determined for each site on the array, and any relative difference in abundance of an allele of BLM, FANCI, 15q26, or chromosome 15 centromere, or of BRCA1, BRCA2,

10 ER, PgR and/or HER2 receptor. Signals can be recorded and, in some embodiments, analyzed by computer. In one embodiment, the scanned image is despeckled using a graphics program (*e.g.*, Hijaak Graphics Suite) and then analyzed using an image gridding program that creates a spreadsheet of the average hybridization at each wavelength at each site. If necessary, an experimentally determined correction for “cross talk” (or overlap) between the

15 channels for the two fluors may be made. For any particular hybridization site on the array, a ratio of the emission of the two fluorophores can be calculated, which may help in eliminating cross hybridization signals to more accurately determining whether a particular SNP locus is heterozygous or homozygous.

F. Labeling

20 **[00294]** In some embodiments, the nucleic acids samples, fragments thereof, or fragments thereof ligated to adaptor regions used in the methods of the invention are detectably labeled. For example, the detectable label can be a fluorescent label, *e.g.*, by incorporation of nucleotide analogues. Other labels suitable for use in the present invention include, but are not limited to, biotin, iminobiotin, antigens, cofactors, dinitrophenol, lipoic

25 acid, olefinic compounds, detectable polypeptides, electron rich molecules, enzymes capable of generating a detectable signal by action upon a substrate, and radioactive isotopes.

[00295] Radioactive isotopes include that can be used in conjunction with the methods of the invention, but are not limited to, ³²P and ¹⁴C. Fluorescent molecules suitable for the present invention include, but are not limited to, fluorescein and its derivatives, rhodamine

30 and its derivatives, texas red, 5'carboxy-fluorescein (“FAM”), 2', 7'-dimethoxy-4', 5'-dichloro-6-carboxy-fluorescein (“JOE”), N, N, N', N'-tetramethyl-6-carboxy-rhodamine (“TAMRA”), 6-carboxy-X-rhodamine (“ROX”), HEX, TET, IRD40, and IRD41.

[00296] Fluorescent molecules which are suitable for use according to the invention further include: cyamine dyes, including but not limited to Cy2, Cy3, Cy3.5, CY5, Cy5.5,

Cy7 and FLUORX; BODIPY dyes including but not limited to BODIPY-FL, BODIPY-TR, BODIPY-TMR, BODIPY-630/650, and BODIPY-650/670; and ALEXA dyes, including but not limited to ALEXA-488, ALEXA-532, ALEXA-546, ALEXA-568, and ALEXA-594; as well as other fluorescent dyes which will be known to those who are skilled in the art.

5 Electron rich indicator molecules suitable for the present invention include, but are not limited to, ferritin, hemocyanin, and colloidal gold.

[00297] Two-color fluorescence labeling and detection schemes may also be used (Shena et al., 1995, Science 270:467-470). Use of two or more labels can be useful in detecting variations due to minor differences in experimental conditions (*e.g.*, hybridization
10 conditions). In some embodiments of the invention, at least 5, 10, 20, or 100 dyes of different colors can be used for labeling. Such labeling would also permit analysis of multiple samples simultaneously which is encompassed by the invention.

[00298] The labeled nucleic acid samples, fragments thereof, or fragments thereof ligated to adaptor regions that can be used in the methods of the invention are contacted to a
15 plurality of oligonucleotide probes under conditions that allow sample nucleic acids having sequences complementary to the probes to hybridize thereto. Depending on the type of label used, the hybridization signals can be detected using methods well known to those of skill in the art including, but not limited to, X-Ray film, phosphor imager, or CCD camera. When fluorescently labeled probes are used, the fluorescence emissions at each site of a transcript
20 array can be, preferably, detected by scanning confocal laser microscopy. In one embodiment, a separate scan, using the appropriate excitation line, is carried out for each of the two fluorophores used. Alternatively, a laser can be used that allows simultaneous specimen illumination at wavelengths specific to the two fluorophores and emissions from the two fluorophores can be analyzed simultaneously (see Shalon *et al.* (1996) *Genome Res.*
25 6, 639-645). In a preferred embodiment, the arrays are scanned with a laser fluorescence scanner with a computer controlled X-Y stage and a microscope objective. Sequential excitation of the two fluorophores is achieved with a multi-line, mixed gas laser, and the emitted light is split by wavelength and detected with two photomultiplier tubes. Such fluorescence laser scanning devices are described, *e.g.*, in Schena *et al.* (1996) *Genome Res.*
30 6, 639-645. Alternatively, a fiber-optic bundle can be used such as that described by Ferguson et al. (1996) *Nat. Biotech.* 14, 1681-1684. The resulting signals can then be analyzed to determine the BLM expression, FANCI expression, 15q26 copy number, or chromosome 15 centromere copy number, using computer software.

G. Algorithms for Analyzing BLM, FANCI, 15q26, or chromosome 15 centromere

[00299] Once the hybridization signal has been detected the resulting data can be analyzed using algorithms. In certain embodiments, the algorithm for determining the expression of BLM or FANCI, or copy number 15q26 or chromosome 15 centromere is based on well-known methods. Additional representative illustrations of such well known algorithms are provided in the Examples section below.

H. Computer Implementation Systems and Methods

[00300] In certain embodiments, the methods of the invention implement a computer program to calculate a copy number, copy number gain, copy number loss, and expression levels. For example, a computer program can be used to perform the algorithms described herein. A computer system can also store and manipulate data generated by the methods of the present invention which comprises a plurality of hybridization signal changes/profiles during approach to equilibrium in different hybridization measurements and which can be used by a computer system in implementing the methods of this invention. In certain embodiments, a computer system receives probe hybridization data; (ii) stores probe hybridization data; and (iii) compares probe hybridization data to determine the state of BLM, FANCI, 15q26, or, chromosome 15 centromere, and/or of BRCA1, BRCA2, ER, PgR and/or HER2 receptor in said nucleic acid sample from cancerous or pre-cancerous tissue. The copy number, copy number gain, copy number loss, or expression levels is then calculated. In some embodiments, a computer system (i) compares the determined copy number, copy number gain, copy number loss, and expression levels to a threshold value or reference value; and (ii) outputs an indication of whether said copy number, copy number gain, copy number loss, and expression levels is above or below a threshold value, or a genetic signature based on said indication. In certain embodiments, such computer systems are also considered part of the present invention.

[00301] Numerous types of computer systems can be used to implement the analytic methods of this invention according to knowledge possessed by a skilled artisan in the bioinformatics and/or computer arts.

[00302] Several software components can be loaded into memory during operation of such a computer system. The software components can comprise both software components that are standard in the art and components that are special to the present invention (e.g., dCHIP software described in Lin *et al.* (2004) *Bioinformatics* 20, 1233-1240; CRLMM software described in Silver *et al.* (2007) *Cell* 128, 991-1002; Aroma Affymetrix software described in Richardson *et al.* (2006) *Cancer Cell* 9, 121-132. The methods of the invention can also be programmed or modeled in mathematical software packages that allow symbolic

entry of equations and high-level specification of processing, including specific algorithms to be used, thereby freeing a user of the need to procedurally program individual equations and algorithms. Such packages include, *e.g.*, Matlab from Mathworks (Natick, Mass.), Mathematica from Wolfram Research (Champaign, Ill.) or S-Plus from MathSoft (Seattle, Wash.). In certain embodiments, the computer comprises a database for storage of hybridization signal profiles. Such stored profiles can be accessed and used to calculate a copy number, copy number gain, copy number loss, or expression level. For example, of the hybridization signal profile of a sample derived from the non-cancerous tissue of a subject and/or profiles generated from population-based distributions of BLM, FANCI, 15q26, or chromosome 15 centromere, and/or of BRCA1, BRCA2, ER, PgR and/or HER2 receptor in relevant populations of the same species were stored, it could then be compared to the hybridization signal profile of a sample derived from the cancerous tissue of the subject.

[00303] In addition to the exemplary program structures and computer systems described herein, other, alternative program structures and computer systems will be readily apparent to the skilled artisan. Such alternative systems, which do not depart from the above described computer system and programs structures either in spirit or in scope, are therefore intended to be comprehended within the accompanying claims.

[00304] Once a laboratory technician or laboratory professional or group of laboratory technicians or laboratory professionals determines whether a sample has a copy number, copy number gain, copy number loss, or expression level as described above (*e.g.*, step (1) in many of the methods above), the same or a different laboratory technician or laboratory professional (or group) can analyze a plurality of test BLM, FANCI, 15q26, or chromosome 15 centromere to determine whether there is a copy number, copy number gain, copy number loss, or expression level (*e.g.*, step (2) in many of the methods above). Next, the same or a different laboratory technician or laboratory professional (or group) can combine the a copy number, copy number gain, copy number loss, or expression level data from the test BLM, FANCI, 15q26, or chromosome 15 centromere to derive a copy number, copy number gain, copy number loss, or expression level (*e.g.*, step (3) in many of the methods above).

Optionally, the same or a different laboratory technician or laboratory professional (or group) can correlate the copy number, copy number gain, copy number loss, or expression level to an increased or decreased likelihood of response to a particular therapy (*e.g.*, those mentioned above).

[00305] In various embodiments, provided herein is a computer readable storage medium comprising: a storing data module containing data from a sample comprising a

cancer cell obtained from a subject that represents an expression level from an assay for BLM and/or FANCI, or copy number of 15q26; a comparison module that compares the data stored on the storing data module with a reference data and/or control data, and to provide a comparison content, and an output module displaying the comparison content for the user, wherein the increased expression of BLM and/or FANCI, or copy number gain of 15q26 indicates that the subject is susceptible to platinum-comprising, or anthracycline-comprising cancer therapy.

[00306] In various embodiments, the control data comprises data from a population of non-cancerous healthy individuals. In various embodiments, the control data comprises data BRAC1 expression, and/or a housekeeping gene expression.

[00307] Embodiments of the invention can be described through functional modules, which are defined by computer executable instructions recorded on computer readable media and which cause a computer to perform method steps when executed. The modules are segregated by function, for the sake of clarity. However, it should be understood that the modules/systems need not correspond to discreet blocks of code and the described functions can be carried out by the execution of various code portions stored on various media and executed at various times. Furthermore, it should be appreciated that the modules may perform other functions, thus the modules are not limited to having any particular functions or set of functions.

[00308] The computer readable storage media **30** can be any available tangible media that can be accessed by a computer. Computer readable storage media includes volatile and nonvolatile, removable and non-removable tangible media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data. Computer readable storage media includes, but is not limited to, RAM (random access memory), ROM (read only memory), EPROM (erasable programmable read only memory), EEPROM (electrically erasable programmable read only memory), flash memory or other memory technology, CD-ROM (compact disc read only memory), DVDs (digital versatile disks) or other optical storage media, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage media, other types of volatile and non-volatile memory, and any other tangible medium which can be used to store the desired information and which can accessed by a computer including and any suitable combination of the foregoing.

[00309] Computer-readable data embodied on one or more computer-readable media may define instructions, for example, as part of one or more programs that, as a result of

being executed by a computer, instruct the computer to perform one or more of the functions described herein, and/or various embodiments, variations and combinations thereof. Such instructions may be written in any of a plurality of programming languages, for example, Java, J#, Visual Basic, C, C#, C++, Fortran, Pascal, Eiffel, Basic, COBOL assembly
5 language, and the like, or any of a variety of combinations thereof. The computer-readable media on which such instructions are embodied may reside on one or more of the components of either of a system, or a computer readable storage medium described herein, may be distributed across one or more of such components.

[00310] The computer-readable media may be transportable such that the instructions
10 stored thereon can be loaded onto any computer resource to implement the aspects of the present invention discussed herein. In addition, it should be appreciated that the instructions stored on the computer-readable medium, described above, are not limited to instructions embodied as part of an application program running on a host computer. Rather, the instructions may be embodied as any type of computer code (e.g., software or microcode)
15 that can be employed to program a computer to implement aspects of the present invention. The computer executable instructions may be written in a suitable computer language or combination of several languages. Basic computational biology methods are known to those of ordinary skill in the art and are described in, for example, Setubal and Meidanis et al., Introduction to Computational Biology Methods (PWS Publishing Company, Boston, 1997);
20 Salzberg, Searles, Kasif, (Ed.), Computational Methods in Molecular Biology, (Elsevier, Amsterdam, 1998); Rashidi and Buehler, Bioinformatics Basics: Application in Biological Science and Medicine (CRC Press, London, 2000) and Ouelette and Bzevanis Bioinformatics: A Practical Guide for Analysis of Gene and Proteins (Wiley & Sons, Inc.,
25 2nd ed., 2001).

[00311] The functional modules of certain embodiments of the invention; for example,
as depicted in Figure 12, include for example, at a measuring module **40**, a storage module
30, a comparison module **80**, and an output module **110**. The functional modules can be
executed on one, or multiple, computers, or by using one, or multiple, computer networks.
The measuring module has computer executable instructions to provide e.g., expression
30 information in computer readable form.

[00312] The measuring module **40**, can comprise any system for detecting the
expression of BLM and/or FANCI, the 15Q26 copy number. Such systems can include DNA
microarrays, RNA expression arrays, any ELISA detection system and/or any Western
blotting detection system.

[00313] The information determined in the determination system can be read by the storage module **30**. As used herein the “storage module” is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of electronic apparatus suitable for use with the present invention include stand-alone computing apparatus, data telecommunications networks, including local area networks (LAN), wide area networks (WAN), Internet, Intranet, and Extranet, and local and distributed computer processing systems. Storage modules also include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage media, magnetic tape, optical storage media such as CD-ROM, DVD, electronic storage media such as RAM, ROM, EPROM, EEPROM and the like, general hard disks and hybrids of these categories such as magnetic/optical storage media. The storage module is adapted or configured for having recorded thereon expression level or protein level information. Such information may be provided in digital form that can be transmitted and read electronically, e.g., via the Internet, on diskette, via USB (universal serial bus) or via any other suitable mode of communication.

[00314] As used herein, “stored” refers to a process for encoding information on the storage module. Those skilled in the art can readily adopt any of the presently known methods for recording information on known media to generate manufactures comprising expression level information.

[00315] In one embodiment the reference data stored in the storage module to be read by the comparison module is e.g., expression data obtained from a population of non-cancer subjects, a population of cancer subjects or expression data obtained from the same subject at a prior time point using the measuring module **40**.

[00316] The “comparison module” **80** can use a variety of available software programs and formats for the comparison operative to compare expression data determined in the measuring module to reference samples and/or stored reference data. In one embodiment, the comparison module is configured to use pattern recognition techniques to compare information from one or more entries to one or more reference data patterns. The comparison module may be configured using existing commercially-available or freely-available software for comparing patterns, and may be optimized for particular data comparisons that are conducted. The comparison module provides computer readable information related to normalized expression of BLM and/or FANCI, the 15Q26 copy number in an individual, efficacy of treatment in an individual, and/or method for treating an individual.

[00317] The comparison module, or any other module of the invention, may include an operating system (e.g., UNIX) on which runs a relational database management system, a World Wide Web application, and a World Wide Web server. World Wide Web application includes the executable code necessary for generation of database language statements (e.g.,
5 Structured Query Language (SQL) statements). Generally, the executables will include embedded SQL statements. In addition, the World Wide Web application may include a configuration file which contains pointers and addresses to the various software entities that comprise the server as well as the various external and internal databases which must be accessed to service user requests. The Configuration file also directs requests for server
10 resources to the appropriate hardware--as may be necessary should the server be distributed over two or more separate computers. In one embodiment, the World Wide Web server supports a TCP/IP protocol. Local networks such as this are sometimes referred to as "Intranets. An advantage of such Intranets is that they allow easy communication with public domain databases residing on the World Wide Web (e.g., the GenBank or Swiss Pro World
15 Wide Web site). Thus, in a particular preferred embodiment of the present invention, users can directly access data (via Hypertext links for example) residing on Internet databases using a HTML interface provided by Web browsers and Web servers.

[00318] The comparison module provides a computer readable comparison result that can be processed in computer readable form by predefined criteria, or criteria defined by a
20 user, to provide a content-based in part on the comparison result that may be stored and output as requested by a user using an output module **110**.

[00319] The content based on the comparison result, may be an expression value compared to a reference showing the susceptibility or nonsusceptibility of treatment with platinum-comprising therapy or anthracycline-comprising therapy.

[00320] In various embodiments of the invention, the content based on the comparison result is displayed on a computer monitor **120**. In various embodiments of the invention, the content based on the comparison result is displayed through printable media **130**. The display module can be any suitable device configured to receive from a computer and display computer readable information to a user. Non-limiting examples include, for example,
30 general-purpose computers such as those based on Intel PENTIUM-type processor, Motorola PowerPC, Sun UltraSPARC, Hewlett-Packard PA-RISC processors, any of a variety of processors available from Advanced Micro Devices (AMD) of Sunnyvale, California, or any other type of processor, visual display devices such as flat panel displays, cathode ray tubes and the like, as well as computer printers of various types.

[00321] In one embodiment, a World Wide Web browser is used for providing a user interface for display of the content based on the comparison result. It should be understood that other modules of the invention can be adapted to have a web browser interface. Through the Web browser, a user may construct requests for retrieving data from the comparison
5 module. Thus, the user will typically point and click to user interface elements such as buttons, pull down menus, scroll bars and the like conventionally employed in graphical user interfaces.

[00322] The present invention therefore provides for systems (and computer readable media for causing computer systems) to perform methods for selecting treatment of cancer in
10 an individual.

[00323] Systems and computer readable media described herein are merely illustrative embodiments of the invention for detecting BLM and/or FANCI expression, or 15Q26 copy number in an individual, and are not intended to limit the scope of the invention. Variations of the systems and computer readable media described herein are possible and are intended to
15 fall within the scope of the invention.

[00324] The modules of the machine, or those used in the computer readable medium, may assume numerous configurations. For example, function may be provided on a single machine or distributed over multiple machines.

[00325] In some cases, a computing system provided herein can include computer-executable instructions or a computer program (e.g., software) containing computer-executable instructions for formatting an output providing an indication BLM and/or FANCI expression, 15q26 copy number, or a likelihood that a cancer patient will respond to a particular cancer treatment regimen (e.g., a regimen as described above), or a combination of these items. In some cases, a computing system provided herein can include computer-
20 executable instructions or a computer program (e.g., software) containing computer-executable instructions for determining a desired cancer treatment regimen for a particular patient based at least in part on increased expression of BLM and/or FANCI, or 15q26 copy number gain.

[00326] In some cases, a computing system provided herein can include a pre-
30 processing device configured to process a sample (e.g., cancer cells) such that a SNP array-based assay or sequencing-based assay can be performed. Examples of pre-processing devices include, without limitation, devices configured to enrich cell populations for cancer cells as opposed to non-cancer cells, devices configured to lyse cells and/or extract genomic

nucleic acid, and devices configured to enrich a sample for particular genomic DNA fragments.

[00327] The following numbered paragraphs provide some embodiments and aspects of the invention.

- 5 1. An assay for selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising:
 - subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;
 - comparing the BLM and FANCI expression to a reference value; and
 - 10 selecting a platinum-comprising cancer therapy for the subject when the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI, or selecting a non-platinum-comprising cancer therapy for the subject when the BLM and FANCI expression is
 - 15 not increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is not effective in subjects whose cancer does not have increased BLM and FANCI expression compared to the reference value.
2. The assay of paragraph 1, further comprising:
 - assaying the BRCA1 and/or BRCA2 status of the subject; and
 - 20 selecting the platinum-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI and who are negative for BRCA1 and/or
 - 25 BRCA2 mutations.
3. The assay of paragraph 1, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.
4. The assay of paragraph 1, further comprising:
 - assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2
 - 30 receptor status of the subject's cancer; and
 - selecting the platinum-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is

effective in subjects whose cancer has increased expression of BLM and FANCI and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor.

5. The assay of paragraph 1, wherein the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.
6. The assay of paragraphs 1-5, further comprising administering the selected therapy to the subject.
7. The assay of any one of the paragraphs 1-6, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.
- 10 8. The assay of paragraphs 1-6, wherein the reference value is BRCA1 expression in the sample and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
9. The assay of paragraphs 1-6, wherein the reference value is based on at least BRCA1 gene expression in the cancer cell.
- 15 10. The assay paragraphs 1-6, wherein the reference value is based on at least one housekeeping gene expression in the cancer cell.
11. A method for selecting platinum-comprising therapy for a subject having cancer, and optionally administering the platinum-comprising therapy, the method comprising:
 - 20 subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;
 - detecting the BLM and FANCI expression in the sample compared to a reference value; and
 - selecting a platinum-comprising cancer therapy for the subject when the BLM and FANCI expression compared to a reference value is increased based on the
25 recognition that platinum-comprising cancer therapy is effective in patients whose cancer has increased BLM and FANCI expression compared to the reference value.
12. The method of paragraph 11, further comprising administering to the subject the platinum-comprising cancer therapy when the platinum-comprising cancer therapy
30 is selected.
13. The method of paragraph 11, wherein the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.

14. The method of paragraph 11, wherein the subject's cancer or cancer cell is known to not or determined to not express a detectable quantity of ER, PgR, and HER2 receptor.
15. The method of any one of the paragraphs 11-14, wherein the cancer is selected
5 from breast cancer, ovarian cancer and lung cancer.
16. The method of paragraph 11-15, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
17. The method of any one of the paragraphs 11-15, wherein the reference value is
10 based on at least BRCA1 gene expression in the cancer cell.
18. The method of any one of the paragraphs 11-15, wherein the reference value is based on at least one housekeeping gene expression in the cancer cell.
19. The method of paragraph 18, wherein the housekeeping gene is selected from beta-actin, GAPDH, RPLP0, GUS, TFRC and any combination thereof.
- 15 20. The method of paragraph 19, wherein the housekeeping gene is RPLP0, and the BLM and/or FANCI expression is increased by at least six-fold.
21. A method for selecting a non-platinum-comprising therapy, and optionally administering the non-platinum-comprising therapy, for a subject having cancer comprising:
- 20 subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;
- detecting the BLM and FANCI expression in the sample compared to a reference value; and
- selecting the non-platinum-comprising cancer therapy for the subject when the
25 BLM and FANCI expression compared to the reference value is not increased based on the recognition that non-platinum-comprising cancer therapy is effective in patients whose cancer does not have increased gene expression of BLM and FANCI compared to the reference value.
22. The method of paragraph 21, further comprising administering to the subject
30 the non-platinum-comprising cancer therapy when non-platinum-comprising cancer therapy is selected.
23. The method of any one of the paragraphs 21-22, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.

24. The method of paragraph 21-23, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
25. The method of any one of the paragraphs 21-24, wherein the reference value is based on at least BRCA1 gene expression in the cancer cell.
26. The method of any one of the paragraphs 21-22, wherein the reference value is based on at least one housekeeping gene expression in the cancer cell.
27. An assay for selecting a therapy for a subject having cancer, comprising:
subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;
comparing the BLM and FANCI expression to a reference value; and
selecting an anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression is increased compared to a reference value based on the recognition that anthracycline-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI, or
selecting a non-anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression is not increased compared to a reference value based on the recognition that anthracycline-comprising cancer therapy is not effective in subjects whose cancer does not have increased BLM expression compared to a reference value.
28. The assay of paragraph 27, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
29. A method for selecting an anthracycline-comprising cancer therapy for a subject having cancer and determined to be negative for BRCA1 and/or BRCA2 mutations, comprising:
subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;
comparing the BLM and FANCI expression to a reference value; and
selecting the anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression compared to the reference value is increased based on the recognition that anthracycline-comprising cancer therapy is effective in patients whose cancer has increased expression of BLM and FANCI compared to the reference value.

30. The method of paragraph 29, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
31. A method of treating cancer in a human subject, comprising:
5 detecting BLM and FANCI expression in a sample comprising a cancer cell taken from the human subject; and
comparing the BLM and FANCI expression to a reference value; and
administering a platinum-comprising cancer therapy to the human subject wherein an increase of BLM and FANCI expression compared to the reference value
10 is detected.
32. The method of paragraph 31, wherein the human subject's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.
33. The method of paragraph 31, wherein the cancer is selected from breast,
15 ovarian, and lung cancers.
34. The method of paragraph 31-33, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
35. The method of any one of the paragraphs 31-33, wherein the reference value is
20 based on BRCA1 gene expression in the cancer cell.
36. The method of any one of the paragraphs 31-33, wherein the reference value is based on a housekeeping gene expression in the cancer cell.
37. A method of treating cancer in a human subject, comprising:
25 detecting BLM and FANCI expression in a sample comprising a cancer cell taken from the human subject; and
comparing the BLM and FANCI expression to a reference value; and
administering an anthracycline-comprising cancer therapy to the human subject wherein an increase of BLM and FANCI expression compared to the reference value is detected.
- 30 38. The method of paragraph 37, wherein the human subject's cancer or cancer cell is known to not or is determined to not to express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.
39. The method of paragraph 37, wherein the cancer is selected from breast, ovarian, and lung cancers.

40. The method of paragraph 37-39, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
41. The method of any one of the paragraphs 37-39, wherein the reference value is based on BRCA1 gene expression in the cancer cell.
42. The method of any one of the paragraphs 37-39, wherein the reference value is based on a housekeeping gene expression in the cancer cell.
43. A method for assessing responsiveness of a cancer cell to cancer therapy, comprising:
- 10 assaying, in a cancer cell or mRNA derived therefrom, BLM and FANCI expression; and
- comparing said BLM and FANCI expression to a reference value, wherein the cancer cell is assessed as responsive to a platinum-comprising therapy if the BLM and FANCI expression is increased compared to the reference value, or wherein the cancer cell is assessed as poorly or not responsive to platinum-comprising cancer therapy if the BLM and FANCI expression is not increased.
- 15
44. The method of paragraph 43, wherein the step of assaying comprises:
- contacting the cancer cell or mRNA derived therefrom with at least one detectably labeled probe capable of specifically binding to BLM mRNA, at least one detectably labeled probe capable of specifically binding to FANCI, at least one detectably labeled probe capable of specifically binding to BRCA1 and/or at least one housekeeping gene; and
- 20 measuring the expression of BLM and FANCI compared to the BRCA1 and/or the at least one housekeeping gene.
- 25
45. The method of paragraph 43-44, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
46. A method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising:
- 30 determining, in a cancer cell from the cancer patient, BLM and FANCI expression; and
- correlating the expression to a reference value, wherein when the expression is increased the patient is predicted to respond well to a cancer treatment regimen comprising platinum or anthracycline.

47. The method of paragraph 46, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
48. A method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising:
5 determining, in a cancer cell or mRNA derived therefrom from said cancer patient, BLM and FANCI expression; and
correlating the expression to a reference value, wherein when the expression is not increased the patient is predicted to respond poorly to a cancer treatment regimen
10 comprising platinum or anthracycline.
49. The method of paragraph 48, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
50. A method of treating cancer, comprising:
15 assaying, in a cancer cell from a cancer patient or mRNA obtained therefrom, the BLM and FANCI expression compared to a reference value; and
administering to the cancer patient a cancer treatment regimen comprising platinum or anthracycline if the BLM and FANCI expression is increased compared to the reference value.
- 20 51. The method of paragraph 50, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
52. Use of platinum comprising cancer therapy for treating a cancer patient that has been determined to have a tumor comprising cancer cells wherein BLM and
25 FANCI expression is increased compared to a reference value.
53. The use of paragraph 52, wherein the cancer patient has been determined to be negative for BRCA1 and/or BRCA2 mutations.
54. The use of paragraph 52, wherein the cancer patient's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor
30 (ER), progesterone receptor (PgR) and HER2 receptor.
55. The use of paragraph 52-54, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

56. A system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising:
a sample analyzer configured to produce a signal for the mRNA from each one of BLM and FANCI from a cancer cell sample of a cancer patient; and
5 a computer sub-system programmed to calculate, based on the mRNA whether the signal is greater or not than a reference value.
57. The system of paragraph 56, wherein said computer sub-system is programmed to compare the mRNA to determine
a likelihood of responsiveness of said cancer cell to platinum-comprising
10 cancer therapy based on an algorithm that classifies the patient as likely to respond to a platinum-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the platinum-comprising therapy if the BLM and FANCI expression is not increased; or
a likelihood of responsiveness of said cancer cell to anthracycline-comprising
15 cancer therapy based on an algorithm that classifies the patient as likely to respond to an anthracycline-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the anthracycline-comprising therapy if the BLM and FANCI expression is not increased.
58. The system of paragraph 56-57, wherein the reference value is BRCA1
20 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
59. A computer program product embodied in a computer readable medium that, when executing on a computer, performs steps comprising:
detecting the BLM and FANCI gene expression in sample comprising a cancer
25 cell from a cancer patient; and
comparing the BLM and FANCI expression to a reference value.
60. The computer program of paragraph 59, wherein the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
- 30 61. A diagnostic kit for detecting a likelihood of a cancer patient to respond to platinum- or anthracycline-comprising comprising cancer therapy, comprising:
no more than 10 probes comprising a combination of detectably labeled probes or primers for BLM and FANCI, and optionally for BRCA1 and/or at least one housekeeping gene; and

the computer program product of Paragraph 59.

62. Use of a plurality of oligonucleotides comprising no more than 10 oligonucleotides capable of hybridizing to BLM and FANCI, and optionally to BRCA1 and/or at least one housekeeping gene, in a diagnostic kit for determining an increased likelihood that a cancer patient will respond to cancer treatment regimen comprising a platinum and/or anthracycline.
63. The use, method or assay of any one of the preceding paragraphs, wherein said anthracycline is epirubicin or doxorubicin.
64. The use, method or assay of any one of the preceding paragraphs, wherein said platinum comprising cancer therapy comprises cisplatinum or cis-diamminedichloroplatinum, phenanthriplatin, carboplatin, oxaliplatin, or a platinum complex that is activated by ultraviolet A light.
65. An assay for selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising:
- assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number;
- comparing the chromosome 15q26 copy number to a reference value; and
- selecting a platinum-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or selecting a non-platinum-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.
66. The assay of paragraph 65, further comprising:
- assaying the BRCA1 and/or BRCA2 status of the subject; and
- selecting the platinum-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and there is a chromosome 15q26 copy number gain based on the recognition that platinum-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain who are negative for BRCA1 and/or BRCA2 mutations.
67. The assay of paragraph 65, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.
68. The assay of paragraph 65, further comprising:
- assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and

selecting the platinum-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when there is a chromosome 15q26 copy number gain based on the recognition that platinum-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor.

69. The assay of paragraph 65, wherein the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.

70. The assay of paragraphs 65-69, further comprising administering the selected therapy to the subject.

71. The assay of paragraphs 65-71, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.

72. The assay of paragraphs 65-71, wherein the reference value is chromosome 15 centromere copy number in the sample.

73. An assay for selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising:

assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number;

comparing the chromosome 15q26 copy number to a reference value; and

selecting an anthracycline-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or selecting a non-anthracycline-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.

74. The assay of paragraph 73, further comprising:

assaying the BRCA1 and/or BRCA2 status of the subject; and

selecting the anthracycline-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and there is a chromosome 15q26 copy number gain based on the recognition that anthracycline-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain who are negative for BRCA1 and/or BRCA2 mutations.

75. The assay of paragraph 73, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.

76. The assay of paragraph 73, further comprising:
assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2
receptor status of the subject's cancer; and
selecting the anthracycline-comprising cancer therapy for the subject when the
subject's cancer does not express a detectable quantity of ER, PgR, and HER2
receptor, and when there is a chromosome 15q26 copy number gain based on the
recognition that anthracycline-comprising cancer therapy is effective in subjects who
have a chromosome 15q26 copy number gain and whose cancer does not express a
detectable quantity of ER, PgR, and HER2 receptor.
77. The assay of paragraph 73, wherein the subject's cancer or cancer cell is
known to not or is determined to not express a detectable quantity of ER, PgR, and
HER2 receptor.
78. The assay of paragraphs 73-77, further comprising administering the selected
therapy to the subject.
79. The assay of paragraphs 73-78, wherein the cancer is selected from breast
cancer, ovarian cancer and lung cancer.
80. The assay of paragraphs 73-79, wherein the reference value is chromosome 15
centromere copy number in the sample.
81. A method of treating cancer in a human subject, comprising:
detecting a chromosome 15q26 copy number in a sample comprising a cancer
cell taken from the subject;
comparing the chromosome 15q26 copy number to a reference value; and
administering an platinum-comprising cancer therapy for the subject if there is
a chromosome 15q26 copy number gain compared to the reference value, or
administering a non-platinum-comprising cancer therapy for the subject if there is not
a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy
number loss.
82. The method of paragraphs 81, wherein the cancer is selected from breast
cancer, ovarian cancer and lung cancer.
83. The method of paragraphs 81-82, wherein the reference value is chromosome
15 centromere copy number in the sample.
84. The method of paragraph 81-83, wherein the subject's cancer is known to not
express a detectable quantity of ER, PgR, and HER2 receptor.
85. A method of treating cancer in a human subject, comprising:

detecting a chromosome 15q26 copy number in a sample comprising a cancer cell taken from the subject;

comparing the chromosome 15q26 copy number to a reference value; and

administering an anthracycline-comprising cancer therapy for the subject if

5 there is a chromosome 15q26 copy number gain compared to the reference value, or administering a non-anthracycline-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.

10 86. The method of paragraphs 85, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.

87. The method of paragraphs 85-86, wherein the reference value is chromosome 15 centromere copy number in the sample.

15 88. The method of paragraph 85-88, wherein the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.

89. A method for assessing responsiveness of a cancer cell to a cancer therapy, and optionally administering the cancer therapy, comprising:
assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number;

20 and comparing the chromosome 15q26 copy number to a reference value, wherein the cancer cell is assessed as responsive to a platinum-comprising therapy if there is a chromosome 15q26 copy number gain compared to the reference value, or wherein the cancer cell is assessed as poorly or not responsive to platinum-comprising cancer therapy cancer if there is not a chromosome 15q26 copy number gain or if
25 there is a chromosome 15q26 copy number loss.

90. The method of paragraph 89, wherein the reference value is copy number of chromosome 15.

91. The method of paragraph 89, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.

30 92. The method of paragraph 89, further comprising administering the platinum-comprising therapy if there is a chromosome 15q26 copy number gain.

93. A method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising:

determining, in a cancer cell from the cancer patient, chromosome 15q26 copy number; and

correlating the chromosome 15q26 copy number to a reference value,

wherein when there is a chromosome 15q26 copy number gain, the patient is predicted to respond well to a cancer treatment comprising platinum or anthracycline, or wherein when there is not a chromosome 15q26 copy number gain or a chromosome 15q26 copy number loss, the patient is predicted respond poorly to a cancer treatment comprising platinum or anthracycline.

94. The method of paragraph 93, wherein the reference value is chromosome 15 centromere copy number in the sample.

95. Use of platinum comprising cancer therapy for treating a cancer patient that has been determined to have a tumor comprising cancer cells wherein a chromosome 15q26 copy gain is detected compared to a reference value.

96. The use of paragraph 95, wherein the cancer patient is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.

97. The use of paragraph 95, wherein the cancer patient's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.

98. The use of paragraph 95-97, wherein the reference value is chromosome 15 centromere copy number in the sample.

99. A system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising:

a sample analyzer configured to produce a signal for chromosome 15q26 copy number from a cancer cell sample of a cancer patient; and

a computer sub-system programmed to calculate, based on the mRNA whether the signal is greater or not than a reference value.

100. The system of paragraph 99, wherein said computer sub-system is programmed to compare the mRNA to determine

a likelihood of responsiveness of said cancer cell to platinum-comprising cancer therapy and/or or a anthracycline-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a platinum-comprising therapy if there is a chromosome 15q26 copy number gain and as unlikely to respond to the platinum-comprising therapy if there is not a chromosome 15q26 copy number gain or if there is a chromosome 15q26 copy number loss.

101. The system of paragraph 99-100, wherein the reference value is chromosome 15 centromere copy number in the sample.
102. A computer program product embodied in a computer readable medium that, when executing on a computer, performs steps comprising:
5 detecting chromosome 15q26 copy number in sample comprising a cancer cell from a cancer patient; and
comparing the chromosome 15q26 copy number to a reference value.
103. The computer program of paragraph 102, wherein the reference value is chromosome 15 centromere copy number in the sample.
- 10 104. A diagnostic kit for detecting a likelihood of a cancer patient to respond to platinum- or anthracycline-comprising cancer therapy, comprising:
no more than 10 probes comprising a combination of detectably labeled probes or primers for chromosome 15q26, and optionally for chromosome 15 centromere; and
15 the computer program product of Paragraph 102.
105. Use of a plurality of oligonucleotides comprising no more than 10 oligonucleotides capable of hybridizing to chromosome 15q26, and optionally for chromosome 15 centromere, in a diagnostic kit for determining an increased likelihood that a cancer patient will respond to cancer treatment regimen comprising a
20 platinum and/or anthracycline.
106. The use, method or assay of paragraphs 65-105, wherein said anthracycline is epirubicin or doxorubicin.
107. The use, method or assay paragraphs 65-105, wherein said platinum comprising cancer therapy comprises cisplatin or cis-diamminedichloroplatinum, phenanthriplatin, carboplatin, oxaliplatin, or a platinum complex that is activated by
25 ultraviolet A light.

[00328] The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit
30 the invention. One skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.

Example 1

[00329] Two clinical trials with cisplatin given to women with triple negative breast cancer were evaluated.

[00330] Cisplatin-1 (DFHCC 04-183; Silver et al., JCO 2010): 28 TNBC patients received neoadjuvant cisplatin as single agent. 10 (36%) achieved at least 90% reduction in tumor size. Good quality RNA and DNA were acquired from 21 tumors. Copy number and gene expression were assayed using AFFYMETRIX arrays.

5 [00331] Cisplatin-2 (DFHCC 06-202; Ryan et al., JCO 2009): 51 TNBC patients received neoadjuvant cisplatin in combination with the angiogenesis inhibitor bevacizumab. 44 patients completed therapy. 17 (39%) achieved at least 90% reduction in tumor size. Frozen DNA samples were acquired from 24 tumors, mRNA from 21. Copy number and gene expression assayed using AFFYMETRIX arrays.

10 *Example 2*

[00332] In order to find regions or genes where gain or loss were significantly associated with sensitivity of resistance cisplatin, ~40,000 SNP probes were used in Cisplatin-1 trial and ~330,000 SNP probes were used in Cisplatin-2 trial to determine sensitivity and resistance. GISTIC identified chromosomal regions that were significantly enriched in either group. Gene copy number comparison showed that genes significantly gained or lost between sensitive and resistant cases, in both cohorts. Comparison to gene expression showed overlap with genes showing differential expression between sensitive and resistant cancers. *See e.g.*, Figures 1-3.

Example 3

20 [00333] In a comparison to gene expression data, the inventors found genes that show both significant gain and higher expression in sensitive sample. In Cisplatin-1 trial, there were 21 cases; Cisplatin-2 trial, there were 21 cases. In an ovarian cancer trial (OV-01 trial; Ahmed et al., Cancer Cell 2007), the two arm carboplatinum had 15 cases and paclitaxel had 19 cases. A leave-one-out analysis of the gene expression data was performed from both platinum breast cancer trials and the carboplatinum arm of OV01. *See e.g.*, Figures 4-5.

Example 4

[00334] In evaluating Hess et al., JCO 2006; Popovici et al., Breast Cancer Res 2010; and André et al., Clin Cancer Res 2009, expression of BLM or FANCI is not found to be associated with response to multi-agent chemotherapy regimens in TNBC. *See e.g.*, Figure 6.

30 *Example 5*

[00335] In evaluating Desmedt et al., JCO 2011, BLM is associated with response to single agent epirubicin. *See e.g.*, Figure 7.

Example 6

*Chromosome 15q26 copy number and overexpression of BLM and FANCI
predict for cisplatin sensitivity*

[00336] To elucidate if particular genomic aberrations may affect cancer cells sensitivity to cisplatin, we compared the tumor DNA copy number profiles in sensitive versus resistant TN breast tumors in the two separate cisplatin clinical trials. We identified several sites of DNA copy number change in each trial, but only a short 15 megabase (MB) region on chromosome 15q26 was significantly different between responders and nonresponders in both trials. In addition to SNP profiles, we have analyzed the pretreatment tumor samples for both Cisplatin1 and Cisplatin2 for mRNA expression profiles on Affymetrix microarrays. In addition, gene expression array data was publically available from the carboplatin arm of a previously published two-arm trial of carboplatin and paclitaxel in serous ovarian cancer[31]. To determine if any specific genes were consistently differentially expressed in platinum sensitive compared to resistant tumors, we performed a leave-one-out analysis in each trial, where we in each round compared the sensitive to the resistant tumors, and scored how many genes showed a significant association. We found that only 3 genes were consistently significantly different in all three platinum-based trials: MCM2, BLM, and FANCI. Interestingly, FANCI and BLM are both located on 15q26.1 and the proteins have been shown to localize to sites of DNA damage. This shows that using two different methods measuring two different biomolecules, high levels of BLM and FANCI DNA and mRNA is associated with greater sensitivity to platinum-based chemotherapy.

[00337] To investigate if higher expression of BLM and FANCI were specifically associated with platinum chemotherapy response, we analyzed the gene expression in the paclitaxel arm of the ovarian trial[31], and across the TN breast cancer subset of three neoadjuvant cohorts that received taxane-containing combination chemotherapy[32-34].

[00338] In the ovarian paclitaxel trial and in the TN subset of the taxane-containing multidrug trials there was no association between either BLM or FANCI and therapy response. These data suggests that high expression of BLM and FANCI are possibly specifically associated with sensitivity to DNA damaging agents like the platinum salts, but not with response to chemotherapeutics that alter microtubules such as taxanes.

[00339] We combined the mRNA results into a predictive gene signature: $(BRCA1 \text{ mRNA}) / (\text{average of FANCI and BLM mRNA})$. ROC analysis demonstrates that this 3gene mRNA signature is significantly associated with cisplatin response in both TN cisplatin trials (**Fig. 10A**). A prediction model combining NtAI and the 3 gene signature improved the prediction of cisplatin sensitivity (**Fig. 10B**). Based on the combined model, 25% of cases are

“biomarker positive” with predictive accuracy of 0.86, a positive predictive value of 0.89, a negative predictive value of 0.85, sensitivity of 0.67, and specificity of 0.96 with a p-value of 0.00016.

Example 7

5 *Optimization of BRCA1-BLM-FANCI mRNA measurement:*

[00340] Several different RT-PCR primer pair assays will be designed to measure mRNA expression for each of the three genes. Data from the Cisplatin2 trial comparing the BRCA1, BLM, and FANCI mRNA levels on microarray to mRNA levels as measured by quantitative real-time PCR and found good correlation. The 3-gene predictive model of
10 BRCA1/(avg of BLM+FANCI) using the RT-PCR measurements performed very well for prediction of cisplatin response (**Fig 11**).

Example 8

[00341] Platinum salts are effective treatment and standard therapy for a number of cancer types including serous ovarian carcinoma, high grade urothelial carcinoma, pancreatic
15 adenocarcinoma, glioblastoma multiforme, and lung squamous cell carcinoma. Breast adenocarcinomas arising in women carrying BRCA1 or BRCA2 mutations are also sensitive to cisplatin chemotherapy (Byrski, 2008). BRCA1 is a tumor suppressor that plays important roles in several aspects of maintenance of genome integrity. Complete absence of functional BRCA1, as occurs in tumors of BRCA1 mutation carriers with loss of the wild-type allele,
20 leads to defective error-free homologous recombination-type double strand break repair. These BRCA1^{-/-} tumors are sensitive to inhibitors of PARP1 (ref) whereas, so far, few or no sporadic BRCA wild-type breast cancers have responded to these agents. Recent studies have shown that in addition to double strand break repair, BRCA1 also plays an important role in response to replication stress and repair of stalled or collapsed replication forks
25 (Pathania, 2011). Preliminary evidence suggests the replication repair functions of BRCA1 may be haploinsufficient in BRCA1 heterozygous cells (Pathania, unpublished data). The platinum salts generate interstrand and intrastrand crosslinks that distort DNA and lead to stalled replication forks. If these stalled forks collapse, double strand breaks will results. It is possible that several BRCA1-dependent pathways are involved in platinum-induced DNA
30 damage response including damage recognition and lesion excision, suppression of translesion synthesis, checkpoint activation, and repair of DS breaks after fork collapse.

[00342] The activity of cisplatin has recently been extended to estrogen, progesterone, and HER2 receptor negative sporadic breast cancers (triple-negative breast cancers, TNBC)(Silver, 2010; Birkbak, 2012; Ryan, 2009). When carboplatin was added to

anthracycline and taxane chemotherapy for treatment of TNBC, the response rate was higher but resulted in notably greater toxicity. Predictors of tumor response to platinum salts are needed to determine which patients may derive the greatest benefit from the addition of platinum. Previous molecular studies have shown the platinum-sensitive TNBC and serous ovarian cancers carry high levels of genomic rearrangements and chromosomal allelic imbalance, suggesting these cancers may share similar defects in DNA repair, which may make them particularly sensitive to platinum chemotherapy (Birkbak, 2012). Many of the platinum-sensitive sporadic TNBCs have promoter methylation and reduction in the expression of BRCA1 (Birkbak, 2012; Silver, 2010). These result suggests that platinum sensitivity may be related to a functional defect that occurs when there is insufficient BRCA1 levels, raising the possibility that defects in a haploinsufficient function of BRCA1, such as replication-dependent stalled fork repair, may be indicative of sensitivity to interstrand cross-linkers such as the platinum salts.

[00343] To further explore and define other specific molecular alterations that might be associated with cisplatin sensitivity, we took and integrated genomic approach combining differential analysis of gene expression and DNA copy number in cisplatin sensitive compared to cisplatin resistant triple negative breast cancers. We identify two genes, the Bloom helicase (BLM) and Fanconi anemia complementation group I (FANCI), that have both increased DNA copy number at chr 15q26 and concordant mRNA overexpression in the TNBC with increased sensitivity to cisplatin therapy. In vitro modulation of BLM and FANCI expression suggest these two genes play a functional role and promote DNA damage and sensitivity to platinum salts, but have no effect on taxane sensitivity.

[00344] Identification of genes critical for tumor response to specific chemotherapy drugs is a challenge, but important for tailoring therapy and avoiding unnecessary toxicity in patients. Integrated genomic approaches that combine DNA copy number analysis with gene expression profile analysis has successfully indicated genomic alterations associated with chemotherapy resistance and tumor response (Li, 2010). We have previously published the results of two trials of cisplatin chemotherapy in TNBC in which presurgical treatment with cisplatin resulted in greater than 90% reduction in tumor volume in 36% and 39% of patients respectively (Silver, 2010; Ryan, 2009). Molecular inversion probe SNP copy number profiles of pretreatment tumors from both cisplatin TNBC trials were reported previously (Birkbak, 2012). Gene expression profiles from the pretreatment tumor samples from the first cisplatin TNBC trial were also reported previously (Silver, 2010). For this study, we

generated gene expression profiles from the pretreatment tumor biopsies from the second cisplatin TNBC trial.

[00345] To determine genes whose expression is significantly and robustly associated with response to cisplatin, we performed a leave-one-out differential gene expression analysis in each trial, comparing the gene expression of tumors resistant to cisplatin to tumors that were sensitive to cisplatin. For each leave-one-out round, one sample was removed and all genes significantly associated with response were determined. The direction of association for each gene (higher in sensitive vs. lower in sensitive) was also noted. Permutation testing of this gene expression comparison exercise indicated that a gene must be present in 85% or more rounds to be significant. This analysis identified only 12 genes whose expression was significantly associated with platinum response, in the same direction, in at least 85% of all rounds in both cisplatin TNBC cohorts.

[00346] We performed next a similar leave one out comparison analysis of the DNA copy numbers of cisplatin sensitive vs. cisplatin resistant TNBC tumors in the two trials. Permutation testing of the DNA copy number LOO analysis indicated that a gene must be present in 50% or more LOO rounds to be significant. This analysis identified 234 genes from four different chromosomes with differential copy number associated with cisplatin response in at least 50% of all rounds in both cisplatin TNBC cohorts.

[00347] Only two genes were identified in both the DNA copy number and gene expression leave-one-out analyses for association with platinum sensitivity, Bloom helicase (BLM) and Fanconi anemia complementation group I (FANCI), both located at chromosome 15q26. The DNA copy number of the 15q26 region containing these two genes was significantly higher in the cisplatin-sensitive tumors in both TNBC cohorts ($p = 0.00236$ and $p = 0.0107$, respectively). Similarly, cisplatin sensitive tumors had significantly higher BLM expression in both TNBC cohorts (cisplatin-1, mean log₂ expression, 8.26 versus 7.54, $p = 0.00278$; cisplatin-2, mean log₂ expression, 10.67 versus 9.41, $p = 0.00745$; Fig 1C-D). FANCI expression was higher in the cisplatin-sensitive TNBCs in both cohorts (cisplatin-1, mean log₂ expression 7.87 versus 6.80, $p = 0.00356$; cisplatin-2, mean log₂ expression 10.74 versus 9.77, $p = 0.0125$).

[00348] The gene expression of BLM and FANCI as measured by Affymetrix U133 array was validated by RT-PCR in the same samples and the results showed good correlation (BLM, $r = 0.866$; FANCI, $r = 0.733$). BLM (and FANCI) are reported to have post-translational mechanisms of protein regulation. To determine if overexpression of BLM and FANCI mRNA also results in increased expression of the protein, we measured BLM (and

FANCI) protein by western blot analysis in protein extracts from a series of frozen breast tumor samples for which mRNA gene array expression levels were known (Lu, 2008). BLM normalized to actin (and FANCI) showed good correlation between mRNA expression levels and protein expression levels ($r = 0.70$).

5 [00349] BRCA1 as measured by RT-PCR was identified in our previous studies as significantly associated with cisplatin resistance (Birkbak, 2012; Silver, 2010). In contrast to BLM and FANCI, BRCA1 expression as measured by microarray was poorly correlated with expression as measured by RT-PCR ($r = \text{xxx}$); the microarray BRCA1 probe performance was especially poor in the data from first cisplatin TNBC cohort. Therefore, we used the RT-
10 PCR expression data to test the association of the ratio of BRCA1/average (BLM+FANCI) expression and cisplatin response. The ratio was significantly higher in the cisplatin sensitive tumors in both cohorts (cisplatin-1, median x vs y , $p = 0.023$; cisplatin-2, median 7.69 vs 4.07, $p = 0.0016$).

[00350] To validate these specific gene associations with platinum response, we tested
15 a publically available gene expression data set from a serous ovarian cancer trial of either carboplatin monotherapy or paclitaxel monotherapy and sought associations with response to the therapy received. The average expression of BLM and FANCI was significantly higher in the carboplatin-sensitive ovarian cancers (median 5.46 versus 4.50, $p = 0.026$). The ratio of BLM+FANCI/BRCA1 was also significantly higher in carboplatin sensitive ovarian
20 cancers (median 1.29 vs 0.42, $p = 0.026$). Interestingly, the association of BLM and FANCI with paclitaxel response was not significant and the trend was in the opposite direction (median 5.17 versus 4.79, $p = 0.27$).

[00351] We also showed protein abundance of BRCA1, BLM, FANCI, and Cyclin A was measured by Western blot analysis in protein extracts from a panel of breast cancer cell
25 lines. The bands were quantitated by densitometry and displayed in bar plots. We showed the quantitation of BLM to Actin and BRCA1 to BLM ratio. Three cell lines (BT549, HCC1143, and HCC38) are normal genotype for BRCA1 and have high BLM/Actin and low ratio of BRCA1/BLM. Two cell lines (MDA231 and MDA453) are also normal genotype for BRCA1 but have relatively higher expression of BRCA1/BLM and lower BLM/actin. HCC1937 and
30 MDA436 have homozygous mutation in BRCA1 and undetectable BRCA1/BLM, and higher expression of BLM/Actin.

[00352] A panel of cell lines was evaluated for sensitivity to various treatments as indicated by colony formation assay and calculation of IC50 values. We showed a pattern of sensitivity to cisplatin, UV radiation treatment, and Parp inhibitor Olaparib across the panel

of cell lines is associated with the pattern of relative expression of BRCA1/BLM and BLM/Actin. The two BRCA1 mutated cell lines and the three cell lines with low BRCA1/BLM and high BLM/actin have greater sensitivity to DNA strand cross-linker cisplatin, PARP inhibitor Olaparib, and UV irradiation. The two cell lines with low BLM and high BRCA1/BLM (MDA231, MDA453) are relatively resistant to these treatments. In contrast, there is no apparent association between BLM and BRCA1 expression with the pattern of sensitivity to the microtubule stabilizer Paclitaxel.

[00353] We also treated U2OS cells treated shRNA to BRCA1. After 1 week, the expression of BRCA1 and BLM were measured by Western blot analysis. Cells treated with the BRCA1 specific shRNA showed increased expression of BLM compared to control cells treated with shRNA to luciferase .

[00354] We further treated BT549 breast cancer cells, with inherent high levels of BLM and FANCI were treated with gene-specific siRNAs to BLM or FANCI or with a scramble control. Gene specific siRNA treatment resulted in reduced mRNA expression as determined by RT-PCR. Sensitivity to cisplatin and to paclitaxel was determined by colony formation assay to calculate the IC50. siRNA knockdown of either BLM or FANCI resulted in increased IC50 (greater resistance) to cisplatin treatment but no significant effect on sensitivity to paclitaxel.

[00355] MDA231 cells have low levels of BLM and relative resistance to cisplatin.

These cells were used in experiments to assess the effect of increasing the expression of BLM. A lentivirus expression vector for HA-tagged BLM cDNA or a control vector was transfected into MDA231 cells. BLM expression was assessed by Western blot analysis for endogenous BLM or for the HA-tag in cells treated with control vector, BLM cDNA, BLM cDNA and a small molecule inhibitor of BLM helicase (BLMi), or BLM cDNA and BLM siRNA. We showed that siRNA for BLM reduced the expression of endogenous and HA-tagged BLM whereas the small molecule inhibitor (BLMi) had no effect on protein expression of BLM.

[00356] IC50 for cisplatin was determined by colony formation assay in MDA231 breast cancer cells treated with control vector, BLM cDNA vector, BLM cDNA plus the BLM small molecule inhibitor, and BLM cDNA plus BLM siRNA. Overexpression of BLM resulted in decrease in the IC50 (greater sensitivity) to cisplatin. Consistent with the other findings, this effect was reversed by treatment with the BLM helicase inhibitor and by siRNA knockdown of BLM.

[00357] We also performed an immunofluorescence assay for markers of DNA damage (H2Ax-p and 53BP1-p) in MDA231 cells treated with control vector, BLM cDNA, BLM cDNA + BLM inhibitor, or BLM cDNA +BLM siRNA. Overexpression of BLM results in increased H2AX and 53BP1 foci in the absence of any cisplatin treatment
5 indicating spontaneous DNA damage. This effect is even greater in cells treated with cisplatin after 4 hours. The quantitation of foci is shown in the lower bar graphs. The addition of a small molecule BLM helicase inhibitor (Bi) or siRNA to BLM (si) blocks the effect of BLM overexpression on DNA damage foci.

10 **Incorporation by Reference**

[00358] All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

15 [00359] Also incorporated by reference in their entirety are any polynucleotide and polypeptide sequences which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) on the world wide web and/or the National Center for Biotechnology Information (NCBI) on the world wide web.

20 **Equivalents**

[00360] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

[00361] Various embodiments of the invention are described above in the Detailed
25 Description. While these descriptions directly describe the above embodiments, it is understood that those skilled in the art may conceive modifications and/or variations to the specific embodiments shown and described herein. Any such modifications or variations that fall within the purview of this description are intended to be included therein as well. Unless specifically noted, it is the intention of the inventors that the words and phrases in the
30 specification and claims be given the ordinary and accustomed meanings to those of ordinary skill in the applicable art(s).

[00362] The foregoing description of various embodiments of the invention known to the applicant at this time of filing the application has been presented and is intended for the purposes of illustration and description. The present description is not intended to be

exhaustive nor limit the invention to the precise form disclosed and many modifications and variations are possible in the light of the above teachings. The embodiments described serve to explain the principles of the invention and its practical application and to enable others skilled in the art to utilize the invention in various embodiments and with various

5 modifications as are suited to the particular use contemplated. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed for carrying out the invention.

[00363] While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein,
10 changes and modifications may be made without departing from this invention and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this invention. It will be understood by those within the art that, in general, terms used herein are generally intended as “open” terms (*e.g.*, the term “including” should be interpreted as “including but
15 not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.).

WHAT IS CLAIMED IS:

1. An assay for selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising:
 - subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;
 - comparing the BLM and FANCI expression to a reference value; and
 - selecting a platinum-comprising cancer therapy for the subject when the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI, or selecting a non-platinum-comprising cancer therapy for the subject when the BLM and FANCI expression is not increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is not effective in subjects whose cancer does not have increased BLM and FANCI expression compared to the reference value.
2. The assay of claim 1, further comprising:
 - assaying the BRCA1 and/or BRCA2 status of the subject; and
 - selecting the platinum-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI and who are negative for BRCA1 and/or BRCA2 mutations.
3. The assay of claim 1, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.
4. The assay of claim 1, further comprising:
 - assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and
 - selecting the platinum-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when the BLM and FANCI expression is increased compared to the reference value based on the recognition that platinum-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor.

5. The assay of claim 1, wherein the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.
6. The assay of claims 1-5, further comprising administering the selected therapy to the subject.
7. The assay of any one of the claims 1-6, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.
8. The assay of claims 1-6, wherein the reference value is BRCA1 expression in the sample and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
9. The assay of claims 1-6, wherein the reference value is based on at least BRCA1 gene expression in the cancer cell.
10. The assay claims 1-6, wherein the reference value is based on at least one housekeeping gene expression in the cancer cell.
11. A method for selecting platinum-comprising therapy for a subject having cancer, and optionally administering the platinum-comprising therapy, the method comprising:
 - subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;
 - detecting the BLM and FANCI expression in the sample compared to a reference value; and
 - selecting a platinum-comprising cancer therapy for the subject when the BLM and FANCI expression compared to a reference value is increased based on the recognition that platinum-comprising cancer therapy is effective in patients whose cancer has increased BLM and FANCI expression compared to the reference value.
12. The method of claim 11, further comprising administering to the subject the platinum-comprising cancer therapy when the platinum-comprising cancer therapy is selected.
13. The method of claim 11, wherein the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.
14. The method of claim 11, wherein the subject's cancer or cancer cell is known to not or determined to not express a detectable quantity of ER, PgR, and HER2 receptor.
15. The method of any one of the claims 11-14, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.
16. The method of claim 11-15, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

17. The method of any one of the claims 11-15, wherein the reference value is based on at least BRCA1 gene expression in the cancer cell.
18. The method of any one of the claims 11-15, wherein the reference value is based on at least one housekeeping gene expression in the cancer cell.
19. The method of claim 18, wherein the housekeeping gene is selected from beta-actin, GAPDH, RPLP0, GUS, TFRC and any combination thereof.
20. The method of claim 19, wherein the housekeeping gene is RPLP0, and the BLM and/or FANCI expression is increased by at least six-fold.
21. A method for selecting a non-platinum-comprising therapy, and optionally administering the non-platinum-comprising therapy, for a subject having cancer comprising:
 - subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;
 - detecting the BLM and FANCI expression in the sample compared to a reference value; and
 - selecting the non-platinum-comprising cancer therapy for the subject when the BLM and FANCI expression compared to the reference value is not increased based on the recognition that non-platinum-comprising cancer therapy is effective in patients whose cancer does not have increased gene expression of BLM and FANCI compared to the reference value.
22. The method of claim 21, further comprising administering to the subject the non-platinum-comprising cancer therapy when non-platinum-comprising cancer therapy is selected.
23. The method of any one of the claims 21-22, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.
24. The method of claim 21-23, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
25. The method of any one of the claims 21-24, wherein the reference value is based on at least BRCA1 gene expression in the cancer cell.
26. The method of any one of the claims 21-22, wherein the reference value is based on at least one housekeeping gene expression in the cancer cell.
27. An assay for selecting a therapy for a subject having cancer, comprising:

subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;

comparing the BLM and FANCI expression to a reference value; and

selecting an anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression is increased compared to a reference value based on the recognition that anthracycline-comprising cancer therapy is effective in subjects whose cancer has increased expression of BLM and FANCI, or

selecting a non-anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression is not increased compared to a reference value based on the recognition that anthracycline-comprising cancer therapy is not effective in subjects whose cancer does not have increased BLM expression compared to a reference value.

28. The assay of claim 27, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

29. A method for selecting an anthracycline-comprising cancer therapy for a subject having cancer and determined to be negative for BRCA1 and/or BRCA2 mutations, comprising:

subjecting a sample comprising a cancer cell taken from the subject to an analysis for BLM and FANCI expression;

comparing the BLM and FANCI expression to a reference value; and

selecting the anthracycline-comprising cancer therapy for the subject when the BLM and FANCI expression compared to the reference value is increased based on the recognition that anthracycline-comprising cancer therapy is effective in patients whose cancer has increased expression of BLM and FANCI compared to the reference value.

30. The method of claim 29, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.

31. A method of treating cancer in a human subject, comprising:

detecting BLM and FANCI expression in a sample comprising a cancer cell taken from the human subject; and

comparing the BLM and FANCI expression to a reference value; and

- administering a platinum-comprising cancer therapy to the human subject wherein an increase of BLM and FANCI expression compared to the reference value is detected.
32. The method of claim 31, wherein the human subject's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.
 33. The method of claim 31, wherein the cancer is selected from breast, ovarian, and lung cancers.
 34. The method of claim 31-33, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
 35. The method of any one of the claims 31-33, wherein the reference value is based on BRCA1 gene expression in the cancer cell.
 36. The method of any one of the claims 31-33, wherein the reference value is based on a housekeeping gene expression in the cancer cell.
 37. A method of treating cancer in a human subject, comprising:
 - detecting BLM and FANCI expression in a sample comprising a cancer cell taken from the human subject; and
 - comparing the BLM and FANCI expression to a reference value; and
 - administering an anthracycline-comprising cancer therapy to the human subject wherein an increase of BLM and FANCI expression compared to the reference value is detected.
 38. The method of claim 37, wherein the human subject's cancer or cancer cell is known to not or is determined to not to express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.
 39. The method of claim 37, wherein the cancer is selected from breast, ovarian, and lung cancers.
 40. The method of claim 37-39, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
 41. The method of any one of the claims 37-39, wherein the reference value is based on BRCA1 gene expression in the cancer cell.
 42. The method of any one of the claims 37-39, wherein the reference value is based on a housekeeping gene expression in the cancer cell.

43. A method for assessing responsiveness of a cancer cell to cancer therapy, comprising:
assaying, in a cancer cell or mRNA derived therefrom, BLM and FANCI expression; and
comparing said BLM and FANCI expression to a reference value, wherein the cancer cell is assessed as responsive to a platinum-comprising therapy if the BLM and FANCI expression is increased compared to the reference value, or wherein the cancer cell is assessed as poorly or not responsive to platinum-comprising cancer therapy cancer if the BLM and FANCI expression is not increased.
44. The method of claim 43, wherein the step of assaying comprises:
contacting the cancer cell or mRNA derived therefrom with at least one detectably labeled probe capable of specifically binding to BLM mRNA, at least one detectably probe capable of specifically binding to FANCI, at least one detectably labeled probe capable of specifically binding to BRCA1 and/or at least one housekeeping gene; and
measuring the expression of BLM and FANCI compared to the BRCA1 and/or the at least one housekeeping gene.
45. The method of claim 43-44, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
46. A method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising:
determining, in a cancer cell from the cancer patient, BLM and FANCI expression; and
correlating the expression to a reference value, wherein when the expression is increased the patient is predicted to respond well to a cancer treatment regimen comprising platinum or anthracycline.
47. The method of claim 46, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
48. A method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising:
determining, in a cancer cell or mRNA derived therefrom from said cancer patient, BLM and FANCI expression; and

- correlating the expression to a reference value, wherein when the expression is not increased the patient is predicted to respond poorly to a cancer treatment regimen comprising platinum or anthracycline.
49. The method of claim 48, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
50. A method of treating cancer, comprising:
- assaying, in a cancer cell from a cancer patient or mRNA obtained therefrom, the BLM and FANCI expression compared to a reference value; and
 - administering to the cancer patient a cancer treatment regimen comprising platinum or anthracycline if the BLM and FANCI expression is increased compared to the reference value.
51. The method of claim 50, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
52. Use of platinum comprising cancer therapy for treating a cancer patient that has been determined to have a tumor comprising cancer cells wherein BLM and FANCI expression is increased compared to a reference value.
53. The use of claim 52, wherein the cancer patient has been determined to be negative for BRCA1 and/or BRCA2 mutations.
54. The use of claim 52, wherein the cancer patient's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.
55. The use of claim 52-54, wherein the reference value is BRCA1 expression in the sample, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
56. A system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising:
- a sample analyzer configured to produce a signal for the mRNA from each one of BLM and FANCI from a cancer cell sample of a cancer patient; and
 - a computer sub-system programmed to calculate, based on the mRNA whether the signal is greater or not than a reference value.
57. The system of claim 56, wherein said computer sub-system is programmed to compare the mRNA to determine

a likelihood of responsiveness of said cancer cell to platinum-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a platinum-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the platinum-comprising therapy if the BLM and FANCI expression is not increased; or

a likelihood of responsiveness of said cancer cell to anthracycline-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a anthracycline-comprising therapy if the BLM and FANCI expression is increased and as unlikely to respond to the anthracycline-comprising therapy if the BLM and FANCI expression is not increased.

58. The system of claim 56-57, wherein the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
59. A computer program product embodied in a computer readable medium that, when executing on a computer, performs steps comprising:
- detecting the BLM and FANCI gene expression in sample comprising a cancer cell from a cancer patient; and
 - comparing the BLM and FANCI expression to a reference value.
60. The computer program of claim 59, wherein the reference value is BRCA1 expression, and the BLM and/or FANCI expression is increased by at least two-fold compared to BRCA1 expression.
61. A diagnostic kit for detecting a likelihood of a cancer patient to respond to platinum- or anthracycline-comprising comprising cancer therapy, comprising:
- no more than 10 probes comprising a combination of detectably labeled probes or primers for BLM and FANCI, and optionally for BRCA1 and/or at least one housekeeping gene; and
 - the computer program product of Claim 59.
62. Use of a plurality of oligonucleotides comprising no more than 10 oligonucleotides capable of hybridizing to BLM and FANCI, and optionally to BRCA1 and/or at least one housekeeping gene, in a diagnostic kit for determining an increased likelihood that a cancer patient will respond to cancer treatment regimen comprising a platinum and/or anthracycline.
63. The use, method or assay of any one of the preceding claims, wherein said anthracycline is epirubicin or doxorubicin.

64. The use, method or assay of any one of the preceding claims, wherein said platinum comprising cancer therapy comprises cisplatin or cis-diamminedichloroplatinum, phenanthriplatin, carboplatin, oxaliplatin, or a platinum complex that is activated by ultraviolet A light.
65. An assay for selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising:
- assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number;
 - comparing the chromosome 15q26 copy number to a reference value; and
 - selecting a platinum-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or selecting a non-platinum-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.
66. The assay of claim 65, further comprising:
- assaying the BRCA1 and/or BRCA2 status of the subject; and
 - selecting the platinum-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and there is a chromosome 15q26 copy number gain based on the recognition that platinum-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain who are negative for BRCA1 and/or BRCA2 mutations.
67. The assay of claim 65, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.
68. The assay of claim 65, further comprising:
- assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and
 - selecting the platinum-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when there is a chromosome 15q26 copy number gain based on the recognition that platinum-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor.
69. The assay of claim 65, wherein the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.

70. The assay of claims 65-69, further comprising administering the selected therapy to the subject.
71. The assay of claims 65-71, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.
72. The assay of claims 65-71, wherein the reference value is chromosome 15 centromere copy number in the sample.
73. An assay for selecting a therapy for a subject having cancer, and optionally administering the therapy, the assay comprising:
- assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number;
 - comparing the chromosome 15q26 copy number to a reference value; and
 - selecting an anthracycline-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or selecting a non-anthracycline-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.
74. The assay of claim 73, further comprising:
- assaying the BRCA1 and/or BRCA2 status of the subject; and
 - selecting the anthracycline-comprising cancer therapy for the subject when the subject is negative for BRCA1 and/or BRCA2 mutations, and there is a chromosome 15q26 copy number gain based on the recognition that anthracycline-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain who are negative for BRCA1 and/or BRCA2 mutations.
75. The assay of claim 73, the subject is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.
76. The assay of claim 73, further comprising:
- assaying the estrogen receptor (ER), progesterone receptor (PgR), and HER2 receptor status of the subject's cancer; and
 - selecting the anthracycline-comprising cancer therapy for the subject when the subject's cancer does not express a detectable quantity of ER, PgR, and HER2 receptor, and when there is a chromosome 15q26 copy number gain based on the recognition that anthracycline-comprising cancer therapy is effective in subjects who have a chromosome 15q26 copy number gain and whose cancer does not express a detectable quantity of ER, PgR, and HER2 receptor.

77. The assay of claim 73, wherein the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.
78. The assay of claims 73-77, further comprising administering the selected therapy to the subject.
79. The assay of claims 73-78, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.
80. The assay of claims 73-79, wherein the reference value is chromosome 15 centromere copy number in the sample.
81. A method of treating cancer in a human subject, comprising:
 detecting a chromosome 15q26 copy number in a sample comprising a cancer cell taken from the subject;
 comparing the chromosome 15q26 copy number to a reference value; and
 administering an platinum-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or administering a non-platinum-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.
82. The method of claims 81, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.
83. The method of claims 81-82, wherein the reference value is chromosome 15 centromere copy number in the sample.
84. The method of claim 81-83, wherein the subject's cancer is known to not express a detectable quantity of ER, PgR, and HER2 receptor.
85. A method of treating cancer in a human subject, comprising:
 detecting a chromosome 15q26 copy number in a sample comprising a cancer cell taken from the subject;
 comparing the chromosome 15q26 copy number to a reference value; and
 administering an anthracycline-comprising cancer therapy for the subject if there is a chromosome 15q26 copy number gain compared to the reference value, or administering a non-anthracycline-comprising cancer therapy for the subject if there is not a chromosome 15q26 copy number gain, or if there is a chromosome 15q26 copy number loss.
86. The method of claims 85, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.

87. The method of claims 85-86, wherein the reference value is chromosome 15 centromere copy number in the sample.
88. The method of claim 85-88, wherein the subject's cancer or cancer cell is known to not or is determined to not express a detectable quantity of ER, PgR, and HER2 receptor.
89. A method for assessing responsiveness of a cancer cell to a cancer therapy, and optionally administering the cancer therapy, comprising:
 assaying a sample comprising a cancer cell taken from the subject for a chromosome 15q26 copy number;
 and comparing the chromosome 15q26 copy number to a reference value, wherein the cancer cell is assessed as responsive to a platinum-comprising therapy if there is a chromosome 15q26 copy number gain compared to the reference value, or wherein the cancer cell is assessed as poorly or not responsive to platinum-comprising cancer therapy cancer if there is not a chromosome 15q26 copy number gain or if there is a chromosome 15q26 copy number loss.
90. The method of claim 89, wherein the reference value is copy number of chromosome 15.
91. The method of claim 89, wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer.
92. The method of claim 89, further comprising administering the platinum-comprising therapy if there is a chromosome 15q26 copy number gain.
93. A method of predicting a cancer patient's response to a cancer treatment regimen comprising platinum or anthracycline, comprising:
 determining, in a cancer cell from the cancer patient, chromosome 15q26 copy number; and
 correlating the chromosome 15q26 copy number to a reference value, wherein when there is a chromosome 15q26 copy number gain, the patient is predicted to respond well to a cancer treatment comprising platinum or anthracycline, or wherein when there is not a chromosome 15q26 copy number gain or a chromosome 15q26 copy number loss, the patient is predicted respond poorly to a cancer treatment comprising platinum or anthracycline.
94. The method of claim 93, wherein the reference value is chromosome 15 centromere copy number in the sample.

95. Use of platinum comprising cancer therapy for treating a cancer patient that has been determined to have a tumor comprising cancer cells wherein a chromosome 15q26 copy gain is detected compared to a reference value.
96. The use of claim 95, wherein the cancer patient is known to be or is determined to be negative for BRCA1 and/or BRCA2 mutations.
97. The use of claim 95, wherein the cancer patient's cancer or cancer cell is known to not or is determined to not express detectable quantities of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor.
98. The use of claim 95-97, wherein the reference value is chromosome 15 centromere copy number in the sample.
99. A system for determining responsiveness of a cancer cell to platinum-comprising therapy from a cancer cell of a cancer patient, comprising:
a sample analyzer configured to produce a signal for chromosome 15q26 copy number from a cancer cell sample of a cancer patient; and
a computer sub-system programmed to calculate, based on the mRNA whether the signal is greater or not than a reference value.
100. The system of claim 99, wherein said computer sub-system is programmed to compare the mRNA to determine
a likelihood of responsiveness of said cancer cell to platinum-comprising cancer therapy and/or or a anthracycline-comprising cancer therapy based on an algorithm that classifies the patient as likely to respond to a platinum-comprising therapy if there is a chromosome 15q26 copy number gain and as unlikely to respond to the platinum-comprising therapy if there is not a chromosome 15q26 copy number gain or if there is a chromosome 15q26 copy number loss.
101. The system of claim 99-100, wherein the reference value is chromosome 15 centromere copy number in the sample.
102. A computer program product embodied in a computer readable medium that, when executing on a computer, performs steps comprising:
detecting chromosome 15q26 copy number in sample comprising a cancer cell from a cancer patient; and
comparing the chromosome 15q26 copy number to a reference value.
103. The computer program of claim 102, wherein the reference value is chromosome 15 centromere copy number in the sample.

104. A diagnostic kit for detecting a likelihood of a cancer patient to respond to platinum- or anthracycline-comprising cancer therapy, comprising:
- no more than 10 probes comprising a combination of detectably labeled probes or primers for chromosome 15q26, and optionally for chromosome 15 centromere; and
 - the computer program product of Claim 102.
105. Use of a plurality of oligonucleotides comprising no more than 10 oligonucleotides capable of hybridizing to chromosome 15q26, and optionally for chromosome 15 centromere, in a diagnostic kit for determining an increased likelihood that a cancer patient will respond to cancer treatment regimen comprising a platinum and/or anthracycline.
106. The use, method or assay of claims 65-105, wherein said anthracycline is epirubicin or doxorubicin.
107. The use, method or assay claims 65-105, wherein said platinum comprising cancer therapy comprises cisplatin or cis-diamminedichloroplatinum, phenanthriplatin, carboplatin, oxaliplatin, or a platinum complex that is activated by ultraviolet A light.

Cisplatin-1




FIG. 1A

2/26

Cisplatin-2




FIG. 1B

3/26





FIG. 2

4/26

**Correlation between copy number and mRNA expression,
Genes on 15q26.1-2**



ABHD2	MAN2A2
AEN	MFGE8
BLM	MRPL46
C15orf42	MRPS11
CIB1	NGRN
CRTC3	POLG
DET1	PRC1
FAM174B	RCCD1
FANCI	SEMA4B
HDDC3	UNC45A
IDH2	VPS33B
IQGAP1	

FIG. 3

5/26




FIG. 4

6/26




FIG. 5A




FIG. 5B




FIG. 6A

8/26




FIG. 6B

9/26

TOP TRIAL, TNBC¹




FIG. 7

10/26




FIG. 8




FIG. 9

— Combined, AUC = 0.9, P = 5.3e-05
- - - BRCA1/BLM+FANCI, AUC = 0.82, P = 0.00068
- · - · NtAI, AUC = 0.83, P = 0.00067

All samples




FIG. 10B

- - - Cis 1, AUC = 0.79, P = 0.023
- · - · Cis 2, AUC = 0.9, P = 0.0023

All samples




FIG. 10A

12/26

--- All, AUC = 0.91, Optimum ratio: 5.5, P = 0.0024
- - - BRCA1 wt, AUC = 0.92, Optimum ratio: 6.6, P = 0.0044




FIG. 11

13/26




FIG. 12

14/26





FIG. 13

--- All, AUC = 0.91, Optimum ratio: 5.5, P = 0.0024
- - - BRCA1 wt, AUC = 0.92, Optimum ratio: 6.6, P = 0.0044

Cisplatin-2, mean(BLM+FANCI) / BRCA1



Cisplatin 2, PCR data




FIG. 14

-- All, AUC = 0.9, Optimum ratio: 7.5, P = 0.0015
- - - BRCA1 wt, AUC = 0.9, Optimum ratio: 7.8, P = 0.0033




FIG. 15

-- All, AUC = 0.89, Optimum ratio: 5.1, P = 0.0029
- - - BRCA1 wt, AUC = 0.9, Optimum ratio: 5.1, P = 0.0033




FIG. 16

-- All, AUC = 0.22, Optimum ratio: -14, P = 0.039
- - - BRCA1 wt, AUC = 0.15, Optimum ratio: -14, P = 0.015




FIG. 17

-- All, AUC = 0.82, Optimum ratio: -7.3, P = 0.017
- - - BRCA1 wt, AUC = 0.79, Optimum ratio: -7.3, P = 0.051




FIG. 18

-- All, AUC = 0.75, Optimum ratio: -11, P = 0.066
- - - BRCA1 wt, AUC = 0.75, Optimum ratio: -11, P = 0.091




FIG. 19

21/26






FIG. 20A

22/26

TCGA BREAST - ERBB2



TCGA BREAST - FANCI




FIG. 20A (cont.)

23/26





FIG. 20A (cont.)






FIG. 20B

25/26

TCGA BREAST - BLM / BRCA1



TCGA BREAST - BLM / RPLP0





FIG. 20B (cont.)

TCGA BREAST - FANCI / BRCA1



TCGA BREAST - FANCI / RPLP0




FIG. 20B (cont.)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2014/025774**A. CLASSIFICATION OF SUBJECT MATTER****C12Q 1/68(2006.01)i, G01N 33/15(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12Q 1/68; C12Q 1/02; A61K 39/395; G01N 33/15; G01N 33/68; G01N 33/574

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: platinum comprising therapy, cancer, BLM, FANCI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIRKBAK, et al., `Abstract 4823: copy number gain and increased expression of BLM and FANCI is associated with sensitivity to genotoxic chemotherapy in triple negative breast and serous ovarian cancer.` Cancer Research, Vol.72, Issue.8, Supplement.1, page.1 (2012). See the whole document.	43,44,52-54,56,57 ,59-62,95-97,99 ,100,102-105
A	SILVER, et al., `Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.` Journal of Clinical Oncology, Vol.28, No.7, pp.1145-1153 (2010). See abstract and pages 1150-1151.	43,44,52-54,56,57 ,59-62,95-97,99 ,100,102-105
A	WO 2012-019000 A2 (ON-Q-ITY) 09 February 2012. See abstract; paragraphs [0101]-[0102]; and claims 1-15.	43,44,52-54,56,57 ,59-62,95-97,99 ,100,102-105
A	US 2009-0081237 A1 (D'ANDREA, et al.) 26 March 2009. See abstract and claims 1-5.	43,44,52-54,56,57 ,59-62,95-97,99 ,100,102-105
A	US 7858331 B2 (D'ANDREA, et al.) 28 December 2010. See abstract and claim 1.	43,44,52-54,56,57 ,59-62,95-97,99 ,100,102-105

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 July 2014 (25.07.2014)

Date of mailing of the international search report

28 July 2014 (28.07.2014)

Name and mailing address of the ISA/KR

International Application Division
Korean Intellectual Property Office
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan City, 302-701,
Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

AHN, Kyu Jeong

Telephone No. +82-42-481-5975



Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-42, 46-51, 65-94
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 1-42, 46-51, and 65-94 pertain to methods for treatment of the human body by therapy as well as diagnostic methods, and thus relate to a subject matter which this International Searching Authority is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.
2. Claims Nos.: 19, 20, 63, 64, 71, 72, 88, 106, 107
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 19 and 20 are unclear since they are referring to the multiple dependent claims which do not comply with PCT Rule 6.4(a).
Claims 71 and 88 refer to claims 71 and 88 themselves, respectively. And claim 72 depends on claim 71. Therefore, claims 71-72 and 88 do not comply with PCT Article 6.
Claims 63, 64, 106, and 107 have more than one subject matter, and thus it is difficult to define the subject matter of claims 63, 64, 106, and 107 (PCT Article 6 and PCT Rule 6.1 (a)).
3. Claims Nos.: See Supplemental Box.
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2014/025774

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2012-019000 A2	09/02/2012	WO 2012-019000 A3	24/05/2012
US 2009-0081237 A1	26/03/2009	CA 2680549 A1	18/09/2008
		EP 2134855 A1	23/12/2009
		EP 2134855 A4	05/01/2011
		JP 2010-521670 A	24/06/2010
		US 2013-280258 A1	24/10/2013
		WO 2008-112193 A1	18/09/2008
US 7858331 B2	28/12/2010	AU 2000-280389 A8	19/05/2003
		AU 2002-18006 A1	15/05/2002
		AU 2005-216013 A1	09/09/2005
		AU 2005-216013 B2	11/11/2010
		AU 2006-249807 A1	30/11/2006
		CA 2465949 A1	15/05/2003
		CA 2552351 A1	09/09/2005
		CA 2609751 A1	30/11/2006
		EP 1349924 A2	08/10/2003
		EP 1451343 A2	01/09/2004
		EP 1451343 B1	17/10/2012
		EP 1728077 A2	06/12/2006
		EP 1904088 A2	02/04/2008
		EP 2298878 A2	23/03/2011
		EP 2298878 A3	16/11/2011
		JP 2004-536555A	09/12/2004
		JP 2005-536981A	08/12/2005
		JP 2007-521811A	09/08/2007
		JP 2008-545965A	18/12/2008
		JP 2009-039100A	26/02/2009
		JP 2010-246550A	04/11/2010
		US 2003-0093819 A1	15/05/2003
		US 2003-0188326 A1	02/10/2003
		US 2005-0255502 A1	17/11/2005
		US 2007-0105130 A1	10/05/2007
		US 2009-0186355 A1	23/07/2009
		US 2011-0151487 A1	23/06/2011
		US 7459287 B2	02/12/2008
		US 7910325 B2	22/03/2011
		US 8597900 B2	03/12/2013
		WO 02-036761 A3	03/07/2003
		WO 02-36761 A2	10/05/2002
		WO 03-039327 A2	15/05/2003
		WO 03-039327 A3	14/08/2003
		WO 2005-081783 A2	09/09/2005
		WO 2005-081783 A3	19/10/2006
		WO 2006-127978 A2	30/11/2006
		WO 2006-127978 A3	30/04/2009

Continuation of Box No. II.

3. Claims Nos: 6-10, 16-18, 24, 25, 34, 40, 45, 55, 58, 63, 64, 70-72, 78-80, 83, 84, 87, 88, 98, 101, 106, 107

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).